<SEC-DOCUMENT>0001193125-26-197402.txt : 20260430
<SEC-HEADER>0001193125-26-197402.hdr.sgml : 20260430
<ACCEPTANCE-DATETIME>20260430162055
ACCESSION NUMBER:		0001193125-26-197402
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260430
DATE AS OF CHANGE:		20260430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		26925784

	BUSINESS ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>achv-20251231.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-04-30T16:13:57.6557+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:achv="http://ir.achievelifesciences.com/20251231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K/A</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_86f1564f-134f-47ea-88ea-abe5cce2350e" name="dei:AmendmentFlag" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" format="ixt:fixed-true">true</ix:nonNumeric><ix:nonNumeric id="F_f61fbbb4-6fe8-4aa9-8736-74c3e6726099" name="dei:DocumentFiscalPeriodFocus" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471">FY</ix:nonNumeric><ix:nonNumeric id="F_709f50ba-ced4-4210-bde2-1a50a0292c13" name="dei:EntityCentralIndexKey" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471">0000949858</ix:nonNumeric><ix:nonNumeric id="F_3a6952d4-a03d-4f6a-8453-592bf7d3cad2" name="dei:EntityAddressStateOrProvince" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471">BC</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="achv-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000949858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bd2bfc9-4d18-460c-ac43-0c2f6a4db5fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000949858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000949858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:OtherAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_778c1ce0-3ed5-4cde-9b17-19895c3b3431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000949858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40.747%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40.741%;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a40fe607-1ec6-41dd-8a54-9dde2c87d9a3" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K/A</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40.747%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40.741%;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:95%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_60ab88cf-3e5d-4ffa-abe1-b6a5ef47bf64" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ee6480a-9b8b-4d07-96ca-226fd79a41b9" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a30c493-4d69-4ca9-a9ec-dc4392512b4a" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d866770b-09f8-41c1-9dd2-7f58afb64e23" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:95%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_57edad57-14d6-4ff0-ac56-c7e8370ce8f4" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
   </table><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af4f5873-f854-4930-9096-35a322c2265a" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">033-80623</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb3051d2-c7e9-4d48-91b0-5f26d182e01f" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achieve Life Sciences, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of the registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:49%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:49%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0659e638-ffdc-40a4-9e39-44d06d02e200" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_69b3dee4-5531-452e-bcfe-3071d083b356" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95-4343413</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c01361e-3720-49be-96b7-152d2595f15a" contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22722 29th Drive SE</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01e70611-9f94-4c60-b8f1-22201c3eb46e" contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47aa7fab-2044-47b6-92f7-0ad63c0f77a7" contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2b724a8-f1f6-45cf-b0fc-bb1135fe4296" contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0e4f7e3-83be-4abd-8dfd-5b4e13b4dceb" contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98021</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ff843e9-c51c-43c9-92a6-67ddbf9c362d" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1040 West Georgia Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6380820b-30ea-4d5d-9328-8e836273750d" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 1030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93e8f4af-f506-4975-b14b-5a146935b707" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vancouver</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3a6952d4-a03d-4f6a-8453-592bf7d3cad2;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.C.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b551ac6-979d-4463-b0db-3405ddb9cd5a" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">V6E 4H1</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Address of principal executive offices, including zip code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdf6d385-f6f6-4197-a1a3-fa074a36f854" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">604</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69362f61-ff5c-44de-98cb-e1d7cae50679" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">210-2217</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:46.029%;box-sizing:content-box;"/>
     <td style="width:6.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:46.629%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Title of Each Class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Name of Exchange on Which Registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5fbd5cbc-b525-49df-875c-b29341131d78" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_307ee518-3d89-4f0f-b299-814831c8f3df" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACHV</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8fd8f9ec-08c0-4ac3-9f0d-10e87a9942fb" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act, as amended.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b31fcd9d-97f8-4b5d-9c77-117c0aed7de3" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08aefa21-9435-47ae-9e3d-1357b7c28610" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50de6ee5-eb27-4e7d-84f4-9b985f839308" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb04f3cb-1dbb-4c16-8363-77941c3b8947" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:47%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_95d0ff99-7f1f-41ac-8f6a-388374f06462" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9181d542-176c-41d3-8c68-023cde69b05c" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_2a5b6166-6511-4152-942f-d61211085348" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e41b9506-413e-41a9-9b0d-f7311e97b578" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_32d4fc83-5c89-438a-8e5c-90abd44e4fc6" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    No   </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3b837ef4-d3d9-47d3-b5ba-e54501764ef4" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, the aggregate market value of the registrant&#8217;s Common Stock held by non-affiliates of the registrant was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45385558-7e20-4339-8a96-0129768dc132" contextRef="C_778c1ce0-3ed5-4cde-9b17-19895c3b3431" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,958,994</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> computed with reference to the price at which the Common Stock was last sold on June 30, 2025.  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 20, 2026, </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7fe364f-8638-4045-8a56-58d30543797d" contextRef="C_3bd2bfc9-4d18-460c-ac43-0c2f6a4db5fa" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">102,659,057</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shar</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es of the registrant&#8217;s Common Stock were outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
     <td style="width:33.333%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Auditor Name: </span><span style="font-size:8pt;"><ix:nonNumeric id="F_d4b6313f-a132-44cb-8473-82f71578f243" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Auditor Location: </span><span style="font-size:8pt;"><ix:nonNumeric id="F_283eff06-4ce9-40fc-b8db-6e302bb705ab" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vancouver, Canada</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Auditor Firm ID: </span><span style="font-size:8pt;"><ix:nonNumeric id="F_eca25279-3902-46a6-bec2-adf747926ae5" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXPLANATORY NOTE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_292720f6-b21e-4828-976c-30080d870a68" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="dei:AmendmentDescription" continuedAt="F_292720f6-b21e-4828-976c-30080d870a68_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Amendment No. 1 on Form 10-K/A (&#8220;Amendment No. 1&#8221;) is being filed to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#8220;Original Filing&#8221;), filed with the U.S. Securities and Exchange Commission (the "SEC") on March 24, 2026 (the &#8220;Original Filing Date&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are amending and refiling Part III to include information required by Items 10, 11, 12, 13 and 14 because our definitive proxy statement will not be filed within 120 days after December 31, 2025, the end of the fiscal year covered by our Annual Report on Form 10-K. </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_292720f6-b21e-4828-976c-30080d870a68_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the rules of the SEC, we have also included as exhibits currently dated certifications required under Section 302 of The Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, certifications pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 are not being furnished herewith.  We are amending and refiling Part IV to reflect the inclusion of those certifications, along with any changes to Part IV that occurred after the date of the Original Filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we made certain revisions to the cover page, including the deletion of the reference to our proxy statement and the amendment to our Annual Report on Form 10-K and inclusion of updated outstanding share information. Except as described above, no other changes have been made to the Original Filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. The filing of this Amendment is not a representation that any statements contained in items of our annual report on Form 10-K other than Part III, Items 10 through 14, Part IV and the aforementioned portions of the cover page are true or complete as of any date subsequent to the Original Filing.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achieve Life Sciences, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:80%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 10.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 11.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 12.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain_b"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 13.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 14.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    </tr>
    <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ITEM 15.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:24pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.227%;text-indent:-2.277%;padding-left:2.227%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OFF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ICERS AND CORPORATE GOVERNANCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board of Directors</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information for each of the members of our Board of Directors as of April 20, 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:19.776%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:5.459%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:62.747%;box-sizing:content-box;"/>
     <td style="width:1.64%;box-sizing:content-box;"/>
     <td style="width:7.099%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Director Since</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stuart Duty</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chairperson of the Audit Committee and Member of the Nominating and Governance Committee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Goldberg</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chief Executive Officer and President</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lucian Iancovici</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas B. King</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chairman of the Board</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridget Martell</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chairperson of the Nominating and Governance Committee and Member of the Compensation Committee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy R. Phelan</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, and Member of the Audit Committee and the Compensation Committee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Royston</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas Sellig</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director, Chairperson of the Compensation Committee and Member of the Audit Committee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kristen Slaoui</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director and Member of the Compensation Committee and Nominating and Governance Committee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stuart Duty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was a Senior Managing Director at Guggenheim Securities, LLC, a global investment and advisory financial services firm, from June 2012 to March 2023.  Previously, he served as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray Companies, a global investment firm, from 2007 to 2012, as the Chief Operating Officer of Oracle Partners, L.P., a private healthcare focused investment fund, from 2002 to 2007, as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray, Inc., a global investment bank, from 1992 to 2002, as Managing Director, Healthcare Investment Banking at Montgomery Securities, an investment bank, from 1993 to 1999 and as the Director of Business Development at Curative Technologies, Inc., a biotherapeutics company, from 1992 to 1993.  Mr. Duty has served on the board of directors of Eyepoint Pharmaceuticals, Inc., a publicly traded pharmaceutical company, since October 2023, on the board of Milestone Pharmaceuticals, Inc. since July 2024 and on the board of Foghorn Therapeutics, Inc. since May 2025.  Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School.  The determination was made that Mr. Duty should serve on our Board of Directors due to his extensive experience in the banking and finance industry.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Andrew D. Goldberg, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Executive Officer and President since April 2026.  Previously, Dr. Goldberg served as a portfolio manager at Marshall Wace North America L.P., an alternative asset manager, from February 2024 to April 2026 and served as Managing Director from March 2021 until February 2024.  Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately-held medical device company, since February 2024.  Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021.  Prior to this, Dr. Goldberg was a consultant at McKinsey &amp; Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&amp;A, sales, marketing, and product development topics.  Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics.  Dr. Goldberg is a U.S. board-certified physician in both Critical Care Medicine and Emergency Medicine.  He has served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine.  He completed Emergency Medicine residency training at Los Angeles County and University of Southern California Medical Center.  Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post-doctoral diploma in translational science from the May Graduate School.  He has held prior academic and clinical appointments at Oregon Health &amp; Science University and the Palo Alto VA Medical Center.  The determination was made that Dr. Goldberg should serve on our Board of Directors due to his extensive experience in life sciences strategy and product development, his governance experience across many life sciences company boards, his experience investing in pharmaceutical companies, and his background as a dual-board-certified physician, academic researcher, and public health advocate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lucian Iancovici, M.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is a Partner of TPG, a global alternative asset manager, where he has worked since January 2018.  From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies, from January 2015 to October 2017, he was general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm, and from 2011 to 2012 he was an associate at McKinsey &amp; Company.  Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. since December 2019 and Rallybio Corporation since May 2020 and serves on the boards of the following private companies: K2 Medical Research, Ceribell, Inc., Ellodi Pharmaceuticals, AnovoRx Holdings, Inc. and Sling Therapeutics Inc.  Dr. Iancovici is a board-certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey &amp; Company.  He received his B.A. in economics and an M.D., both from Tufts University.  The determination was made that Dr. Iancovici should serve on our Board of Directors due to his extensive experience in the venture capital industry, and given that his medical and scientific background and training provide him with the appropriate set of skills to serve as a member of our Board of Directors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Thomas B. King </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is the Chair of our Board of Directors.  He served as Achieve&#8217;s Interim Executive Chair from August 2024 to June 2025, and as a director since March 2023.  Mr. King also serves on the board of Kinaset Therapeutics, Inc., a clinical stage, privately held biopharmaceutical company.  Previously, Mr. King served on the board of TFF Pharmaceuticals Inc., a publicly traded clinical-stage biopharmaceutical company from December 2023 to 2024 and on the board of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, acting as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018.  He was President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from June 2003 to August 2016, when it was acquired by Grupo Ferrer, also serving as Chief Financial Officer and Chief Accounting Officer from October 2015 to August 2016.  Prior to this, he was President, Chief Executive Officer, and a board member of Cognetix, Inc., a privately held biopharmaceutical from September 2002 to April 2003.  At Anesta Corporation, a publicly traded pharmaceutical company, he held various senior roles, including President and Chief Operating Officer, 1995 to 1997, and President and Chief Executive Officer, 1997 to 2000 and served on the board until its acquisition by Cephalon, Inc. in October 2000.  Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.  The determination was made that Mr. King should serve on our Board of Directors due to his wealth of knowledge from his experience in biopharma leadership positions ranging from large to development-stage companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bridget Martell, M.A., M.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has been an Operating Partner and now Senior Advisor at Two Bear Capital since 2024 and the Founder and Managing Partner of her consultancy practice, BAM Consultants, which she started in 2013.  She previously served as President and Chief Executive Officer of the privately held biotechnology company Artizan Biosciences, Inc. from July 2021 until August 2023.  Concurrently, she was a Venture Partner at AlleyCorp Healthcare Fund from June 2021 to May 2023.  Prior to that, Dr. Martell was at Kura Oncology, Inc., a public, clinical-stage biopharmaceutical company, where she served in varied roles first as VP, Clinical Development, Acting Chief Medical Officer, and Senior Scientific Advisor from October 2017 until December 2021.  She has served as the Acting Chief Medical Officer of a number of privately held early-stage biotechnology companies, including Nobias Therapeutics, Inc. from August 2020 to August 2021 and from July 2023 to June 2024 and Verseau Therapeutics, Inc. from October 2020 to September 2021.  Additionally, Dr. Martell served as Chief Medical Officer of RRD International, Inc., a privately held boutique contract research organization, from April 2018 to January 2020.  From 2015 to 2017, Dr. Martell served as Senior Vice President, New Product Development and Chief Medical Officer at Juniper Pharmaceuticals, a publicly traded specialty pharmaceuticals company.  Prior to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly traded biopharmaceutical company, from 2005 to 2011.  Dr. Martell currently serves as an independent director of Aligos Therapeutics, Inc. and Delcath Systems, Inc., each a publicly traded biotechnology company, and previously served as a director of POINT Biopharma Global, Inc., a cancer treatment biotechnology company, from June 2023 until its acquisition by Eli Lilly and Company, a pharmaceutical company, in December 2023 and Ayala Pharmaceuticals, Inc., acquired by Immunome, Inc. in February 2024.  Dr. Martell holds a B.S. in microbiology from Cornell University, an M.A. in molecular immunology from Boston University and an M.D. from the Chicago Medical School.  She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University.  Dr. Martell is board certified in both internal and addiction medicine.  Dr. Martell was a Teaching Attending and Clinical Associate Professor at Yale from 2005 to 2020 and has continued her engagement at Yale as an Entrepreneur in Residence at Yale Ventures since 2017.  The determination was made that Dr. Martell should serve on the Board of Directors due to her diverse background of scientific, clinical and leadership experience in clinical development, the success of numerous marketed products across multiple therapeutic categories, leadership in her operational roles, and engagement with key industry and business stakeholders in the biopharmaceutical space.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nancy R. Phelan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> serves as the Senior Vice President of Marketing and Analytics for Phathom Pharmaceuticals, Inc.  She previously served as Senior Vice President &amp; Head of Customer Engagement at Trinity Life Sciences, a life sciences consultancy.  She also serves as a member of the board of directors of Medexus Pharmaceuticals, a specialty pharmaceutical company, since September 2023.  She also served as a board member of FemmePharma Consumer Healthcare, a pharmaceutical company, from 2018 to 2025.  From May 2022 to May 2024, Ms. Phelan served as Senior Vice President of Indegene, a technology-led healthcare solutions provider.  Prior to that, she held roles of increasing responsibility with Novartis AG, a multinational pharmaceutical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">company, including as Vice President, Business Transformation, Patient Engagement and Integrated Marketing Team Lead from April 2021 to May 2022 and Vice President, Patient and Specialty Services, Neuroscience from June 2002 to April 2021.  She served as Chief Executive Officer and Secretary of Adhera Therapeutics, Inc., a clinical stage biopharmaceutical company, from April 2019 to June 2020 and as a director from October 2018 to June 2020.  Ms. Phelan received a B.A. with Honors from Franklin &amp; Marshall College and completed coursework towards an M</span><span style="color:#b5082e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B</span><span style="color:#b5082e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#b5082e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from Villanova University.  She also received certificates from Wharton Executive Education and the Harvard School of Public Health.  The determination was made that Ms. Phelan should serve on our Board of Directors due to her executive leadership in biopharma and expertise in data-driven insights, digital innovation and digital-first marketing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aaron Royston, M.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as managing partner at venBio Partners, a life sciences investment firm, since April 2020 and has been with venBio Partners since 2015. Prior to joining venBio Partners, Dr. Royston served as a Senior Associate at Vivo Capital, a global life sciences investment firm from July 2014 to November 2015. Previously, Dr. Royston served as a consultant at Bain &amp; Company, Inc. from July 2013 to July 2014 where he advised biotechnology companies on a broad range of strategic and operational issues.  Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences.  Dr. Royston previously served on the boards of directors of Rayze Bio, from August 2020 until November 2023, Ventyx Biosciences, Inc., a publicly traded biotechnology company, from March 2021 until January 2023, Akero Therapeutics, Inc., a publicly traded biotechnology company, from June 2018 until August 2019, and VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.), a publicly traded biotechnology company, from June 2017 until August 2019.  Dr. Royston currently serves on the board of directors of several private companies. Dr. Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania.  The determination was made that Dr. Royston should serve on our Board of Directors due to his clinical and biotechnology industry experience and his service on the boards of directors of other biopharmaceutical companies.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Thomas Sellig </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as the Chief Executive Officer of Adare Pharmaceuticals, Inc., a global technology-driven Contract Development and Manufacturing Organization since January 2022.  From July 2019 to October 2021, Mr. Sellig served as Chief Executive Officer of LabConnect, Inc., a clinical trial laboratory services organization. Prior to LabConnect, Inc., Mr. Sellig was Chief Commercial Officer at PSKW, LLC (doing business as ConnectiveRx), a biopharmaceutical services company, from September 2018 to July 2019. From November 2014 to August 2017, Mr. Sellig was Senior Vice President of Global Sales at Patheon N.V., and continued to serve as Senior Vice President of Global Sales at Thermo Fisher Scientific Inc., a life, science and clinical research company, following its acquisition of Patheon N.V. in August 2017.  Previously, he served as the Global Vice President of Sales and Client Services from 2011 to 2014, and as the Vice President of Strategic Partnering/ Alliance Management from 2007 to 2011 at Covance, the drug development business of Laboratory Corporation of America Holdings, a contract research organization.  Early in his career, Mr. Sellig had a variety of sales and marketing leadership roles at Procter &amp; Gamble Company, a multinational consumer goods company, Wyeth, LLC (formerly American Home Products), a pharmaceutical company, and Ascent Pediatrics, Inc., a drug development company.  Mr. Sellig received his B.A. in Economics from Vanderbilt University and an M.B.A. from New York University. The determination was made that Mr. Sellig should serve on our Board of Directors due to his extensive global experience in the life sciences and pharmaceutical services industries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Kristen Slaoui</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, served as Chief Corporate Development Officer at Galderma S.A., a global dermatology company, from September 2020 to July 2025.  From March 2019 to November 2022, she also served as a member of the board of directors of Villaris Therapeutics, Inc., a biopharmaceutical company.  She has served on the Board of Sensory Cloud Therapeutics since March 2026 and as a Board Observer of Kinaset Therapeutics, a private biotechnology company, since August 2020.  She has served as a member of the Board of Directors of Achieve since January 2025 and advises private equity and pharmaceutical companies on growth strategy, portfolio optimization and transactions.  Prior to Galderma, Dr. Slaoui spent over 20 years at GlaxoSmithKline plc, a multinational pharmaceutical and biotechnology company where she held roles of increasing responsibility, including Vice President &amp; Head, Business Development &#8211; North America from March 2015 to March 2019, and Vice President &amp; Head Business Development, Pharmaceuticals Commercial Portfolio from March 2019 to August 2020.  Dr. Slaoui earned a B.S. in Biology and a B.A. in Classical Studies from Gettysburg College.  She earned her Ph.D. in Physiology from Johns Hopkins Bloomberg School of Public Health and completed a post-doctoral fellowship at the University of Washington School of Medicine.  The determination was made that Dr. Slaoui should serve on our Board of Directors due to her extensive experience in corporate strategy, business development and transactions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Richard Stewart</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> served as our Chief Executive Officer from August 2024 to April 2026, and served as our Executive Chairman from September 2020 to August 2024.  Previously, Mr</span><span style="color:#b5082e;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Stewart served as Chief Executive Officer from the consummation of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve in August 2017 to September 2020.  Previously, Mr. Stewart was Chairman and a director of Achieve, from its founding in May 2015 to August 2017.  Mr. Stewart is also a founder and has served as a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009.  Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson&#8217;s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">system company, during 2009, prior to Huxley Pharmaceuticals, Inc.&#8217;s acquisition by BioMarin Pharmaceutical Inc., a biotechnology company. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc., a biopharmaceutical company.  He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson&#8217;s disease and Huntington&#8217;s disease, from 2000 to 2007.  Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such position from 1995 until 1998.  Mr. Stewart holds a B.S. in Business Administration from the University of Bath.  The determination was made that Mr. Stewart should serve on our Board of Directors due to his prior service on other boards of directors, and extensive experience and innovations in the field of biotechnology.  In addition, Mr. Stewart&#8217;s accomplishments provide our Board of Directors with in-depth product and field knowledge.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the standing committees of our Board of Directors has diverse representation.  In addition, on our Board of Directors there are four directors who hold medical doctorates, one director who holds a doctorate in scientific fields and five directors who hold master&#8217;s degrees in business administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Officers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The names of our named executive officers, their ages, their positions, and other biographical information as of April 20, 2026 are set forth below.  Executive officers are appointed by our Board of Directors to hold office until their successors are elected and qualified.  There are no family relationships among our directors or executive officers.  During 2025, Dr. Cindy Jacobs served as our Chief Medical Officer and President until her resignation effective October 6, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:37.133%;box-sizing:content-box;"/>
     <td style="width:2.08%;box-sizing:content-box;"/>
     <td style="width:10.538%;box-sizing:content-box;"/>
     <td style="width:2.08%;box-sizing:content-box;"/>
     <td style="width:48.17%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position With the Company</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Goldberg</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Erik Atkisson</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Craig Donnelly</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Operations Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Oki</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Rubinstein</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jaime Xinos</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Commercial Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following are the biographies of Erik Atkisson, Craig Donnelly, Mark Oki, Mark Rubinstein and Jaime Xinos.  The biography of Dr. Goldberg is located above under the heading &#8220;Board of Directors.&#8221;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Erik Atkisson</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Legal Officer since October 2025. From January 2024 to October 2025, Mr. Atkisson served as a Strategic Life Sciences Consultant where he provided legal, business and compliance advice to small and mid-size life sciences companies. From February 2023 through January 2024, Mr. Atkisson served as General Counsel and Chief Compliance Officer of Rain Oncology Inc., a clinical-stage biotechnology research company formerly listed on Nasdaq. From August 2021 to February 2023, Mr. Atkisson served as General Counsel, Corporate Secretary and Chief Compliance Officer of Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company formerly listed on Nasdaq. From August 2019 to August 2021, Mr. Atkisson served as Chief Compliance Officer and Legal Counsel of Cytokinetics, Inc., a late-stage biotechnology research company. From 2014 to 2018, Mr. Atkisson held several positions at Impax Laboratories, LLC (now Amneal Pharmaceuticals), a commercial-stage biopharmaceuticals company, most recently as Senior Director &#8211; Healthcare, Commercial and Employment Law. From 2010 to 2014, Mr. Atkisson served as Senior Counsel of BioMarin Pharmaceutical Inc., a commercial-stage pharmaceutical company.  Mr. Atkisson began his career as an associate at the law firms Bingham McCutchen LLP and Reed Smith LLP.  Mr. Atkisson received his bachelor's degree from Harvard University, a Master of Science degree from The University of Edinburgh, and his Juris Doctorate from the Georgetown University Law Center.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Craig Donnelly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Operations Officer since September 2025. From March 2024 to September 2025, Mr. Donnelly served as our Executive Vice President, CMC and Regulatory CMC, and from March 2023 to February 2024, he served as our Senior Vice President, CMC and Regulatory CMC. Prior to joining us, from October 2022 to February 2023, Mr. Donnelly served as Vice President, CMC and Regulatory CMC at NuCana plc, a clinical-stage biopharmaceutical company, and as Senior Director, CMC and Regulatory Affairs, from January 2021 to October 2022. Previously, Mr. Donnelly held senior roles in CMC and regulatory functions at ICON plc (formerly Mapi), a contract research organization, and F. Hoffmann-La Roche Ltd., a multinational healthcare company. He began his career at Pfizer Inc. as an analytical chemist before advancing to a project leadership role, and served as a Team Leader at Almac Sciences, a contract development and manufacturing organization. Mr. Donnelly holds a Bachelor&#8217;s degree with Honors in Chemical and Pharmaceutical Sciences from the University of Sunderland.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mark Oki</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial-stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte &amp; Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration &#8211; Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mark L. Rubinstein, M.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Chief Medical Officer since October 2025. From September 2024 to October 2025, Dr. Rubinstein served as our Vice President, Head of Medical Affairs, and from June 2024 to September 2024, he served as a Medical Affairs consultant to the Company. Prior to joining Achieve, from May 2022 to June 2024, Dr. Rubinstein served as Head of Medical Affairs at Blip, a smoking cessation products company. From July 2019 to May 2022, he served as Vice President, Global Scientific Affairs and Clinical Operations at Juul Labs, Inc., an electronic cigarette company. From 2003 to 2019, Dr. Rubinstein served as a Professor in the Department of Pediatrics at the University of California, San Francisco (UCSF), and is now Professor Emeritus of Pediatrics. Dr. Rubinstein earned his M.D. from Yale School of Medicine and completed his Internal Medicine residency at Yale&#8211;New Haven Hospital. He is board certified in Internal Medicine and Adolescent Medicine.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Jaime Xinos </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as Chief Commercial Officer since October 2024 and served as our Executive Vice President, Commercial, since September 2017.  She previously served as the Vice President, Marketing and Corporate Communications of OncoGenex Pharmaceuticals, Inc. and as OncoGenex&#8217;s Senior Director, Global Oncology Commercial Development.  Prior to OncoGenex, Ms. Xinos held various commercial roles in marketing, commercial development, and sales at Pfizer, Novartis, and Abbott Laboratories. She holds an undergraduate degree in Communications and a Master of Business Administration (MBA) both from the University of Illinois.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Governance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of the members of our Board of Directors, officers, and employees, and we expect our agents, representatives, consultants and contractors to conform to the standards of our Code of Business Conduct and Ethics.  Our Code of Business Conduct and Ethics is posted on the &#8220;Investor Relations&#8221; section of our website, which is located at https://ir.achievelifesciences.com under &#8220;Corporate Governance Documents&#8221; in the &#8220;Corporate Governance&#8221; section of our website.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Code of Business Conduct and Ethics requires our executive officers and directors to report any conflicts of interest with our interests to our Audit Committee and generally prohibits our executive officers and directors from conflicts of interest with our interests.  Waivers of our Code of Business Conduct and Ethics with respect to an executive officer or director may only be granted by the Board of Directors or, if permitted by Nasdaq and any other applicable stock exchange rules, our Nominating and Governance Committee.  We have a Related Party Transactions Policy concerning approval of transactions with stockholders who own more than 5% of our outstanding shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Independence</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors has determined that Mr. Duty, Dr. Iancovici, Mr. King, Dr. Martell, Ms. Phelan, Dr. Royston, Mr. Sellig and Dr. Slaoui are &#8220;independent&#8221; under the applicable Securities and Exchange Commission, or the SEC, rules and the criteria established by</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nasdaq.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relationships Among Directors and Executive Officers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no family relationships among any of our directors or executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with a private placement and the securities purchase agreement entered into in connection therewith in April 2026, for so long as TPG Life Sciences Innovations (&#8220;TPG&#8221;) and venBio Partners (&#8220;venBio&#8221;) each beneficially own five percent or more of the outstanding shares of our common stock, we have agreed to take all necessary action to cause directors designated by TPG and venBio, respectively, to be included in the slate of nominees recommended by our Board of Directors for election as directors at our 2026 annual meeting of stockholders and 2027 annual meeting of stockholders or applicable special meeting in lieu thereof at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which such director is to be elected. On April 15, 2026, our Board of Directors appointed each of Lucian Iancovici and Aaron Royston, as designated by TPG and venBio, respectively, to serve as a director, effective April 17, 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors&#8217; Committees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors has established an Audit Committee, a Compensation Committee, and a Nominating and Governance Committee to assist it in performing its responsibilities.  The Board of Directors designates the members of these committees and the committee chairs annually, based on the recommendations of the Nominating and Governance Committee in consultation with the Chief Executive Officer and the Chairman of the Board of Directors. The Nominating and Governance Committee reviews committee assignments from time to time and considers the rotation of committee chairpersons and members with a view towards balancing the benefits derived from the diversity of experience and viewpoints of the directors. The Board of Directors has adopted written charters for each of these committees, which are available on our website at ir.achievelifesciences.com under &#8220;Corporate Governance Documents&#8221; in the &#8220;Corporate Governance&#8221; section.  The chairperson of each committee develops the agenda for that committee and determines the frequency and length of committee meetings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee and Audit Committee Financial Expert</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has been established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is currently comprised of Stuart Duty, Chairperson, Nancy Phelan and Thomas Sellig, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements for audit committee members.  The Board of Directors has also determined that Mr. Duty is an &#8220;audit committee financial expert,&#8221; as defined by the applicable rules of the SEC. The Audit Committee held four meetings during fiscal year 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Committee Responsibilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee is responsible for, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the integrity of our financial statements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our internal control systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our external audit process;</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our internal audit and assurance process;</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management of financial risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investment opportunities and the raising of funds; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:7.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.617714099641811%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our compliance with legal and regulatory requirements.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee currently consists of Thomas Sellig, Chairperson, Bridget Martell, Nancy Phelan and Kristen Slaoui, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements.  In addition, each member of the Compensation Committee has been determined to be a non-employee director under Rule 16b-3 as promulgated under the Exchange Act.  The Compensation Committee reviews and makes recommendations to the Board of Directors regarding the compensation of our executive officers and our non-employee directors, human resource policies for our executive officers and administers our compensation and benefits plans.  The Compensation Committee does not have any explicit authority to delegate its duties.  The Compensation Committee held six meetings during fiscal year 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nominating and Governance Committee</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating and Governance Committee currently consists of Bridget Martell, Chairperson, Stuart Duty and Kristen Slaoui, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating and Governance Committee reviews, evaluates and proposes candidates for election to our Board of Directors, and considers any nominees properly recommended by stockholders.  The Nominating and Governance Committee promotes the proper constitution of our Board of Directors in order to meet its fiduciary obligations to our stockholders, and oversees all matters relating to the stewardship role of our Board of Directors in respect of the management of the Company, the size and composition of our Board of Directors, including the candidate selection process, the orientation of new members and such procedures as may be necessary to allow our Board of Directors to function independently of management and compliance with policies associated with an efficient system of corporate governance.  The Nominating and Governance Committee held one meeting during fiscal year 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors Leadership Structure</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thomas King serves as our independent Chairman of the Board, and provides independent leadership to the Board and oversight over management and strategic matters. Mr. King brings extensive leadership experience in the pharmaceutical and biopharmaceutical industry in leading the Board. Dr. Goldberg has served as our Chief Executive Officer since April 2026. Dr. Goldberg brings extensive experience in life sciences strategy and product development, governance experience across many life sciences company boards, experience investing in pharmaceutical companies, and a background as a dual-board-certified physician, academic researcher, and public health advocate.  Independent directors and management sometimes have different perspectives and roles in strategy development. Our independent directors bring experience, oversight and expertise from outside of our Company. The Board of Directors also believes the separation of the Chairman and Chief Executive Officer roles allows the Chief Executive Officer to focus his time and energy on operating and managing the Company and leverages the Chairman&#8217;s experience and perspective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors&#8217; Role in Risk Oversight</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with our leadership structure, our management is charged with the day-to-day management of risks that we face or may face and provides our Board of Directors with quarterly risk assessment and mitigation strategy updates, while our Board of Directors and its committees are responsible for oversight of risk management. The Audit Committee has responsibility for oversight of financial reporting related risks, including those related to our accounting, auditing and financial reporting practices, as well as cybersecurity risks. In addition, the Audit Committee annually reviews and assesses the adequacy of our risk management policies and procedures with regard to identifying our management of financial risks, cybersecurity risks, reviews the quarterly updates on these risks that are received from management, and assesses the adequacy of management&#8217;s implementation of appropriate systems to mitigate and manage financial risks.  Furthermore, under our Code of Business Conduct and Ethics, the Audit Committee is responsible for considering reports of conflicts of interest involving officers and directors. The Nominating and Governance Committee oversees corporate governance risks, including implementing procedures to ensure that the Board of Directors operates independently of management and without conflicts of interest.  In addition, the Nominating and Governance Committee oversees compliance with our Code of Business Conduct and Ethics. The Compensation Committee oversees risks associated with our compensation policies, plans and practices. The Audit Committee, the Nominating and Governance Committee and the Compensation Committee each report to the Board of Directors regarding the foregoing matters, and the Board of Directors approves any changes in corporate policies, including those pertaining to risk management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors has also adopted a Whistleblower Policy to provide a means by which concerns about actual and suspected violations of laws, governmental rules or regulations; accounting, internal accounting controls or auditing matters; our Code of Business Conduct and Ethics or other policies; and other public interest matters are to be reported. We recognize that individuals may not feel comfortable reporting a matter directly to the appropriate persons at the Company and therefore the Whistleblower Policy provides a mechanism by which a person may report a matter to Nasdaq OMX Group Corporate Services, Inc., a third party retained by us. Under the policy, the Chairperson of the Audit Committee determines whether and, if so, how an investigation is to be conducted and, together with the full Audit Committee in certain instances, resolves reported violations.  In all cases, a report of the outcome is to be made to the Board of Directors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Assessment of Compensation Programs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined that our compensation policies, plans and practices are appropriately balanced and do not create risks that are reasonably likely to have a material adverse effect on our Company. To make this determination, our management reviewed the compensation policies, plans and practices for our executive officers, as well as for all other employees. We assessed the following features of our compensation, plans and practices: design, payment methodology, potential payment volatility, relationship to our financial results, length of performance period, risk-mitigating features, performance measures and goals, oversight and controls, and plan features and values compared to market practices. Based on this annual review, we believe that our compensation policies, plans and practices do not create risks that are reasonably likely to have a material adverse effect on our Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No member of the Compensation Committee during fiscal year 2025 served as one of our officers, former officers or employees. On November 10, 2025, we entered into a consulting agreement with Kristen Slaoui to provide strategic business development and transaction advisory support services.  For additional information regarding Dr. Slaoui&#8217;s consulting arrangement with us, see the section entitled &#8220;Related-Party Transactions.&#8221;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> There was no direct or indirect control by the members of the Compensation Committee of the Company. No member of the Compensation Committee, directly or indirectly, is the beneficial owner of more than 10% of the Company&#8217;s equity, nor are they an executive officer, employee, director, general partner or a managing member of one or more entities that are together the beneficial owners of more than 10% of the Company&#8217;s equity. The Compensation Committee members are not aware of any business or personal relationship between (i) a member of the Compensation Committee and any person who has provided or is providing advice to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee; and (ii) an executive officer of the Company and any firm or other person who is employed or is employing such person to provide advice to the Compensation Committee.  During fiscal year 2025, none of our executive officers served as a member of the compensation committee of any other entity, one of whose executive officers served as a member of our Board of Directors or Compensation Committee, and none of our executive officers served as a member of the Board of Directors of any other entity, one of whose executive officers served as a member of our Compensation Committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging and Pledging Prohibitions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our Insider Trading Policy, our employees (including our executive officers) and the non-employee members of our Board of Directors are prohibited from or require pre-clearance approval by our Compliance Officer before: (i) engaging in transactions involving options or other derivative securities on our securities, such as puts and calls, whether on an exchange or in any other market; (ii) engaging in hedging or monetization transactions involving our securities, such as zero-cost collars and forward sale contracts; (iii) engaging in short sales of our securities, including short sales &#8220;against the box&#8221;; and (iv) using or pledging our securities as collateral in a margin account or as collateral for a loan.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cc9f198-baa3-4908-a3b1-b82baa4b6444" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an Insider Trading Policy that governs the purchase, sale and/or other dispositions of our securities by directors, officers and employees. Our Insider Trading Policy also provides that we will not transact in any of our own securities unless in compliance with U.S. securities laws. We believe that our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the Nasdaq listing standards applicable to us. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Timing of Equity Grants</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef10b0ff-6f54-414f-b5c8-40ca8aa2d12b" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="ecd:AwardTmgMnpiDiscTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_805e1ed0-1e62-4ade-9772-91e660dba7ec" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a198bd97-8155-42b3-906c-3009440336de" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="ecd:AwardTmgMnpiCnsdrdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do not time</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equity grants to take advantage of a depressed stock price or an anticipated increase in stock price and generally grant awards in January and ensure that awards cannot be timed to take advantage of material non-public information.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e83401d-3091-4b9d-850f-3f209a613aaf" contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471" name="ecd:AwardTmgMethodTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New hire stock awards to employees, including executive officers, are generally granted at the next Board of Directors&#8217; meeting following their start date, and initial awards to non-employee directors are granted on the date of the non-employee director&#8217;s initial appointment or election to our Board of Directors.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Recovery Policy</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, our Board of Directors adopted a Compensation Recovery Policy intended to comply with applicable SEC rules and Nasdaq listing standards. The Compensation Recovery Policy is administered by our Compensation Committee and enables us to recover from current and former officers, and such additional employees as may be identified by our Compensation Committee from time to time, incentive-based compensation, as defined in the Compensation Recovery Policy, in the event of an accounting restatement resulting from material noncompliance with any financial reporting requirements under federal securities laws.  For more information, see the full text of our Compensation Recovery Policy, which is filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) Beneficial Ownership Reporting Compliance</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Such persons are also required to provide us with copies of all such reports filed with the SEC. Based solely upon the information supplied to us by these persons, we are required to report any known failure to file these reports within the specified period. To our knowledge, based solely upon a review of the Section 16(a) reports furnished to us and the written representations of these reporting persons, these persons complied with all filing requirements in a timely fashion for fiscal year 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During fiscal year 2025, our named executive officers, who are our principal executive officer and the two most highly compensated executive officers, and their respective positions were as follows:  Richard Stewart, former Chief Executive Officer, Erik Atkisson, Chief Legal Officer, and Jaime Xinos, Chief Commercial Officer (collectively referred to herein as the NEOs, or individually as an NEO).  Mr. Stewart resigned from his position as Chief Executive Officer on April 17, 2026.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information regarding the compensation of our NEOs for each of the fiscal years ended December 31, 2025 and 2024.  The components of the compensation reported in the Summary Compensation Table are described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:25.77%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:4.322%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.643%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.863%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.963%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.623%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.983%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.321%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and<br/>Principal Position</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary<br/>($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Equity<br/>Incentive<br/>Plan<br/>Compensation<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other Compensation ($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart,</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">615,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522,900</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">230,625</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,368,525</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Former Chief Executive Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">509,879</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">637,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">206,420</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">382,253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,735,552</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Erik Atkisson</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,255</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">853,148</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">983,403</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jaime Xinos,</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,601</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944,601</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Commercial Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">414,166</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,950</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,854</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,056,470</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dollar amounts in this column reflect the aggregate grant date fair value of performance-based restricted stock units, or PSUs, granted during the fiscal year in accordance with Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718 for stock-based compensation, based upon the probable outcome of the performance conditions as of the grant date.  The assumptions used in calculating the grant date fair value of the stock options reported in the Option Awards column are set forth in Note 10 to the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.  These amounts do not correspond to the actual cash value that will be recognized by each of the NEOs when received.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dollar amounts in this column reflect the aggregate grant date fair value of shares of common stock subject to stock options granted during the fiscal year in accordance with FASB ASC Topic 718 for stock-based compensation.  These amounts do not correspond to the actual cash value that will be recognized by each of the NEOs when received.  For a discussion of the assumptions and methodologies used to value the awards reported in this column, see Note 10 to our audited consolidated financial statements, which are included in our Annual Report on Form 10-K for the year ended December 31, 2025. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dollar amounts in this column reflect the aggregate non-equity incentive plan compensation earned by each NEO in 2025 and paid in early 2026.  For more information, see &#8220;&#8212;2025 Bonuses&#8221; below.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Atkisson's employment commenced in October 2025.  The dollar amount in this column reflects his 2025 pro-rated salary.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Compensation Philosophy and 2025 Executive Compensation Program</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Compensation Committee has adopted a pay for performance philosophy.  We do not have any formal policies for allocating compensation among salary, annual cash incentive awards and long-term incentive equity grants, short- and long-term compensation or among cash and non-cash compensation.  Instead, our Compensation Committee and our Board of Directors exercise judgment to establish a total compensation program for each NEO that is a mix of current, short- and long-term incentive compensation, and cash and non-cash compensation, that our Compensation Committee and Board of Directors believe is appropriate to achieve the goals of our executive compensation program and our corporate objectives.  In setting the elements of compensation, our Compensation Committee considers prior compensation paid and amounts realizable from prior stock-based awards, as well as other benefits provided by the Company.  Our 2025 executive compensation program was designed to motivate our executive officers to achieve key business goals and objectives by linking their performance and the Company&#8217;s performance to the compensation our executive officers receive. As such, we intend for a significant portion of the total compensation of our executive officers to be based on measures that support our Company goals and objectives over both the long and short term. To strengthen this link, we define clear and measurable quantitative objectives that are designed to foster achievement of results and returns to stockholders. Our Compensation Committee undertakes to maintain an overall compensation structure designed to attract, retain and motivate management and employees by providing appropriate incentives based on individual contribution and performance and avoiding undue emphasis on short-term market value.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Compensation Committee engages the services of Aon Human Capital Solutions practice, a division of Aon plc, or Aon, to assist with ensuring that the goals of the compensation program are met and is consistent with the compensation of companies that are similar in size, stage of development and complexity as our Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each compensation element is discussed in more detail below and in the section titled "Summary Compensation Table" above and "Outstanding Equity Awards at Fiscal Year-End" below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Base Salary</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base salaries for executive officers are reviewed annually in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels for similar positions at peer companies after taking into account individual responsibilities, performance, experience and other factors. Our Compensation Committee reviews competitive market data prepared by Aon when determining base salaries of our NEOs.  Base salaries are targeted to approximately the 50</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentile range of comparable peer companies in aggregate.  Salary increases are recommended to, and approved at the discretion of, the Board of Directors. The following table shows the annual base salaries for 2024 and 2025 for our named executive officers:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:62.68%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.28%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.28%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025 Base Salary ($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024 Base Salary ($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">615,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">615,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Erik Atkisson</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">440,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jaime Xinos</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Equity Awards</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity awards are granted to executive officers at the discretion of the Compensation Committee. Our Compensation Committee reviews competitive market data prepared by Aon in connection with its grant of long-term equity incentive awards to the named executive officers at the market 50</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to 75</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentile which is a higher target than our cash compensation to provide economic value as we are a clinical development-stage specialty pharmaceutical company and have not generated revenue to date. A blended approach of options and PSUs were awarded to attract and retain highly skilled employees and provide long term incentive and performance-based goals which we believe are aligned with motivating our NEOs to enhance stockholder value.  Our Compensation Committee believes that this mix of stock options and PSUs is appropriate given the Company's stage of development and the Company's pay for performance philosophy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, the Compensation Committee granted options to purchase 67,500 shares of common stock to Richard Stewart, and 20,000 shares of common stock to Jaime Xinos.  The stock options have an exercise price of $3.32 per share, which was the closing price of our stock on the date of grant, and vest for Mr. Stewart as to one-third of the total on August 26, 2025, and thereafter vest in equal monthly installments over 24 months; and vest for Ms. Xinos as to one-fourth of the total on December 6, 2025, and thereafter vest in equal monthly installments over 36 months.  The Compensation Committee also granted 157,500 PSUs to Richard Stewart that vested as to 100% on the acceptance of our New Drug Application, or NDA, for cytisinicline with the U.S. Food and Drug Administration, or FDA and 100,000 PSUs to Ms. Xinos that vested as to 20% on the acceptance of our NDA for cytisinicline with the FDA; 80% on the FDA approval of the NDA; or 100% upon consummation of a corporate transaction, in each case within the applicable performance period specified in the award agreement.  The Compensation Committee determined these goals were rigorous, but achievable, and as the NDA submission and acceptance is our next pivotal stage for the advancement of cytisinicline, will provide value to our stockholders and reflect our commitment to move cytisinicline to commercialization.  In December 2025, the Compensation Committee granted an option to purchase 250,000 shares of common stock to Erik Atkisson as an inducement to his employment.  The stock options have an exercise price of $4.78 per share, which was the closing price of our stock on the date of grant, and vest as to one-fourth on October 20, 2026, and thereafter vest in equal monthly installments over 36 months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Bonuses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual cash bonuses for our executive officers are based on the achievement of corporate performance objectives that our Compensation Committee determined were rigorous, but achievable.  In 2025, these goals included the achievement of an NDA submission accepted by the FDA for filing, CMC and commercial readiness activities for cytisinicline launch, and stretch goals that would have significant US public health impact.  Our Compensation Committee determined that in aggregate, 75% of our 2025 corporate performance objectives were achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the payment of these bonuses, Mr. Stewart&#8217;s target bonus was equal to 50% of his annual base salary of $615,000 and Ms. Xinos&#8217; target bonus was equal to 40% of her annual base salary of $450,000.  Mr. Atkisson commenced</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employment in October 2025 and was not eligible for a bonus.  The aggregate 2025 non-equity incentive compensation awarded to each of these individuals is equal to 75% of their target bonus, which reflects the achievement level of our 2025 corporate goals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year-End</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding the outstanding equity awards held by the NEOs as of December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:11.475%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.457%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.457%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.457%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.057%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.599%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.057%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.279%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.457%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.057%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.599%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.057%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">OPTION AWARDS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="15" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STOCK AWARDS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#) Exercisable</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(#) Unexercisable</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Exercise<br/>Price<br/>($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Expiration<br/>Date</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Unearned<br/>Shares, Units<br/>or Other<br/>Rights that<br/>Have Not<br/>Vested (#)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market Value<br/>of Unearned<br/>Shares, Units,<br/>or Other<br/>Rights that<br/>Have Not<br/>Vested ($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares or<br/>Units or<br/>Other Rights<br/>that Have<br/>Not Vested(#)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market Value<br/>of Shares or<br/>Units or Other<br/>Rights <br/>that Have<br/>Not Vested<br/>($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart,</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,600</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/26/28</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Former Chief Executive</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,050</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/20/28</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,750</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/29/29</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,250</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/29/29</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/28/30</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/16/30</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.09</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/26/31</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.26</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/03/32</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,917</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,083</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.90</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/25/33</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,333</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,667</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.55</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/22/34</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372,750</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Erik Atkisson,</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.78</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/04/35</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Legal Officer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jaime Xinos,</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,370</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">578.00</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">08/01/27</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13)</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Commercial</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">07/26/28</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officer</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,850</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">09/20/28</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/29/29</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.40</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/29/29</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/28/30</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/16/30</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.09</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/26/31</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.26</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/03/32</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,597</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">903</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.90</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/25/33</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,583</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.55</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/22/34</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.52</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/06/34</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.32</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">01/13/35</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,525</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,600</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2017 Equity Incentive Plan and were fully vested on July 26, 2022. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on September 20, 2022.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on January 29, 2023.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and vested on June 12, 2021.  </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on January 28, 2024.  </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on June 30, 2023.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on January 26, 2025. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and were fully vested on January 3, 2025.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and vested as to one-third on January 25, 2024 and then vest monthly over a 24-month period.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and vested as to one-third on January 22, 2025 and then vest monthly over a 24-month period.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These PSUs were granted under the 2018 Equity Incentive Plan and vest as to 50% upon the filing of a NDA for cytisinicline with the FDA, within the applicable performance period specified in the award agreements, and 50% upon FDA acceptance of the NDA within 60 days of submission; or 100% upon either marketing approval of cytisinicline by the FDA or an acquisition of us occurring within the applicable performance period specified in the award agreements.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2024 Equity Inducement Plan and vest as to one-fourth on October 20, 2026 and then vest monthly over a 36-month period.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2017 Equity Incentive Plan and were fully vested on August 15, 2021.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and vest as to one-fourth on December 6, 2025 and then vest monthly over a 36-month period.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These stock options were granted under the 2018 Equity Incentive Plan and vest as to one-fourth on December 6, 2025 and then vest monthly over a 36-month period.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(16)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These PSUs were granted under the 2018 Equity Incentive Plan and vest as to 20% upon the acceptance of a NDA for cytisinicline by the FDA; and 80% upon approval of cytisinicline for smoking cessation by FDA.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potential Payments Upon Termination/Change of Control</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control Under Our Equity Compensation Plans</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion sets forth the change of control provisions provided for in our various equity compensation plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2017 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2017 Equity Incentive Plan, or the 2017 Plan, unless otherwise determined by our Compensation Committee, all outstanding awards will be subject to the agreement governing the change of control transaction. Such agreement need not treat all such awards in an identical manner, and it will provide for one or more of the following with respect to each award: the continuation of the award, the assumption of the award, the substitution of the award, the full or partial acceleration of the award, the settlement of the award in cash, cash equivalents or securities of the successor entity (or its parent, if any) or the cancellation of the award in exchange for no consideration. In the event the successor corporation in the change of control transaction refuses to either assume, convert, replace or substitute awards, then our Compensation Committee will notify the award holder in writing or electronically that such award will be exercisable for a period of time determined by our Compensation Committee (in its sole discretion) and that the award will terminate upon expiration of such period. Upon the effectiveness of our 2018 Equity Incentive Plan, we ceased granting equity awards under our 2017 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the event of a change of control, the vesting of all awards granted to our non-employee directors shall accelerate and any stock option shall become exercisable (as applicable) in full as of the time of consummation of such change in control transaction.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2018 Equity Incentive Plan, unless otherwise determined by our Compensation Committee, all outstanding awards will be subject to the agreement governing the change of control transaction. Such agreement need not treat all such awards in an identical manner, and it will provide for one or more of the following with respect to each award: the continuation of the award, the assumption of the award, the substitution of the award, the full or partial acceleration of the award, the settlement of the award in cash, equivalents or securities of the successor entity (or its parent, if any) or the cancellation of the award in exchange for no consideration. In the event the successor corporation in the change of control transaction refuses to either assume, convert, replace or substitute awards, then our Compensation Committee will notify the award holder in writing or electronically that such award will be exercisable for a period of time determined by our Compensation Committee (in its sole discretion) and that the award will terminate upon expiration of such period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the event of a change of control, the vesting of all awards granted to our non-employee directors shall accelerate and any stock options shall become exercisable in full as of the time of consummation of such change in control transaction.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 Non-Employee Director Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2023 Non-Employee Director Equity Incentive Plan, unless otherwise determined by our Compensation Committee, all outstanding awards will be subject to the agreement governing such change of control transaction. Such agreement need not treat all such awards in an identical manner, and it will provide for one or more of the following with respect to each award: the continuation of the award, the assumption of the award, the substitution of the award, the settlement of the award in cash, equivalents or securities of the successor entity (or its parent, if any).  In addition, in the event of a change of control, the vesting of all awards granted to our non-employee directors shall accelerate and any stock options shall become exercisable in full as of the time of consummation of such change in control transaction.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination and Change of Control Provisions Under Employment Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, we had at-will employment agreements in place with each of our NEOs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that provided for compensation upon the termination of their employment under certain circumstances, as described below.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stewart Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our agreement (through a United Kingdom subsidiary) with Richard Stewart, referred to as the Stewart Agreement, provided Mr. Stewart with termination benefits in the event of a Qualifying Termination, which is a termination without cause or for good reason (each as defined in the Stewart Agreement), provided that, in the case of termination for good reason, Mr. Stewart provided us within 60 days of becoming aware of conditions giving rise to a good reason written notice and an opportunity to cure such breach within 30 days of being served the notice.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Stewart Agreement provided that if a Qualifying Termination occurred, we were obligated to pay Mr. Stewart a lump sum payment equal to 18 months of his then-current base salary and continue paying his monthly health insurance premiums for a period determined by us, not to exceed the applicable COBRA continuation period.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, if there was a Qualifying Termination, each of Mr. Stewart&#8217;s then outstanding equity awards, including awards that would otherwise vest only upon satisfaction of performance criteria, accelerated and became vested and exercisable as to an additional 18 months as if Mr. Stewart had continued in employment for 18 months following his Qualifying Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Stewart Agreement provided for specific termination benefits upon a Qualifying Termination that occurred within 12 months after the Company was subject to a corporate transaction, or Corporate Qualifying Termination.  Upon such a Corporate Qualifying Termination, we would be obligated to pay Mr. Stewart a lump sum equal to (i) his monthly salary at the rate in effect immediately prior to the termination multiplied by 24, plus (ii) 100% of his target annual bonus for the year during which the termination occurred.  In addition, we would be obligated to continue payment of his health insurance premiums for a period determined by us, not to exceed the applicable COBRA continuation period, subject to certain limitations.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, upon a Corporate Qualifying Termination, each of Mr. Stewart&#8217;s then outstanding equity awards, including awards that would otherwise vest only upon satisfaction of performance criteria, would accelerate and become vested and exercisable as to 100% of the then unvested shares subject to the equity award, effective as of Mr. Stewart&#8217;s separation from service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 15, 2026, Mr. Stewart informed our Board of Directors of his intention to step down from his position as our Chief Executive Officer and President, effective as of April 18, 2026 (the &#8220;Separation Date&#8221;). In connection with his separation, we and Mr. Stewart expect to enter into a Settlement Agreement (the &#8220;Separation Agreement&#8221;) that provides for payment consistent with the terms of the Stewart Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All termination benefits in the event of a Qualifying Termination or a Corporate Qualifying Termination are subject to Mr. Stewart&#8217;s execution, delivery and non-revocation of a general release of all litigation and other claims against us and our affiliates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Atkisson Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our agreement with Erik Atkisson, referred to as the Atkisson Agreement, provides Mr. Atkisson with termination benefits in the event of an Involuntary Termination, which is a termination without cause, a resignation for good reason or a termination for disability (each as defined in the Atkisson Agreement), provided that, in the case of termination for good reason, Mr. Atkisson has provided us with 30 days&#8217; advance written notice and an opportunity to cure such breach during such 30-day period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Atkisson Agreement provides that if an Involuntary Termination occurs, we will be obligated to pay Mr. Atkisson a lump sum payment equal to 12 months of his then-current base salary.  In addition, if Mr. Atkisson elects to continue his and his dependents&#8217; health insurance coverage under COBRA, we must pay up to 12 months of Mr. Atkisson's monthly premium under COBRA.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, if there is an Involuntary Termination, then the time-based vesting restrictions, if any, will immediately lapse on an additional number of shares under all of Mr. Atkisson&#8217;s outstanding compensatory equity awards, which includes outstanding stock options granted to Mr. Atkisson under our equity compensation plans, that would have time-vested if Mr. Atkisson had continued in employment for 12 months following his Involuntary Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Atkisson Agreement provides for specific termination benefits if an Involuntary Termination occurs during the period beginning three months before and ending 12 months after a change in control or if such Involuntary Termination is required by the merger agreement, purchase agreement or other instrument relating to such change in control, or such Involuntary Termination is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made at the express request of the other party or parties to the transaction constituting such change in control, each of which events is referred to as a Change in Control Termination.  Upon such a Change in Control Termination, we will be obligated to pay Mr. Atkisson 24 months of his then-current base salary, plus a sum equal to 24 months of his average monthly bonus earnings, where such average is calculated over the 24-month period immediately preceding Mr. Atkisson's separation from services and based on Mr. Atkisson's bonuses paid in such 24-month period.  In addition, our payment of monthly COBRA premiums as described above will be for up to 24 months instead of up to 12 months.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, upon a Change in Control Termination, all vesting restrictions, if any, including performance vesting restrictions, will immediately lapse on all of Mr. Atkisson's compensatory equity effective as of his separation from service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All termination benefits in the event of an Involuntary Termination or Change in Control Termination are subject to Mr. Atkisson's execution, delivery and non-revocation of a general release of all litigation and other claims against us and our affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xinos Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our agreement with Jaime Xinos, referred to as the Xinos Agreement, provides Ms. Xinos with termination benefits in the event of an Involuntary Termination, which is a termination without cause, a resignation for good reason or a termination for disability (each as defined in the Xinos Agreement), provided that, in the case of termination for good reason, Ms. Xinos has provided us with 30 days&#8217; advance written notice and an opportunity to cure such breach during such 30-day period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Xinos Agreement provides that if an Involuntary Termination occurs, we will be obligated to pay Ms. Xinos a lump sum payment equal to 12 months of her then-current base salary.  In addition, if Ms. Xinos elects to continue her and her dependents&#8217; health insurance coverage under COBRA, we must pay up to 12 months of Ms. Xinos&#8217; monthly premium under COBRA.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, if there is an Involuntary Termination, then the time-based vesting restrictions, if any, will immediately lapse on an additional number of shares under all of Ms. Xinos&#8217; outstanding compensatory equity awards, which includes outstanding stock options granted to Ms. Xinos under our equity compensation plans, that would have time-vested if Ms. Xinos had continued in employment for 12 months following her Involuntary Termination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Xinos Agreement provides for specific termination benefits if an Involuntary Termination occurs during the period beginning three months before and ending 12 months after a change in control or if such Involuntary Termination is required by the merger agreement, purchase agreement or other instrument relating to such change in control, or such Involuntary Termination is made at the express request of the other party or parties to the transaction constituting such change in control, each of which events is referred to as a Change in Control Termination.  Upon such a Change in Control Termination, we will be obligated to pay Ms. Xinos 24 months of her then-current base salary, plus a sum equal to 24 months of her average monthly bonus earnings, where such average is calculated over the 24-month period immediately preceding Ms. Xinos&#8217; separation from services and based on Ms. Xinos&#8217; bonuses paid in such 24-month period.  In addition, our payment of monthly COBRA premiums as described above will be for up to 24 months instead of up to 12 months.  Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, upon a Change in Control Termination, all vesting restrictions, if any, including performance vesting restrictions, will immediately lapse on all of Ms. Xinos&#8217; compensatory equity effective as of her separation from service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All termination benefits in the event of an Involuntary Termination or Change in Control Termination are subject to Ms. Xinos&#8217; execution, delivery and non-revocation of a general release of all litigation and other claims against us and our affiliates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The charter of the Compensation Committee provides that the Compensation Committee is to recommend to the Board of Directors matters related to director compensation.  The director compensation package for non-employee directors consists of annual cash compensation and stock options exercisable to purchase shares of our common stock.  None of our employees who also serve as directors are entitled to receive compensation for service as a director.  Therefore, Richard Stewart did not receive compensation for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">his service as a director and during his employment as Chief Executive Officer, and Cindy Jacobs did not receive compensation for her service as a director during her employment as President and Chief Medical Officer.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Compensation Policy</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 Director Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of its evaluation of compensation levels for the 2025 fiscal year, the Compensation Committee recommended, and the Board of Directors approved, the retention of Aon to review compensation levels of our independent directors and committee members.  Aon was instructed to benchmark and make recommendations regarding the annual retainer amounts for directors and chairpersons of the Board of Directors and the various committees, as well as the amounts and terms of initial and annual long-term equity incentive awards for directors.  On recommendation by Aon in 2024, the equity compensation and cash compensation for non-employee directors in connection with their service on the Board of Directors in 2025 is as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An annual retainer of $60,000 to be paid to the Lead Independent Director and $40,000 to be paid to all other non-employee directors.  These retainers were paid in quarterly installments, with the Lead Independent Director retainer paid to Mr. King between August 2024 to June 2025 when he served as Interim Executive Chairman.  Each quarterly payment was conditioned on the director remaining a director on the date of actual payment, which was typically within 10 days following the completion of the respective calendar quarter.  Retainers are pro-rated for the portion of the year during which a director was on the Board of Directors.  These annual retainers have remained the same since 2017.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional annual cash compensation for the chairpersons and members of each committee as set forth in the following table, are the same as the previous year, and are paid on the same schedule and terms as the non-employee director compensation described above:</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:56.28%;box-sizing:content-box;"/>
     <td style="width:2.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:17.959999999999997%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.959999999999997%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chairperson</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other Members</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nominating and Governance Committee</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any new director would have received a one-time initial grant of a stock option to acquire 47,250 shares of our common stock upon becoming a director, which would vest monthly over three years from the date of grant, subject to continued service as a director.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, each director then seated received a grant of a stock option to acquire 31,500 shares of our common stock, with 100% vesting on the earlier of June 6, 2026 or the date immediately prior to our 2026 annual meeting of stockholders, subject to the grantee&#8217;s continued service as a director.  </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director Compensation Paid for 2025</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes all compensation earned or awarded to non-employee directors who served during 2025 as compensation for board service during the 2025 fiscal year.  Mr. King became a non-employee director and independent Chairman of the Board in June 2025 following his time as Interim Executive Chairman.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:32.226%;box-sizing:content-box;"/>
     <td style="width:1.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.2%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.743%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.803%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees Earned or<br/>Paid in Cash</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option Awards</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All other compensation</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">($)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stuart Duty</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,930</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140,430</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas B. King</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,286</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,930</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,216</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vaughn Himes</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridget Martell</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,750</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,930</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,680</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas Sellig</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,930</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,430</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy Phelan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,845</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,262</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kristen Slaoui</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,083</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,845</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">259,928</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dollar amounts reflect the aggregate grant date fair value of equity awards granted within the fiscal year in accordance with FASB ASC Topic 718 for stock-based compensation.  These amounts do not correspond to the actual cash value that will be recognized by the directors when received.  Assumptions used in the calculation of the amounts in this column are included in Note 10 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.  As of December 31, 2025, the following directors had the following numbers of options outstanding: </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stuart Duty: options to purchase 110,250 shares of our common stock, of which 74,813 were vested as of December 31, 2025.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thomas B. King: options to purchase 110,250 shares of our common stock, of which 74,813 were vested as of December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bridget Martell: options to purchase 104,550 shares of our common stock, of which 73,050 were vested as of December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thomas Sellig: options to purchase 110,250 shares of our common stock, of which 74,813 were vested as of December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nancy R. Phelan: options to purchase 78,750 shares of our common stock, of which 14,438 were vested as of December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kristen Slaoui: options to purchase 78,750 shares of our common stock, of which 14,438 were vested as of December 31, 2025.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options to purchase an aggregate of 189,000 shares of our common stock were granted on June 6, 2025 to each of Messrs. Duty, King, and Sellig, Drs. Martell and Slaoui, and Ms. Phelan under our 2018 Equity Incentive Plan.  The shares subject to these options will vest 100% on June 6, 2026.  Options to purchase an aggregate of 94,500 shares of our common stock were granted on January 13, 2025 to each of Ms. Phelan and Dr. Slaoui under our 2018 Equity Incentive Plan and vest over 36 months commencing January 6, 2025.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. King received compensation as a director commencing June 2025 following his employment as Interim Executive Chairman.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Himes resigned as a member of the Board of Directors in January 2025.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Slaoui received compensation pursuant to a consulting agreement entered into with us in 2025.  For additional information regarding Dr Slaoui's consulting arrangement with us, see the section entitled &#8220;Related-Party Transactions.&#8221;</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain_b"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth certain information with respect to the beneficial ownership of our common stock by the following persons as of April 20, 2026, except as otherwise noted in the footnotes to the table:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each person, entity or group who we know to beneficially own five percent or more of our voting securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each of our NEOs identified in the Summary Compensation Table; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all of our directors and executive officers as a group. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address of each beneficial owner listed in the table is c/o Achieve Life Sciences, Inc., 22722 29</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Drive SE, Suite 100, Bothell, Washington 98021.  The percentages in the table below are based on 102,659,057 shares of our common stock outstanding as of April 20, 2026.  Except as indicated in the footnotes to the table and pursuant to applicable community property laws, to our knowledge, each stockholder named in the table has sole voting and investment power with respect to the shares set forth opposite such stockholder&#8217;s name.  The information provided in the table is based on our records and information filed with the SEC, unless otherwise noted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.967%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.357%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.357%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Beneficial Owner</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount and<br/>Nature of<br/>Beneficial<br/>Ownership</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percent of<br/>Class(%)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">5% or Greater Stockholders:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">venBio Global Strategic Fund V, L.P.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,163,246</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paradigm BioCapital International Fund Ltd.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,903,712</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.65</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Franklin Resources, Inc.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,294,915</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.08</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Frazier Life Sciences </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,464,836</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.27</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TPG LSI Rise Auriga L.P.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877,580</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.70</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Venrock Healthcare Capital Partners III, L.P.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,502,064</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Named Executive Officers and Directors:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Erik Atkisson</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stuart Duty</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,250</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Goldberg</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lucian Iancovici</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas B. King</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">425,392</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridget Martell</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,550</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy R. Phelan</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,813</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Royston</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas Sellig</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,250</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kristen Slaoui</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(12)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,813</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(13)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">506,933</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jaime Xinos</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(14)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,735</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All current officers and directors as a group (16 persons)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(15)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,988,711</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Less than 1%</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.  Shares of common stock subject to options, common warrants and pre-funded warrants currently exercisable, or exercisable within 60 days of April 20, 2026, are deemed outstanding for computing the percentage of the person holding such options, common warrants or pre-funded warrants but are not deemed outstanding for computing the percentage of any other person.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Schedule 13D filed by venBio Global Strategic Fund V, L.P. ("venBio Fund") and venBio Global Strategic GP V, LLC ("General Partner V"), venBio Fund entered into a securities purchase agreement on April 15, 2026 and directly holds 5,914,720 shares of common stock. In addition to the aforementioned securities, venBio Fund owns an aggregate of 4,822,597 shares of common stock that venBio Fund has the right to acquire within 60 days upon exercise of common warrants. As reported in the statement, the common warrants are subject to a beneficial ownership limitation, such that the holders may not exercise the warrants to the extent such exercise would result in the holders or any member of the holder&#8217;s Section 13(d) affiliate &#8220;group&#8221; beneficially owning more than 9.99% of our common stock. In this regard, the beneficial ownership reflected in the table above includes an aggregate of 4,248,526 shares underlying common warrants that are held by venBio Fund and are deemed exercisable for shares of common stock within the beneficial ownership limitation, and it excludes an aggregate of 574,071 shares underlying such common warrants. Aaron Royston, a member of our board of directors, Robert Adelman and Corey Goodman are each a member of General Partner V and may be deemed to share voting and dispositive power over the shares held by venBio Fund.  The address is 1700 Owens Street, Suite 595, San Francisco, CA 94158.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on a Schedule 13G filed by Paradigm BioCapital Advisors LP (the "Adviser"), Paradigm BioCapital Advisors GP LLC (the "Adviser GP"), Senai Asefaw, M.D. ("Senai Asefaw"), and Paradigm BioCapital International Fund Ltd. (the "Fund").  The Fund is a private investment vehicle.  The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the common stock as reported. The Fund beneficially owns 4,343,768 shares of common stock and an additional 4,343,768 shares of common stock underlying common warrants and the Account beneficially owns 608,088 shares of common stock and an additional 608,088 shares of common stock underlying the common warrants.  The Adviser is the investment manager of the Fund and the Account.  The Adviser GP is the general partner of the Adviser.  Senai Asefaw is the managing member of the Adviser GP.  The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the common stock directly beneficially owned by the Fund and the Account.  The address of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands.  The address of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based together on the investment in our April 2026 private placement described under the heading "Certain Relationships and Related Transactions, and Director Independence&#8212;Sales of Securities&#8212;April 2026 Private Placement" and on a Schedule 13G filed by Franklin Resources, Inc. ("FRI"); Charles B. Johnson ("C. Johnson"); Rupert H. Johnson, Jr. ("R. Johnson"); and Franklin Advisers, Inc.  Franklin Advisers, Inc. owns 6,369,193 shares of common stock which includes 2,000,000 shares of common stock issuable on the exercise of common warrants. C. Johnson and R. Johnson may each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. The securities reported are beneficially owned by one or more open or closed end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries of FRI.  The investment management subsidiaries may be deemed to be the beneficial owners in this Schedule 13G.  The address for FRI is One Franklin Parkway, San Mateo, CA 94403-1906.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on a Schedule 13G filed by Frazier Life Sciences Public Fund, L.P. ("FLSPF"); FHMLSP, L.P.; FHMLSP, L.L.C.; Frazier Life Sciences XI, L.P. ("FLS XI"); FHMLS XI, L.P.; FHMLS XI, L.L.C.; Frazier Life Sciences XII, L.P. ("FLS XII"); FHMLS XII, L.P.; FHMLS XII, L.L.C.  FLSPF directly holds 6,625,788 shares of common stock, pre-funded warrants to purchase 89,204 shares of common stock and common warrants to purchase 6,714,992 shares of common stock, FLS XI directly holds 61,958 shares of common stock, pre-funded warrants to purchase 834 shares of common stock and common warrants to purchase 62,792 shares of common stock, and FLS XII directly holds 777,090 shares of common stock, pre-funded warrants to purchase 10,462 shares of </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock and common warrants to purchase 787,552 shares of common stock. As reported in the statement, the common warrants and pre-funded warrants are subject to a beneficial ownership limitation, such that the holders may not exercise the common warrants or pre-funded warrants to the extent such exercise would result in the holders or any member of the holder&#8217;s Section 13(d) affiliate &#8220;group&#8221; (as such term is used in Rule 13d-5 of the Exchange Act) beneficially owning more than 9.99% of our common stock.  FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote.  Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF.  FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote.  Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI.  FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. The address for each of the reporting persons is c/o Frazier Life Sciences Management, L.P., 1001 Page Mill Rd, Building 4, Suite 200B, Palo Alto, CA 94304.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based solely on the investment in our April 2026 private placement described under the heading "Certain Relationships and Related Transactions, and Director Independence&#8212;Sales of Securities&#8212;April 2026 Private Placement."  The common warrants are subject to a beneficial ownership limitation, such that the holders may not exercise the warrants to the extent such exercise would result in the holders or any member of the holder&#8217;s Section 13(d) affiliate &#8220;group&#8221; beneficially owning more than 19.99% of our common stock.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on a Schedule 13G filed by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"); VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III"); Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG"); VHCP Management III, LLC (VHCP Management III"); VHCP Management EG, LLC ("VHCP Management EG"); Nimish Shah ("Shah"); and Bong Y. Koh ("Koh").  The reporting persons' ownership consists of (i) 1,843,960 shares of common stock and common warrants immediately exercisable for up to 1,843,960 shares of common stock held by VHCP III, (ii) 184,376 shares of common stock and common warrants immediately exercisable for up to 184,376 shares of common stock held by VHCP Co-Investment III, and (iii) 722,696 shares of common stock and common warrants immediately exercisable for up to 722,696 shares of common stock held by held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.  As reported in the statement, the warrants are subject to a beneficial ownership limitation, such that the holders may not exercise the warrants to the extent such exercise would result in the holders or any member of the holder&#8217;s Section 13(d) affiliate &#8220;group&#8221; (as such term is used in Rule 13d-5 of the Exchange Act) beneficially owning more than 9.99% of our common stock.  The New York address is 7 Bryant Park, 23rd Floor, New York, NY 10018 and the Palo Alto address is 3340 Hillview Avenue Palo Alto, CA 94304.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents options to purchase 110,250 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 315,142 shares of common stock owned directly, and options to purchase 110,250 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents options to purchase 104,550 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents options to purchase 53,813 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(11)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents options to purchase 110,250 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(12)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents options to purchase 53,813 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(13)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 228,875 shares of common stock owned directly, common warrants to purchase 10,000 shares of our common stock, options to purchase 266,817 shares of our common stock exercisable within 60 days of April 20, 2026, and 359 shares owned indirectly by his spouse, and 882 shares owned indirectly through Ricanto Limited, of which Mr. Stewart is the principal owner.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(14)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents 74,432 shares of common stock owned directly, and options to purchase 143,303 shares of our common stock exercisable within 60 days of April 20, 2026.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(15)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents for the current officers and directors as a group, 882,296 shares of common stock owned directly or indirectly as indicated above, and options to purchase 1,106,415 shares of common stock exercisable within 60 days of April 20, 2026.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth certain information regarding our equity compensation plans as of December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44.542%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.674%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.719%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.194%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.674%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.719%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">remaining available for</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities to be</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">future issuance under</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">issued upon exercise of</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">equity compensation</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">outstanding options,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">exercise price of</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">plans (excluding</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">restricted stock units,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">outstanding options,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">securities reflected in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan category</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">warrants and rights</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">warrants and rights</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">column (a))</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,052,541</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.04</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">160,164</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security<br/>&#160;&#160;&#160;holders</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">762,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.58</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">445,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,814,541</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.08</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">605,164</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we maintained the following equity compensation plans, which were approved by security holders: (a) the 2010 Performance Incentive Plan, (b) the 2017 Equity Incentive Plan, (c) the 2018 Equity Incentive Plan and (d) the 2023 Non-Employee Director Equity Incentive Plan. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under our 2024 Equity Inducement Plan as inducements to new employees for entering into employment agreements with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For descriptions of the 2010 Performance Incentive Plan, the 2017 Equity Incentive Plan, the 2018 Equity Incentive Plan and the 2023 Non-Employee Director Equity Incentive Plan, see Note 10 to the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item13"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than compensation arrangements for our directors and named executive officers, or NEOs, which are described in &#8220;Item 10. Directors, Executive Officers and Corporate Governance&#8221; and &#8220;Item 11. Executive Compensation&#8221;, below we describe transactions since January 1, 2025 to which we were a party or will be a party, in which:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amounts involved exceeded or will exceed $120,000; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related-Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for reviewing and approving all related-party transactions and conflict of interest situations involving a principal stockholder, a member of the Board of Directors or senior management. From September 25, 2025 to December 22, 2025, we entered into three development agreements, or the Adare Agreements, with Adare Pharma Solutions, or Adare, to perform analytical and drug product development for cytisinicline. Thomas Sellig is the current Chief Executive Officer of Adare. Mr. Sellig is also a member of our Board of Directors, chairs the Compensation Committee and is a member of the Audit Committee.  Mr. Sellig was recused from our Audit Committee's review and approval of the Adare Agreements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to incur approximately $3.2 million in expenses over the term of the Adare Agreements. Adare will invoice us for work completed under the agreements based on standard industry payment terms. Pursuant to the Adare Agreements, from January 1, 2025 to April 20, 2026, we have paid approximately $0.5 million to Adare, which does not exceed 5% of Adare&#8217;s consolidated gross revenues pursuant to Nasdaq Rule 5605(a)(2)(E).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 10, 2025, we entered into a consulting agreement with Kristen Slaoui to provide strategic business development and transaction advisory support services, pursuant to which Dr. Slaoui received $8,250 per month in compensation. Dr. Slaoui is a member of our Board of Directors, our Compensation Committee and our Nominating and Governance Committee.  We incurred consulting fees from Dr. Slaoui of $13,750 for the year ended December 31, 2025.  As of December 31, 2025, we recorded amounts payable to Dr. Slaoui of $8,250 in accounts payable and $5,500 in accrued liabilities on our balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of Securities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 2025 Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 26, 2025, we entered into an underwriting agreement, or Underwriting Agreement, with Citizens JMP Securities, LLC and Raymond James &amp; Associates, Inc., or the Underwriters, as representatives of the underwriters, pursuant to which we agreed to issue and sell to the Underwriters 15,000,000 shares of our common stock, and accompanying common warrants to purchase up to 15,000,000 shares of common stock or pre-funded warrants to purchase shares of our common stock in lieu thereof.  The shares and accompanying warrants were sold collectively at a public offering price of $3.00 per share and accompanying warrant.  Each accompanying warrant is exercisable, at the purchaser&#8217;s election, for either warrant shares at an exercise price of $3.00 per share or for pre-funded warrants at an exercise price of $2.999 per pre-funded warrant. The accompanying warrants are exercisable any time after the date of issuance, subject to certain ownership limitations, and will expire on the fifth anniversary of the date of issuance.  The June 2025 public offering raised total gross proceeds of approximately $45.0 million, and after deducting approximately $3.8 million in underwriting discounts and offering expenses, we received net proceeds of approximately $41.2 million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the June 2025 public offering, on June 30, 2025, (a) Franklin Advisers, Inc. purchased 2,000,000 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $6,000,000; and (b) Alyeska Investment Group, L.P. purchased 2,333,333 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $6,999,999.  The terms of such parties' participation in the offering were identical to those available to all other investors in the offering.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2026 Private Placement</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 15, 2026, we entered a securities purchase agreement with certain institutional and accredited investors, pursuant to which we agreed to issue and sell to the investors in a private placement an aggregate of (i) 49,418,069 shares of our common stock, and, in lieu of shares for an investor, pre-funded warrants to purchase up to 100,500 shares of our common stock, and (ii) accompanying warrants to purchase up to 49,518,569 shares of our common stock or pre-funded warrants to purchase our common stock at a collective purchase price of (a) $3.635 per combination of shares and accompanying common warrants or (b) $3.634 per combination of pre-funded warrants and accompanying common warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each pre-funded warrant has an exercise price of $0.001 per share of common stock. The pre-funded warrants are exercisable at any time after their original issuance, subject to certain ownership limitations, and will not expire. Each common warrant will be exercisable at an exercise price of $3.51 per share of common stock. The common warrants are exercisable at any time after the date of issuance, subject to certain ownership limitations, and will expire on the later of the twentieth business day following (i) the date on which we publicly announce that the U.S. Food and Drug Administration has approved cytisinicline for smoking cessation in adults, or the FDA Approval, and (ii) the date on which we notify the holders of the FDA Approval, provided that if a common warrant is not fully exercisable because we have insufficient authorized and unreserved shares of common stock at the time of the public announcement of the FDA Approval, the common warrant will be exercisable for two years following the date on which we obtain stockholder approval for an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The April 2026 private placement raised total gross proceeds of approximately $180.0 million, before deducting placement agent fees and other expenses.  Pursuant to the April 2026 private placement, on April 15, 2026, (a) Franklin Advisers, Inc. agreed to purchase 1,925,722 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $6,999,999; (b) Alyeska Investment Group, L.P. purchased 1,925,722 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $6,999,999; and (c) Dialectic Capital Management, LP purchased 1,237,965 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $4,500,000; (d) Frazier Life Sciences purchased 7,464,836 shares of our common stock and accompanying common warrants, and 100,500 pre-funded warrants to purchase our common stock for an aggregate purchase price of $27,499,985; (e) TPG LSI Rise Auriga L.P. purchased 6,877,580 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $25,000,003; and (f) venBio Global Strategic Fund I, L.P. purchased 5,914,720 shares of our common stock and accompanying common warrants, for an aggregate purchase price of $21,500,007.  The terms of such parties&#8217; participation in the offering were identical to those available to all other investors in the offering.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and procedures for related party transactions</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors has adopted a written policy governing the review and approval of related-party transactions. Our Audit Committee has the primary responsibility for reviewing and approving or disapproving related party transactions, as designated in the audit committee charter. In approving or rejecting any such proposal, we expect that our Audit Committee (or the committee composed solely of independent directors, if applicable) will consider the relevant facts and circumstances available and deemed relevant to the Audit Committee (or the committee composed solely of independent directors, if applicable), including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our Code of Business Conduct and Ethics requires that each of our employees and directors inform his or her superior or our compliance officer, of any material transaction or relationship that comes to his or her attention. Further, at least annually, each director and executive officer will complete a detailed questionnaire that asks questions about any business relationship that may give rise to a conflict of interest and all transactions in which we are involved and in which an executive officer, a director or a related person has a direct or indirect material interest.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Independence</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Please see &#8220;Item 10.  Directors, Executive Officers and Corporate Governance&#8211;Director Independence&#8221; and &#8220;&#8211;Board of Directors&#8217; Committees&#8221; for information regarding the independence of our Board of Directors and the committees of our Board of Directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTANT FEES AND SERVICES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents fees for professional audit services and other services rendered to us by PricewaterhouseCoopers LLP, or PwC, for our fiscal years ended December 31, 2025 and 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.393%;box-sizing:content-box;"/>
     <td style="width:1.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.12%;box-sizing:content-box;"/>
     <td style="width:1.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.602%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.12%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fee Category</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal<br/>Year 2025<br/>PwC Fees</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal<br/>Year 2024<br/>PwC Fees</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221,859</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,687</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit-Related Fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,926</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,092</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Fees</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">308,785</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">330,779</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accountant fees and services charged by PwC are paid in Canadian dollars and shown in USD.  For fiscal year 2025, the fees were CDN$431,404 and were converted at an average exchange rate of US$1.00=CDN$1.3971. For fiscal year 2024, the fees were CDN$453,102 and were converted at an average exchange rate of US$1.00=CDN$1.3698.     </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Audit Fees for fiscal year 2025 and fiscal year 2024 were fees billed and to be billed for the audit of our consolidated financial statements, review of the consolidated financial statements included in our quarterly reports, and for services in connection with regulatory filings and engagements.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee has established a policy governing our use of the services of our independent registered public accounting firm.  Under the policy, our Audit Committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firm&#8217;s independence. All fees paid to PwC for our fiscal years ended December 31, 2024 and 2025 were pre-approved by our Audit Committee.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ART IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-11.441%;padding-left:10.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15. EXHIBITS AND FINAN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIAL STATEMENT SCHEDULES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits &#8211; The exhibits required to be filed as part of this report are listed  in the Exhibit List attached hereto and are incorporated herein by  reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executiveofficer"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32.134%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:9.978%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.477%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:5.899%;box-sizing:content-box;"/>
     <td style="width:6.439%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/<br/>Furnished<br/>Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312523164423/d503566dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation, filed June 8, 2023</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 9, 2023</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459019046457/achv-ex31_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Designation of Preferences, Rights and Limitations, with respect to the Series B Convertible Preferred Stock, filed</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 20, 2019</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517003020/d310875dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sixth Amended and Restated Bylaws</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 5, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459018028073/achv-ex31_529.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Sixth Amended and Restated Bylaws</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2018</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459020010642/achv-ex412_639.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 13, 2020</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000091228208001616/ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Certificate of Common Stock</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-21243</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 10, 2008</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459018015850/achv-ex42_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Preferred Stock Certificate</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 20, 2018</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8.65pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459020036208/achv-ex41_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (August 2020)</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 4, 2020</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459020055567/achv-ex411_234.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Underwriter&#8217;s Warrant</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-250074</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 30, 2020</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459022038025/achv-ex41_55.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Purchase Warrant (November 2022)</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 18, 2022</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459022038025/achv-ex102_53.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 18, 2022</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000949858/000095017024087118/achv-20240725.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 29, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017025091055/achv-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant to Purchase Common Stock or Pre-Funded Warrants</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 27, 2025</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095012310057889/c02409exv10w1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of OncoGenex Pharmaceuticals, Inc. 2010 Stock Option Agreement&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 14, 2010</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095012311094853/c23793exv10w2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of OncoGenex Pharmaceuticals, Inc. 2010 Restricted Stock Unit Agreement&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 3, 2011</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32.134%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:9.978%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.477%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:12.338%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/<br/>Furnished<br/>Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312515133164/d850968ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OncoGenex Pharmaceuticals, Inc. 2010 Performance Incentive Plan, as amended and restated&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Appendix A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 16, 2015</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517290461/d435757ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Achieve Life Sciences 2017 Equity Incentive Plan&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Appendix A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 21, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459018004159/achv-ex107b_794.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Achieve Life Sciences Stock Option Agreement&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7b</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 1, 2018</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459018004159/achv-ex107c_793.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Achieve Life Sciences Restricted Stock Unit Agreement&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7c</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 1, 2018</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517290461/d435757ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Achieve Life Sciences 2017 Employee Stock Purchase Plan&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Appendix B</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 21, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-ex108_499.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Achieve Life Sciences 2018 Equity Incentive Plan, as amended, and forms of award agreements thereunder&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 16, 2023</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312523125216/d464571ddef14a.htm#toc464571_15"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Achieve Life Sciences, Inc. 2023 Non-Employee Director Equity Incentive Plan, and forms of award agreements thereunder&#134;&#134;</span></a><span style="color:#b5082e;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Appendix B</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 28, 2023</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;"><span style="text-decoration:underline solid;"></span>&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017024133703/achv-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2024 Equity Inducement Plan and forms of award agreements thereunder</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-283630</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 5, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0200000000000005pt;font-kerning:none;min-width:fit-content;"><span style="text-decoration:underline solid;"></span>&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000949858/000095017024038049/achv-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for Officers and Directors of the Company</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312518171467/d587288dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Company and Richard Stewart, executed May 22, 2018 &#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 23, 2018</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="achv-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated October 20, 2025, between Achieve Life Sciences, Inc. and Erik Atkisson&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated October 16, 2024, between Achieve Life Sciences, Inc. and Jaime Xinos&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2026</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017025104571/achv-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated May 9, 2025, by and between Achieve Life Sciences, Inc. and Richard Stewart</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 7, 2025</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement, by and between Sopharma Joint Stock Company and Extab Corporation, dated May 26, 2009*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#b5082e;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Commercial Agreement on Supply of Pharmaceutical Products, by and between Sopharma AD and Extab Corporation, dated February 1, 2010*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32.134%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:9.978%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.477%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:5.899%;box-sizing:content-box;"/>
     <td style="width:6.439%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/<br/>Furnished<br/>Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Variation of Contract, by and between Sopharma AD and Extab Corporation, dated May 14, 2015*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Variation of Contract, by and between Sopharma AD and Extab Corporation, dated May 14, 2015*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Technical and Quality Agreement, by and between Sopharma AD and Extab Corporation, dated May 14, 2015*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/949858/000095017024038049/achv-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Share Purchase Agreement, by and between Sopharma AD and Achieve Life Sciences, Inc., dated May 14, 2015*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312517156177/d177072dex1027.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License of Technology, by and between University of Bristol and Achieve Life Science, Inc., dated July 13, 2016*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-4/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-216961</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 3, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312518171458/d587186dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment One to License of Technology, dated January 22, 2018, by and between Achieve Life Science, Inc., and the University of Bristol*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q/A</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#b5082e;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 23, 2018</span></p></td>
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#b5082e;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459017023285/achv-ex101_1096.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Commercial Agreement on Supply of Pharmaceutical Products, dated July 28, 2017, by and between Achieve Life Science, Inc., and Sopharma AD*</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 9, 2017</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459020053567/achv-ex101_273.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Richard Stewart&#134;&#134;</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 12, 2020</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000949858/000095017024087118/achv-20240725.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Contingent Convertible Debt Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">July 29, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017024023189/achv-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Securities Purchase Agreement, dated as of February 28, 2024, by and among Achieve Life Sciences, Inc. and the purchasers identified on the signature pages thereto</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 29, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459019007838/achv-ex1025_660.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease by and between 0846869 B.C. Ltd. and Achieve Life Sciences Technologies Inc., commencing February 1, 2019</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March, 14, 2019</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000156459023003800/achv-ex1022_725.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Extension Agreement, dated December 16, 2022, by and between 0846869 B.C. Ltd. and Achieve Life Sciences Technologies Inc.</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 16, 2023</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32.134%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:9.978%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.477%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:12.338%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/<br/>Furnished<br/>Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/949858/000095017024038049/achv-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease by and between Regus Management Group, LLC and Achieve Life Sciences, Inc., commencing March 1, 2024</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/achv-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Extension Agreement by and between Regus Management Group, LLC and Achieve Life Sciences, Inc., commencing March 1, 2024</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Agreement, dated November 10, 2025, by and between Achieve Life Sciences, Inc. and Kristen Slaoui</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2026</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017025036831/achv-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 11, 2025</span></p><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of PricewaterhouseCoopers LLP</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;23.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-20251231.htm#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on the signature page hereto)</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;033-80623</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;24.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (included on the signature page hereto)</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="achv-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="achv-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer (Principal Executive Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;033-80623</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;32.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 24, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000119312526120690/achv-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.0</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/949858/000095017024038049/achv-ex97_0.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Compensation Recovery Policy</span></a></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">033-80623</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.0</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2024</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
     <td style="width:7.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32.134%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:7.758%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:9.978%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.477%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:12.338%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td colspan="7" style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/<br/>Furnished<br/>Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.013in;padding-left:0in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;display:none;vertical-align:top;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0.013in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document&#8211;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover page formatted as Inline XBRL and contained in Exhibit 101</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.013in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.013in;text-align:left;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.013in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.013in;text-align:center;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Schedules and similar attachments to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the SEC upon request.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134;&#134; Indicates management contract or compensatory plan or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* The Company has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16. FORM </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K SUMMARY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:14pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:43%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACHIEVE LIFE SCIENCES, INC.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Registrant)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ MARK OKI</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Oki</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Power of A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ttorney</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Andrew Goldberg, Mark Oki and Erik Atkisson, jointly and severally, as such person&#8217;s attorneys-in-fact, each with the power of substitution, for such person in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.9%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:46.4%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:20.62%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ ANDREW GOLDBERG</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;President, Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(Principal Executive Officer)</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Goldberg</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ MARK OKI</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Financial Officer (Principal Financial Officer)</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Oki</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Vice President, Finance (Principal Accounting Officer)</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jerry Wan</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.75pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chairman of the Board of Directors</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas B. King</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stuart Duty</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lucian Iancovici</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lucian Iancovici</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bridget Martell</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nancy R. Phelan</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Royston</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aaron Royston</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:30.9%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:46.4%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:20.62%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas Sellig</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:144pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:144pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:26.667%;text-indent:9.091%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Director</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kristen Slaoui</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:432pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:80%;text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:432pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:80%;text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By: /s/ *</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Stewart</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:432pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:80%;text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:31.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:13.29%;box-sizing:content-box;"/>
     <td style="width:86.71%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:3pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ MARK OKI</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td rowspan="2" style="padding-top:0.02in;padding-left:0.01in;vertical-align:top;padding-bottom:0.02in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*By:</span></p></td>
     <td style="padding-top:0.02in;padding-left:0.01in;vertical-align:top;padding-bottom:0.02in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Oki</span></p></td>
    </tr>
    <tr style="height:14.4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.02in;padding-left:0.01in;vertical-align:top;padding-bottom:0.02in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Oki</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Attorney-in-fact</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>achv-ex10_13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-04-30T16:13:57.2317+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.13</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><h1 style="margin-left:0.65pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.015277777777777779in;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><h1 style="margin-left:0.65pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.015277777777777779in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.13</font></h1><h1 style="margin-left:0.65pt;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.015277777777777779in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement</font></h1><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08055555555555555in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS EMPLOYMENT AGREEMENT (the &#x201c;Agreement&#x201d;) is entered into by and between Erik Atkisson (the &#x201c;Employee&#x201d;) and Achieve Life Sciences, Inc., a Washington corporation (the &#x201c;Employer&#x201d; or the &#x201c;Company&#x201d;) as of October 20, 2025 (the &#x201c;Effective Date&#x201d;).</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;" id="x__duties_and_scope_of_employment_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties and Scope of Employment.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07916666666666666in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the term of this Agreement (&#x201c;Employment&#x201d;), the Employer agrees to employ the Employee in the position of Chief Legal Officer. The Employee shall report directly to Richard Stewart, Chief Executive Officer of the Company. The Employee shall have such duties, authority and responsibilities that are commensurate with his being an executive officer of the Employer. During your employment, Employee will perform his duties faithfully and to the best of his ability and will devote his full business efforts and time to the Employer. For the duration of the Employee&#x2019;s Employment term, Employee agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration without the prior written approval, such approval not to be unreasonably withheld, provided that such activities do not materially adversely affect Employee&#x2019;s ability to perform and discharge his duties to the Employer or competes with the Company.</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;" id="x__cash_and_incentive_compensation_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Incentive Compensation.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__salary__the_employer_shall_pay_the_e"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Employer shall pay the Employee as compensation for his services a base salary at a gross annual rate of not less than $440,000. Such salary shall be payable in accordance with the Employer&#x2019;s standard payroll procedures. The annual compensation specified in this Section 2(a), together with any increases in such compensation that the Employer may grant from time to time, is referred to in this Agreement as &#x201c;Base Compensation.&#x201d;</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__incentive_bonuses__the_employee_shal"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Bonuses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Employee shall be eligible to receive a discretionary annual fiscal year incentive bonus (&#x201c;Bonus&#x201d;) that the Board or Compensation Committee of the Board (the &#x201c;Committee&#x201d;) shall determine and award in its sole discretion. Initially, the Employee shall be eligible to receive a target Bonus of 40% of the Employee&#x2019;s Base Compensation. Such percentage may be modified by the Board or the Committee in its discretion from time to time. The Bonus will be based upon the achievement of specific milestones that will be determined by the Board and/or the Committee and confirmed to the Employee. Payment for each year&#x2019;s Bonus, if awarded, shall be made to the Employee no later than the fifteenth day of the third month after the later of the end of the calendar year or the Employer&#x2019;s taxable year in which the Bonus payment is no longer subject to a substantial risk of forfeiture for purposes of Section 409A of the Internal Revenue Code, as amended (&#x201c;Section 409A&#x201d;). The Board or the Committee may, in its sole discretion, determine not to award a Bonus or to award a Bonus at less than maximum eligibility. The Employee acknowledges that a Bonus is neither required nor guaranteed by this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08055555555555555in;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retention Bonus.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Employee shall receive a Retention Bonus of $40,000, less applicable taxes, to be paid with his initial payroll payment. The amount must be paid back to the Employer if the Employee terminates his Employment with the Employer within six months of the Employee&#x2019;s date of hire.   </font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(d)</font><div style="display:inline;" id="xc__equity_terms__during_the_employee_s_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Employee&#x2019;s Employment, at the discretion of the Committee, the Employee shall be entitled to participate in the Company&#x2019;s equity compensation plans, as in effect from time to time, and the Employee shall be eligible to receive grants of Company equity (&#x201c;Compensatory Equity&#x201d;), as determined by the Committee, in its discretion from time to time. We will recommend to the Board or Committee that you be granted a stock option to purchase up to 250,000 shares of Common Stock of the Company (the &#x201c;Option&#x201d;) at the fair market value of the Company's Common Stock, as determined by the Board on the date the Board approves such grant.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(e)</font><div style="display:inline;" id="xd__employee_benefits__during_the_employ"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the Employee&#x2019;s Employment, the Employee will be entitled to participate in the employee benefit plans of general applicability to other Employees of the Company, as in effect from time to time, including, without limitation, the Company&#x2019;s group medical, dental, vision, disability, life insurance, director and officer liability insurance and flexible-spending account plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(f)</font><div style="display:inline;" id="xe___service__definition__for_purposes_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Service&#x201d; Definition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of Section 3(b) of this Agreement, &#x201c;Service&#x201d; shall mean service by the Employee as an employee, consultant, advisor, director or other service provider of the Employer (or any subsidiary or parent </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or affiliated entity of the Employer).</font></div></div><p style="margin-left:41pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.08263888888888889in;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;" id="x__vacation_and_indemnification_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vacation.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:left;" id="xa__vacation__the_employee_will_be_eligi"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Employee will be eligible for paid vacation in accordance with the Employer&#x2019;s vacation policy. Under the Employer&#x2019;s current vacation policy, the Employee is eligible for twenty-five (25) days per year of paid vacation.</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="xb__indemnification__d_o_liability_insur">&#160;</p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;" id="x__business_expenses_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Expenses.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During your Employment, the Employee shall be authorized to incur necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder. The Employer shall promptly reimburse the Employee for such expenses upon presentation of appropriate supporting documentation, all in accordance with the Employer&#x2019;s generally applicable policies.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;" id="x__term_of_employment_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term of Employment.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__employment_at_will__the_employer_and"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment-at-Will</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Employer and the Employee hereby acknowledge that the Employee&#x2019;s Employment is at-will. The Employer may terminate the Employee&#x2019;s Employment with or without Cause, by giving the Employee either, in the Employer&#x2019;s sole discretion, (a) thirty (30) days advance notice in writing, or (b) a cash payment equivalent to 30 calendar days of the then-effective Base Compensation in lieu of providing such notice. The Employee may terminate his Employment by giving the Employer thirty (30) days advance notice in writing. The Employee&#x2019;s Employment shall terminate automatically in the event of his death.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__rights_upon_termination__upon_the_te"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights Upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the termination of the Employee&#x2019;s Employment for any reason (including death or Disability (as defined below)), the Employee shall be entitled to the compensation, benefits and reimbursements described in this Agreement through the effective date of the termination (the &#x201c;Termination Date&#x201d;), and the Employer shall make the following payments to the Employee (or his beneficiary) within 10 business days following the Termination Date: (i) all unpaid salary and accrued but unused vacation accrued through the Termination Date, (ii) any bonuses that have been determined to be awarded by the Board or the Committee, in accordance with the terms of any applicable plan, for any fiscal year of the Employer ended prior to the Termination Date but that remain unpaid to Employee as of the Termination Date, and (iii) any unreimbursed business expenses provided that Employee has submitted appropriate documentary substantiation as required by Company policy. The Employee may also be eligible for other post-Employment payments and benefits as provided in this Agreement or pursuant to other agreements (other than the Prior Agreements) or plans with the Employer. Upon the Termination Date, the Employee shall have no further rights to receive compensation or benefits from the Employer except as set forth in Section 6 and pursuant to the terms of any benefit plans (including without limitation any equity compensation plans) of the Company in which the Employee is a participant.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;" id="x__termination_benefits_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination Benefits.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__severance_pay__if_there_is_an_involu"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If there is an Involuntary Termination (as defined below) of the Employee&#x2019;s Employment, then, subject to the Employee&#x2019;s execution, delivery and non-revocation of a Release (defined below) within the time period described below, following the Employee&#x2019;s &#x201c;separation from service&#x201d; within the meaning of Section 409A, the Employer shall pay the Employee a single lump sum of cash in an amount equal to twelve (12) months (the &#x201c;Severance Period&#x201d;) of the Employee&#x2019;s Base Compensation (not giving effect to any reduction in Base Compensation made in connection with such Involuntary Termination or giving rise to Good Reason). The cash lump sum amount payable under this Section 6(a) shall be made to the Employee on the first payroll date in the month following the month containing the Release Deadline. The Employee shall also receive the benefits provided in Sections 6(b) and 6(c), and all such payments and benefits shall not be subject to mitigation or offset (except as specified in Section 6(b)). In order to be entitled to receive the severance described in this Section 6(a) (including the benefits provided in Sections 6(b), 6(c) and, if applicable, 6(d)), the Employee must execute, deliver and not revoke the Release within forty-five (45) calendar days following the Employee&#x2019;s separation from service (the date that is forty-five (45) calendar days following the Employee&#x2019;s separation from service is the &#x201c;Release Deadline&#x201d;). The Employer shall furnish the Release to the Employee on the date of his Involuntary Termination. The &#x201c;Release&#x201d; shall be a general release of all litigation and other claims against the Employer and all affiliates by the Employee and on Employee&#x2019;s behalf in a form satisfactory to the Employer.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__health_insurance__if_the_employee_is"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Employee is entitled to receive the severance payment in Section 6(a), and if the Employee elects to continue his (and his dependents&#x2019;) health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#x201c;COBRA&#x201d;), then the Employer shall pay Employee a lump sum cash payment that is equivalent </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the value of Employee&#x2019;s monthly premium under COBRA for the number of months in the Severance Period. The cash lump sum amount payable under this Section 6(b) shall be made to the Employee on the first payroll date in the month following the month containing the Release Deadline.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(c)</font><div style="display:inline;" id="xc__equity_vesting__notwithstanding_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding the terms of any equity compensation plan of the Company or any agreement in connection with a grant of Compensatory Equity, if the Employee is entitled to receive the payments in Section 6(a), then the time-based vesting restrictions (if any) shall immediately lapse on an additional number of shares of Company common stock under all of the Employee&#x2019;s outstanding Compensatory Equity that is equal to the number of shares that would have time-vested if the Employee had continued in employment for the number of additional months following the Termination Date that is equal to the number of months in the Severance Period. The Employee shall be entitled to exercise any of his Compensatory Equity to the extent vested pursuant to this Section 6(c) or otherwise for such period as set forth in the terms of that Compensatory Equity.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(d)</font><div style="display:inline;" id="xd__effect_of_change_in_control__if_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect of Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company is subject to a Change in Control (as defined below) and there is an Involuntary Termination of the Employee&#x2019;s Employment within the period beginning three (3) months before and ending twelve (12) months after a Change in Control (or more than three (3) months prior to a Change in Control but in connection with a Change in Control), then following the Employee&#x2019;s separation from service, the Employee will be entitled to all benefits described in Sections 6(a), 6(b) and 6(c) of this Agreement subject to the same terms and conditions and payment dates described above, except that (x) the cash payment amount under Section 6(a) shall be an amount equal to the sum of twenty four (24) months of the Employee&#x2019;s then annual Base Compensation (not giving effect to any reduction in Base Compensation made in connection with such Involuntary Termination or giving rise to Good Reason), plus an amount equal to the sum of twenty four (24) months of the Employee&#x2019;s average monthly Bonus earnings, where such average is calculated over the twenty four (24) month period immediately preceding the Employee&#x2019;s separation from service and based on the Employee&#x2019;s Bonus paid in such 24 month period, (y) the payment under Section 6(b) shall be equivalent to the amount of Executive&#x2019;s monthly premiums under COBRA for twenty four (24) months and (z) notwithstanding the terms of any equity compensation plan of the Company or any agreement in connection with a grant of Compensatory Equity, all vesting restrictions (if any) shall immediately lapse on all of the Employee&#x2019;s Compensatory Equity effective as of the Employee&#x2019;s separation from service. For purposes of the preceding sentence, an Involuntary Termination shall be deemed to be in connection with a Change in Control if such termination (i) is required by the merger agreement, purchase agreement or other instrument relating to such Change in Control or (ii) is made at the express request of the other party (or parties) to the transaction constituting such Change in Control.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(e)</font><div style="display:inline;" id="xe__parachute_payments__in_the_event_tha"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event that the payments and benefits provided for in this Agreement and the payments and/or benefits provided to, or for the benefit of, the Employee under any other Employer plan or agreement (such payments or benefits are hereinafter collectively referred to as the &#x201c;Benefits&#x201d;) (i) constitute &#x201c;parachute payments&#x201d; within the meaning of Section 280G of the Internal Revenue Code and (ii) but for this Section 6(e), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code (the &#x201c;Excise Tax&#x201d;), then the Benefits shall either be:</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:1.0701388888888888in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:8.223866028483059%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;" id="xi__delivered_in_full__or"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivered in full, or</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(ii)</font><div style="display:inline;" id="xii__delivered_as_to_such_lesser_extent_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivered as to such lesser extent which would result in no portion of such Benefits being subject to the Excise Tax (such reduced amount is hereinafter referred to as the &#x201c;Limited Amount&#x201d;), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by the Employee on an after-tax basis, of the greatest amount of Benefits, notwithstanding that all or some portion of such Benefits may be subject to the Excise Tax. If applicable, in order to effectuate the Limited Amount, the Employer shall first reduce those Benefits which are payable in cash and then reduce non-cash payments, in each case in reverse order beginning with Benefits which are to be paid the farthest in time from the date of determination that the Benefits will be limited by (e)(ii) above. Any calculations and determinations required under this Section 6(e) shall be made in writing by the Company&#x2019;s independent auditor (the &#x201c;Accountant&#x201d;) whose determination shall be conclusive and binding. The Employee and the Company shall furnish the Accountant such documentation as the Accountant may reasonably request in order to make a determination. The Employer shall pay for all costs that the Accountant may reasonably incur in connection with performing any calculations contemplated by this Section 6(e).</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(f)</font><div style="display:inline;" id="xf___change_in_control__definition__for_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; Definition. For purposes of this Agreement, &#x201c;Change in Control&#x201d; shall mean the occurrence of any of the following events:</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(i)</font><div style="display:inline;" id="xi__the_consummation_of_a_merger_or_cons"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if the Company&#x2019;s stockholders immediately prior to such merger, consolidation or </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reorganization cease to directly or indirectly own immediately after such merger, consolidation or reorganization at least a majority of the combined voting power of the continuing or surviving entity&#x2019;s securities (or, if the continuing or surviving entity is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the ultimate parent corporation of such surviving or resulting corporation) outstanding immediately after such merger, consolidation or other reorganization;</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(ii)</font><div style="display:inline;" id="xii__the_consummation_of_the_sale__trans"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the consummation of the sale, transfer or other disposition of all or substantially all of the Company&#x2019;s assets (other than (1) to a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company, (2) to a corporation or other entity owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company or</font></div></div><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.08472222222222221in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) to a continuing or surviving entity described in subsection (i) in connection with a merger, consolidation or corporate reorganization which does not result in a Change in Control under subsection (i));</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iii)</font><div style="display:inline;" id="xiii__a_change_in_the_composition_of_the"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a change in the composition of the Board, as a result of which fewer than one-half of the incumbent directors are directors who either (1) had been directors of the Company on the date twenty-four (24) months prior to the date of the event that may constitute a Change in Control (the &#x201c;original directors&#x201d;) or (2) were elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved;</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iv)</font><div style="display:inline;" id="xiv__the_consummation_of_any_transaction"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the consummation of any transaction as a result of which any person becomes the &#x201c;beneficial owner&#x201d; (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), directly or indirectly, of securities of the Company representing at least thirty-five percent (35%) of the total voting power represented by the Company&#x2019;s then outstanding voting securities. For purposes of this subsection, the term &#x201c;person&#x201d; shall have the same meaning as when used in sections 13(d) and 14(d) of the Exchange Act but shall exclude:</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8339914561851764%;">(1)</font><div style="display:inline;" id="x1__a_trustee_or_other_fiduciary_holding"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a trustee or other fiduciary holding securities under an employee benefit plan of the Company or an affiliate of the Company;</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8339914561851764%;">(2)</font><div style="display:inline;" id="x2__a_corporation_or_other_entity_owned_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a corporation or other entity owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company;</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:1.5701388888888892in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:8.960789338800618%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;" id="x3__the_company__and"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company; and</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8339914561851764%;">(4)</font><div style="display:inline;" id="x4__a_corporation_or_other_entity_of_whi"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company; or</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:1.0701388888888888in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:8.223866028483059%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;" id="xv__a_complete_winding_up__liquidation_o"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a complete winding up, liquidation or dissolution of the Company.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.08194444444444444in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Section 6(f), a transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company&#x2019;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transactions.</font></p><p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(g)</font><div style="display:inline;" id="xg___cause__definition__for_all_purposes"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Cause&#x201d; Definition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes under this Agreement, &#x201c;Cause&#x201d; shall mean any of the following committed by the Employee:</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(i)</font><div style="display:inline;" id="xi__willful_failure_to_follow_the_reason"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Willful failure to follow the reasonable and lawful directions relating to the performance of Employee&#x2019;s duties and responsibilities under this Agreement;</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(ii)</font><div style="display:inline;" id="xii__conviction_of_a_felony__or_a_plea_o"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conviction of a felony (or a plea of guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nolo contendere </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Employee to a felony) that materially harms the Company;</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iii)</font><div style="display:inline;" id="xiii__acts_of_fraud__dishonesty__misappr"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acts of fraud, dishonesty, misappropriation or any other misconduct committed by the Employee which has caused or is reasonably expected to result in material injury to the Company;</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iv)</font><div style="display:inline;" id="xiv__willful_misconduct_by_the_employee_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Willful misconduct by the Employee in the performance of the Employee&#x2019;s material duties required by this Agreement; or</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:1.0701388888888888in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:8.223866028483059%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="display:inline;" id="xv__a_material_breach_of_this_agreement_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material breach of this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing is an exclusive list of the acts or omissions that shall be considered &#x201c;Cause&#x201d; for the termination of the Employee&#x2019;s Employment by the Employer. With respect to the acts or omissions set forth in clauses (i), (iii), (iv) and (v) above, (x) the Chief Commercial Officer or Chief Financial Officer (or other representative of the Company) shall provide the Employee with one (1) month advance written notice detailing the basis for the termination of Employment for Cause, (y) during the one-month period after the Employee has received such notice, the Employee shall have an opportunity to cure such alleged Cause events before any termination for Cause is finalized and (z) the Employee shall continue to receive the compensation and benefits provided by this Agreement during the one-month cure period. In addition, no act or failure to act of Employee shall be willful or intentional if performed in good faith with the reasonable belief that the action or inaction was in the best interest of the Employer.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(h)</font><div style="display:inline;" id="xh___involuntary_termination__definition"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Involuntary Termination&#x201d; Definition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes under this Agreement, &#x201c;Involuntary Termination&#x201d; shall mean any of the following: (i) termination of the Employee&#x2019;s Employment by the Employer without Cause; (ii) the Employee&#x2019;s resignation of Employment for Good Reason; or (iii) termination of the Employee&#x2019;s Employment by the Employer for Disability.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(i)</font><div style="display:inline;" id="xi___good_reason__definition__for_all_pu"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Good Reason&#x201d; Definition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes under this Agreement, &#x201c;Good Reason&#x201d; shall mean any of the following that occurs without the Employee&#x2019;s prior written consent: (i) a material reduction of the Employee&#x2019;s Base Compensation or Employee&#x2019;s employee benefits; (ii) any material reduction or diminution of the Employee&#x2019;s duties, authority or responsibilities; (iii) the Employer&#x2019;s material breach of this Agreement; (iv) the failure of any successor of the Company to expressly in writing assume the Company&#x2019;s obligations under this Agreement, in each case, provided that the Employee shall have provided the Employer with thirty (30) days advance written notice and an opportunity to cure such breach during such 30-day period; or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirement that the Employee relocate to, or regularly perform services at, a physical office or location that is more than 30 miles from the Employee&#x2019;s current residence, and such change is imposed without the Employee&#x2019;s prior written consent.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(j)</font><div style="display:inline;" id="xj___disability__definition__for_all_pur"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Disability&#x201d; Definition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For all purposes under this Agreement, &#x201c;Disability&#x201d; shall mean the Employee&#x2019;s incapacity due to physical or mental illness to perform his full-time duties with the Employer for a continuous period of three </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) months or an aggregate of six (6) months in any eighteen (18) month period.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;" id="x__non_solicitation__non_compete_and_non"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information and Non-Disparagement</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xc__confidential_information__except_as_"><font id="xa__non_solicitation__during_the_period_"></font><font id="xb__non_compete__during_the_period_comme"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as required in the good faith opinion of the Employee in connection with the performance of the Employee&#x2019;s duties hereunder or as specifically set forth in this Section 7(a), the Employee shall, in perpetuity, maintain in confidence and shall not directly, indirectly or otherwise, use, disseminate, disclose or publish, or use for his benefit or the benefit of any person, firm, corporation or other entity any confidential or proprietary information or trade secrets of or relating to the Company or any of its affiliates, including, without limitation, information with respect to the Company&#x2019;s operations, processes, products, inventions, business practices, finances, principals, vendors, suppliers, customers, potential customers, marketing methods, costs, prices, contractual relationships, regulatory status, business plans, designs, marketing or other business strategies, compensation paid to employees or other terms of employment, or deliver to any person, firm, corporation or other entity any document, record, notebook, computer program or similar repository of or containing any such confidential or proprietary information or trade secrets. The Company and the Employee stipulate and agree that as between them the foregoing matters are important, material and confidential proprietary information and trade secrets and affect the successful conduct of the businesses of the Company (and any successor or assignee of the Company). Upon termination of the Employee&#x2019;s employment with the Company for any reason, the Employee shall promptly deliver to the Company all correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the Company&#x2019;s customers, business plans, designs, marketing or other business strategies, products or processes, provided that the Employee may retain his address book and similar information, whether or not the Company specifically requests it. Notwithstanding the foregoing, the Parties acknowledge that the confidential information covered by this paragraph shall not include any such information which Employee can establish (i) was publicly known prior to the time of disclosure by the Company to Employee; (ii) becomes publicly known after disclosure by the Company to Employee through no wrongful action or omission by Employee; or (iii) is in Employee&#x2019;s rightful possession, without confidentiality obligations, at the time of disclosure by the Company as shown by Employee&#x2019;s then- contemporaneous written records. Employee understands that nothing herein is intended to limit Employee&#x2019;s ability to discuss or disclose conduct, or the existence (but not the amount) of a settlement involving conduct, that Employee reasonably believes under Washington state, federal or common law to be illegal discrimination, illegal harassment, illegal retaliation, a wage and hour violation, or sexual assault, or conduct that is recognized as against a clear mandate of public policy, and Employee understands that </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information concerning any of the foregoing does not constitute confidential or proprietary information hereunder. Additionally, Employee understands that information regarding working conditions, wages, benefits, and/or other terms and conditions of employment does not constitute confidential or proprietary information hereunder to the extent disclosure of such information is protected by applicable law.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xd__non_disparagement__the_employee_and_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Disparagement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Employee and the Company mutually agree not to disparage or defame, in writing or orally, the other party, and as applicable, its or his services, products, subsidiaries and affiliates, and/or their respective directors, officers, and successors and assigns. This non-disparagement provision shall not apply to statements made by non- management employees of the Company, so long as such statements did not originate from and were not induced or encouraged (directly or indirectly) by an officer, director or management employee of the Company. Notwithstanding the foregoing, nothing in this Section 7(b) shall limit the ability of the Company or the Employee, as applicable, to provide truthful testimony as required by law or any judicial or administrative process.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(c)</font><div style="display:inline;" id="xe__remedies__without_limiting_the_right"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Without limiting the right of the Employer to pursue all other legal and equitable rights available to the Employer for violation of the provisions of Section 7 of this Agreement by Employee, it is agreed that (a) other remedies cannot fully compensate the Employer for such a violation, (b) such a violation will cause the Employer irreparable harm which may not be adequately compensated by money damages and (c) the Employer shall each be entitled to a temporary, preliminary and permanent injunctive or other equitable relief, without or posting a bond therefore, to prevent a violation, continuing violation or threatened violation of the provisions of Section 7 of this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;" id="x__inventions_and_patents_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventions and Patents.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__for_purposes_of_this_agreement___inv"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, &#x201c;Inventions&#x201d; includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours. Subject to Section 8(d) below, Employee agrees that all Inventions conceived or made by Employee during the period of employment with Employer belong to Employer, provided they grow out of Employee&#x2019;s work with Employer or are related in some manner to the Company Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies. Accordingly, Employee will:</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:1.0701388888888888in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:8.223866028483059%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;" id="xi__make_adequate_written_records_of_suc"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make adequate written records of such Inventions, which records will be Employer&#x2019;s property;</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(ii)</font><div style="display:inline;" id="xii__assign__and_hereby_does_irrevocably"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assign (and hereby does irrevocably assign and transfer) to Employer or its designee, at Employer&#x2019;s request, any rights, title and interest Employee may have to such Inventions for the U.S. and all foreign countries;</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iii)</font><div style="display:inline;" id="xiii__waive_and_agree_not_to_assert_any_"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waive and agree not to assert any moral rights Employee may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer; and</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.09416374635171%;">(iv)</font><div style="display:inline;" id="xiv__assist_employer__at_employer_s_expe"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assist Employer (at Employer&#x2019;s expense) in obtaining and maintaining patents or copyright registrations with respect to such Inventions.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__employee_understands_and_agrees_that"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee understands and agrees that Employer or its designee will determine, in its sole and absolute discretion, whether an application for patent will be filed on any Invention that is the exclusive property of Employer, as set forth above, and whether such an application will be abandoned prior to issuance of a patent. Employer will pay to Employee, either during or after the term of this Agreement, the following amounts if Employee is sole inventor, or Employee&#x2019;s proportionate share if Employee is joint inventor: $750 upon filing of the initial application for patent on such Invention; and</font></div></div><p style="margin-left:5pt;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.08124999999999999in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$1,500 upon issuance of a patent resulting from such initial patent application, provided Employee is named as an inventor in the patent.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(c)</font><div style="display:inline;" id="xc__employee_further_agrees_that_employe"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee further agrees that Employee will promptly disclose in writing to Employer during the term of Employee&#x2019;s employment, all Inventions whether developed by Employee alone or jointly with others (whether or not Employer has rights in such Inventions) so that Employee&#x2019;s rights and Employer&#x2019;s rights in such Inventions can be determined. Except as set forth on the initialed Exhibit A (List of Inventions) to this Agreement, if any, Employee represents and warrants that Employee has no Inventions, software, writings or other works of authorship useful to Employer in the normal course of the Company Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(d)</font><div style="display:inline;" id="xd__notice__in_accordance_with_washingto"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICE</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: In accordance with Washington law, this Section 8 does not apply to Inventions for which no equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee&#x2019;s own time, unless: (a) the Invention relates (i) directly to the business of Employer or (ii) to Employer&#x2019;s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Employee for Employer.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;" id="x__successors_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__employer_s_successors__this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer&#x2019;s Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Employer&#x2019;s business and/or assets. For all purposes under this Agreement, the term &#x201c;Employer&#x201d; shall include any successor to the Employer&#x2019;s business and/or assets which becomes bound by this Agreement.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__employee_s_successors__this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee&#x2019;s Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement and all rights of the Employee hereunder shall inure to the benefit of, and be enforceable by, the Employee&#x2019;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</font></div></div><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;" id="x0__section_409a_of_the_internal_revenue"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Internal Revenue Code.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Employer determines that any of the benefits payable under this Agreement would violate Section 409A, then the Employer and the Employee shall, in good faith, agree to implement adjustments needed to comply with Section 409A. Additionally, notwithstanding anything contained in this Agreement to the contrary, if Employee is deemed by the Employer at the time of Employee&#x2019;s &#x201c;separation from service&#x201d; to be a &#x201c;specified employee,&#x201d; each within the meaning of Section 409A, any compensation or benefits to which Employee becomes entitled under this Agreement (or any agreement or plan referenced in this Agreement) in connection with such separation that are subject to Section 409A shall not be made or commence until the date which is six (6) months after Employee&#x2019;s &#x201c;separation from service&#x201d; (or, if earlier, Employee&#x2019;s death). Such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) in the absence of such deferral. Upon the expiration of the applicable deferral period, any compensation or benefits which would have otherwise been paid during that period (whether in a single lump sum or in installments) in the absence of this Section 10 shall be paid to Employee or Employee&#x2019;s beneficiary in one lump sum. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with Section 409A, the provision will be read in such a manner so that such payments hereunder are exempt from Section 409A to the maximum permissible extent, and for any payments where such construction is not tenable, that those payments comply with Section 409A to the maximum permissible extent. To the extent any nonqualified deferred compensation subject to Section 409A payable to Employee hereunder could be paid in one or more taxable years depending upon Employee completing certain employment-related actions (such as resigning after a failure to cure a Good Reason event and/or returning an effective release), then any such payments will commence or occur in the later taxable year to the extent required by Section 409A. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the U.S. Treasury Regulations.</font></p><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="display:inline;" id="x1__repayment_provisions_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Repayment Provisions.</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07916666666666666in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the Employee&#x2019;s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the Sarbanes-Oxley Act of 2002, or a successor provision, is then in effect, the Company may require the Employee to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Employee from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888886in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:7.06228097637827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="display:inline;" id="x2__miscellaneous_provisions_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous Provisions.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(a)</font><div style="display:inline;" id="xa__notice__notices_and_all_other_commun"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered, when mailed by overnight courier, or when sent by email (provided such email is not returned as undelivered). In the case of the Employee, mailed notices shall be addressed to him at the home address that he most recently communicated to the Employer in writing or the personal email address most recently communicated to the Employer in writing. In the case of the Employer, mailed notices shall be addressed to:</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(b)</font><div style="display:inline;" id="xb__modifications_and_waivers__no_provis"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications and Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the Employee and by an authorized officer of the Employer (other than the Employee). No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(c)</font><div style="display:inline;" id="xc__whole_agreement__except_for_those_ag"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whole Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except for those agreements or plans referenced herein (including without limitation any employee benefit plans of the Company in which the Employee is a participant in as of the Effective Date and the Indemnification Agreement), this Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) with respect to the subject matter hereof. In the event of any conflict in terms between this Agreement and any other agreement executed by and between the Employee and the Employer, the terms of this Agreement shall prevail and govern.</font></div></div><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(d)</font><div style="display:inline;" id="xd__withholding_taxes__all_payments_made"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(e)</font><div style="display:inline;" id="xe__choice_of_law__the_validity__interpr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Washington (except their provisions governing the choice of law).</font></div></div><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(f)</font><div style="display:inline;" id="xf__severability__blue_penciling__the_in"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability; Blue-Penciling</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. Furthermore, it is the intent, agreement and understanding of each party hereto that if, in any action before any court or agency legally empowered to enforce this Agreement, any term, restriction, covenant or promise in this Agreement is found to be unreasonable and for that or any other reason unenforceable, then such term, restriction, covenant or promise shall be deemed modified to the minimum extent necessary to make it enforceable by such court or agency; provided further that any such court or agency shall have the power to modify such provision, to the extent necessary to make it enforceable (for the maximum duration and geographic scope permissible), and such provision as so modified shall be enforced.</font></div></div><p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(g)</font><div style="display:inline;" id="xg__protected_activity__employee_underst"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protected Activity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Employee understands that nothing in this Agreement limits or prohibits Employee from filing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (&#x201c;Government Agencies&#x201d;), including disclosing documents or other information as permitted by law.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.0798611111111111in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(h)</font><div style="display:inline;" id="xh__assignment__the_employer_may_assign_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Employer may assign its rights under this Agreement to any entity that expressly in writing assumes the Employer&#x2019;s obligations hereunder in connection with any sale or transfer of all or substantially all of the Company&#x2019;s assets to such entity.</font></div></div><p style="font-size:10pt;margin-top:2.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.07013888888888889in;text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:0.09027777777777778in;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.5522273503065065%;">(i)</font><div style="display:inline;" id="xi__counterparts__this_agreement_may_be_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACHIEVE LIFE SCIENCES, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.5in;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: /s/Rick Stewart</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		<br>Name: Richard Stewart		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Chief Executive Officer</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signed:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.5in;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: /s/Erik Atkisson</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		 	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">		<br>Name: Erik Atkisson</font></p><p style="font-size:10pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div class="absolute-block-container" style="margin-left:-0.68in;z-index:6;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-0.68in;z-index:1;position:relative;"><div style="align-content:start;display:inline;padding-top:0in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.1675in;left:4.139in;padding-left:0in;width:0.2375in;padding-bottom:0in;position:absolute;padding-right:0in;height:0.1813in;"><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div style="padding-top:0.13in;z-index:2;min-height:0.79in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><p style="font-size:10pt;margin-top:2.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.015277777777777779in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.015277777777777779in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Inventions</font></p><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:5pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</font></p></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:0.68in;width:7.15in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.67in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.81in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;">&#160;</p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>achv-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-04-30T16:13:57.1101+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Andrew Goldberg, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this annual report on Form 10-K of Achieve Life Sciences, Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ ANDREW GOLDBERG</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew Goldberg</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer (Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>achv-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-04-30T16:13:57.1203+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="kl40901_exhibit_31_1"><font id="toc_kl40901_1"></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Mark Oki, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Achieve Life Sciences, Inc.;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;text-indent:4.985%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: April 30, 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ MARK OKI</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Oki</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>achv-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-04-30T16:14:00.2203+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ir.achievelifesciences.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:achv="http://ir.achievelifesciences.com/20251231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk" id="Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk">
        <link:definition>995467 - Disclosure - Nature of Business, Basis of Presentation and Liquidity Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPolicies" id="Role_DisclosureAccountingPolicies">
        <link:definition>995477 - Disclosure - Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRisk" id="Role_DisclosureFinancialInstrumentsAndRisk">
        <link:definition>995487 - Disclosure - Financial Instruments and Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrant" id="Role_DisclosureGovernmentGrant">
        <link:definition>995497 - Disclosure - Government Grant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangibles" id="Role_DisclosureIntangibles">
        <link:definition>995507 - Disclosure - Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>995517 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995527 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>995537 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebt" id="Role_DisclosureConvertibleDebt">
        <link:definition>995547 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTax" id="Role_DisclosureIncomeTax">
        <link:definition>995557 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995567 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995577 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995587 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>995597 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies" id="Role_DisclosureAccountingPoliciesPolicies">
        <link:definition>995607 - Disclosure - Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesTables" id="Role_DisclosureAccountingPoliciesTables">
        <link:definition>995617 - Disclosure - Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesTables" id="Role_DisclosureIntangiblesTables">
        <link:definition>995627 - Disclosure - Intangibles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995637 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>995647 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtTables" id="Role_DisclosureConvertibleDebtTables">
        <link:definition>995657 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables" id="Role_DisclosureIncomeTaxTables">
        <link:definition>995667 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995677 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995687 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail">
        <link:definition>995697 - Disclosure - Nature of Business, Basis of Presentation and Liquidity Risk - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995707 - Disclosure - Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail" id="Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail">
        <link:definition>995717 - Disclosure - Accounting Policies - Summary of Depreciation on Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail">
        <link:definition>995727 - Disclosure - Financial Instruments and Risk - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails" id="Role_DisclosureGovernmentGrantAdditionalInformationDetails">
        <link:definition>995737 - Disclosure - Government Grant - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail" id="Role_DisclosureIntangiblesAdditionalInformationDetail">
        <link:definition>995747 - Disclosure - Intangibles - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" id="Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail">
        <link:definition>995757 - Disclosure - Intangibles - Components of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" id="Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail">
        <link:definition>995767 - Disclosure - Intangibles - Estimated Future Amortization Expense Related to Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetail">
        <link:definition>995777 - Disclosure - License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995787 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>995797 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" id="DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>995807 - Disclosure - Fair Value Measurements - Summary of Cash, Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails" id="DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails">
        <link:definition>995817 - Disclosure - Fair Value Measurements - Schedule of Corporate Bonds and Commercial Paper (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail" id="Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail">
        <link:definition>995827 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails" id="DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails">
        <link:definition>995837 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Level 3 Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
        <link:definition>995847 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails" id="Role_DisclosureConvertibleDebtAdditionalInformationDetails">
        <link:definition>995857 - Disclosure - Convertible Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails" id="DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails">
        <link:definition>995867 - Disclosure - Convertible Debt - Schedule of Convertible Term Loan Balance Including Convertible Debt Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail" id="Role_DisclosureIncomeTaxAdditionalInformationDetail">
        <link:definition>995877 - Disclosure - Income Tax - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail">
        <link:definition>995887 - Disclosure - Income Tax - Summary of U.S. and Foreign Components of Income (Loss) before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail" id="Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail">
        <link:definition>995897 - Disclosure - Income Tax - Reconciliation of Income Tax Attributable to Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>995907 - Disclosure - Income Tax - Summary of Tax Effects of Temporary Differences and Carryforwards Rise to Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails" id="DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails">
        <link:definition>995917 - Disclosure - Income Tax - Summary of Components of Cash Income Taxes Paid Net of Refunds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail" id="Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail">
        <link:definition>995927 - Disclosure - Income Tax - Reconciliation of Unrecognized Tax Benefits of Uncertain Tax Positions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail" id="Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail">
        <link:definition>995937 - Disclosure - Income Tax - Summary of Years Open to Examination under Different Jurisdiction (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail" id="Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail">
        <link:definition>995947 - Disclosure - Common Stock - Authorized - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail" id="Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail">
        <link:definition>995957 - Disclosure - Common Stock - Issued and Outstanding Shares - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail" id="DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail">
        <link:definition>995967 - Disclosure - Common Stock - Open Market Sale Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails" id="DisclosureCommonStockPublicOfferingAdditionalInformationDetails">
        <link:definition>995977 - Disclosure - Common Stock- Public Offering - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail" id="DisclosureCommonStockEquityAwardsAdditionalInformationDetail">
        <link:definition>995987 - Disclosure - Common Stock - Equity Awards - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail" id="Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail">
        <link:definition>995997 - Disclosure - Common Stock - Summary of Fair Value of Option Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail" id="DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail">
        <link:definition>996007 - Disclosure - Common Stock - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail" id="Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail">
        <link:definition>996017 - Disclosure - Common Stock - Summary of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail" id="Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail">
        <link:definition>996027 - Disclosure - Common Stock - Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Outstanding Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail" id="Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail">
        <link:definition>996037 - Disclosure - Common Stock - Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Vested Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail" id="Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail">
        <link:definition>996047 - Disclosure - Common Stock - Restricted Stock Unit Awards - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail" id="Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail">
        <link:definition>996057 - Disclosure - Common Stock - Summary of Restricted Stock Unit Award Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail" id="DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail">
        <link:definition>996067 - Disclosure - Common Stock - Employee Stock Purchase Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail" id="Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail">
        <link:definition>996077 - Disclosure - Common Stock - Summary of Outstanding Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail" id="Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail">
        <link:definition>996087 - Disclosure - Common Stock - Stock Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail" id="Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail">
        <link:definition>996097 - Disclosure - Common Stock - Computation of Basic and Diluted Net Loss Attributable to Common Shareholders Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail" id="Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail">
        <link:definition>996107 - Disclosure - Common Stock - Loss Per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>996117 - Disclosure - Related Party Transactions (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
        <link:definition>996127 - Disclosure - Commitments and Contingencies - Summary of Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>996137 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail">
        <link:definition>996147 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Annual Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail">
        <link:definition>996157 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>996167 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails" xlink:href="achv-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="achv-20251231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails" xlink:href="achv-20251231.xsd#DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails" xlink:href="achv-20251231.xsd#DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="achv-20251231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="achv-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail" xlink:href="achv-20251231.xsd#Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails" xlink:href="achv-20251231.xsd#Role_DisclosureGovernmentGrantAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="achv-20251231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="achv-20251231.xsd#DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail" xlink:href="achv-20251231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails" xlink:href="achv-20251231.xsd#DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails" xlink:href="achv-20251231.xsd#Role_DisclosureConvertibleDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail" xlink:href="achv-20251231.xsd#DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails" xlink:href="achv-20251231.xsd#DisclosureCommonStockPublicOfferingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#DisclosureCommonStockEquityAwardsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail" xlink:href="achv-20251231.xsd#DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:href="achv-20251231.xsd#DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="achv-20251231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk" xlink:href="achv-20251231.xsd#Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPolicies" xlink:href="achv-20251231.xsd#Role_DisclosureAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRisk" xlink:href="achv-20251231.xsd#Role_DisclosureFinancialInstrumentsAndRisk" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrant" xlink:href="achv-20251231.xsd#Role_DisclosureGovernmentGrant" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangibles" xlink:href="achv-20251231.xsd#Role_DisclosureIntangibles" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="achv-20251231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="achv-20251231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="achv-20251231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebt" xlink:href="achv-20251231.xsd#Role_DisclosureConvertibleDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTax" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTax" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="achv-20251231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="achv-20251231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies" xlink:href="achv-20251231.xsd#Role_DisclosureAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesTables" xlink:href="achv-20251231.xsd#Role_DisclosureAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesTables" xlink:href="achv-20251231.xsd#Role_DisclosureIntangiblesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="achv-20251231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="achv-20251231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtTables" xlink:href="achv-20251231.xsd#Role_DisclosureConvertibleDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIntangiblesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail" xlink:href="achv-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="achv-20251231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock" xlink:label="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IndemnificationExpense" xlink:label="achv_IndemnificationExpense"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmendmentToLicenseAgreementMember" xlink:label="achv_AmendmentToLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PikeMember" xlink:label="achv_PikeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RestrictedCashMember" xlink:label="achv_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_KristenSlaouiMember" xlink:label="achv_KristenSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:label="us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AreaOfOfficeSpaceLeased" xlink:label="achv_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfSecurities" xlink:label="achv_MaturityPeriodOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyConsultingFeeIncurred" xlink:label="achv_RelatedPartyConsultingFeeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EmployeesAndConsultantsMember" xlink:label="achv_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccretionOfDiscountOnModificationDebt" xlink:label="achv_AccretionOfDiscountOnModificationDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtTable" xlink:label="achv_ConvertibleDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesTable" xlink:label="achv_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrantAwarded" xlink:label="achv_GrantAwarded"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentWithdrawalAmount" xlink:label="achv_DebtInstrumentWithdrawalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockSharesAvailableForFutureGrant" xlink:label="achv_CommonStockSharesAvailableForFutureGrant"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesOfCommonStock" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ReimbursementsReceived" xlink:label="achv_ReimbursementsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ResearchAndDevelopmentExpensesIncreaseDecrease" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RegistrationRightsAgreementMember" xlink:label="achv_RegistrationRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BoardOfDirectorsMember" xlink:label="achv_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DirectOfferingMember" xlink:label="achv_DirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantLineItems" xlink:label="achv_GovernmentGrantLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantTable" xlink:label="achv_GovernmentGrantTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndTenPerformanceIncentivePlanMember" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_November2022PrivatePlacementMember" xlink:label="achv_November2022PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" xlink:label="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DefferedTaxLiabilitiesRightOfUseAssets" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PublicOfferingMember" xlink:label="achv_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JuneTwentyTwentyFivePublicOfferingMember" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingDiscounts" xlink:label="achv_UnderwritingDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAugustTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SopharmaMember" xlink:label="achv_SopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesLineItems" xlink:label="achv_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCosts" xlink:label="achv_AmortizationOfTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositAnnualPayment" xlink:label="achv_LeaseSecurityDepositAnnualPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositThereafter" xlink:label="achv_LeaseSecurityDepositThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsPolicyTextBlock" xlink:label="achv_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SeattleOfficeOperatingLeaseMember" xlink:label="achv_SeattleOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseAgreementCommencementDate" xlink:label="achv_LeaseAgreementCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TaxCreditCarryForwardExpirationYear" xlink:label="achv_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewConvertibleTermLoanMember" xlink:label="achv_NewConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PlacementAgentFeesAndOfferingExpenses" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DiscountOnModificationOfDebt" xlink:label="achv_DiscountOnModificationOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtLineItems" xlink:label="achv_ConvertibleDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ComputerSoftwareMember" xlink:label="achv_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperCashEquivalentsMember" xlink:label="achv_CommercialPaperCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromIssuanceOfCommonStockGross" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AverageDailyTradingVolumeForMeasurementPeriod" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_StockUnitsDescription" xlink:label="achv_StockUnitsDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JefferiesOpenMarketSaleAgreementMember" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseMember" xlink:label="achv_NationalInstituteOnDrugAbuseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ORCAV1ClinicalStudyCostsMember" xlink:label="achv_ORCAV1ClinicalStudyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesAcquired" xlink:label="achv_PercentageOfOutstandingSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfUnitsIssuedInFinancing" xlink:label="achv_NumberOfUnitsIssuedInFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromFinancing" xlink:label="achv_ProceedsFromFinancing"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsLiabilitiesValuationAllowance" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearOne" xlink:label="achv_LeaseSecurityDepositYearOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConsiderationMember" xlink:label="achv_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesLineItems" xlink:label="achv_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInMayTwoThousandNinteenMember" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MeasurementInputProbabilityOfSuccessMember" xlink:label="achv_MeasurementInputProbabilityOfSuccessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfAverageClosingSalePrice" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConvertibleDebtAgreementMember" xlink:label="achv_ContingentConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionAmountsPayable" xlink:label="achv_RelatedPartyTransactionAmountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfVotingPower" xlink:label="achv_PercentageOfVotingPower"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumMaturityPeriodOfCashAndCashEquivalents" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtAgreementMember" xlink:label="achv_ConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AtMarketSalesAgreementMember" xlink:label="achv_AtMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrantPolicyTextBlock" xlink:label="achv_GrantPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonConvertibleTermLoansMember" xlink:label="achv_NonConvertibleTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCost" xlink:label="achv_AmortizationOfTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DrSlaouiMember" xlink:label="achv_DrSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfSecuritiesExercisedAccompanyingWarrants" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementMember" xlink:label="achv_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAndWarrantsMember" xlink:label="achv_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantsOrRightExpirationDate" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsIndefinitely" xlink:label="achv_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherAddressMember" xlink:label="dei_OtherAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionExpensesExpectedToIncur" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfClosingTradingSharePrice" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPayments" xlink:label="achv_MonthlyBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAggregateMaximumOfferingAmount" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RegulatoryAssetsAbstract" xlink:label="achv_RegulatoryAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExercisableSubjectToCertainOwnershipLimitationsMember" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SweepAccountMember" xlink:label="achv_SweepAccountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WorkingCapitalBalance" xlink:label="achv_WorkingCapitalBalance"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UniversityOfBristolMember" xlink:label="achv_UniversityOfBristolMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonCapitalGainLossCarryforwardsAmount" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearTwo" xlink:label="achv_LeaseSecurityDepositYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AfterEighteenMonthAnniversaryMember" xlink:label="achv_AfterEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PaymentsUnderLicenseAgreement" xlink:label="achv_PaymentsUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingMember" xlink:label="achv_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" xlink:label="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BeforeEighteenMonthAnniversaryMember" xlink:label="achv_BeforeEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperMarketableSecuritiesMember" xlink:label="achv_CommercialPaperMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndLenderMember" xlink:label="achv_SiliconValleyBankAndLenderMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockPricePerUnit" xlink:label="achv_CommonStockPricePerUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsExpirationYear" xlink:label="achv_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantsTextBlock" xlink:label="achv_GovernmentGrantsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MinimumMarketCapitalization" xlink:label="achv_MinimumMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_Rule10B51ArrModifiedFlag" xlink:label="achv_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleTermLoanMember" xlink:label="achv_ConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA-BC" xlink:label="stpr_CA-BC"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrepaidExpensesRelatedParty" xlink:label="achv_PrepaidExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonRule10B51ArrModifiedFlag" xlink:label="achv_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDevelopmentAgreements" xlink:label="achv_NumberOfDevelopmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesTable" xlink:label="achv_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrimeRateMinusOnePercentageMember" xlink:label="achv_PrimeRateMinusOnePercentageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewEmployeeInducementGrantsMember" xlink:label="achv_NewEmployeeInducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Cash Income Taxes Paid Net of Refunds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares reserved for issuance under incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase agreement contingent consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Agreement Contingent Consideration [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Purchase Agreement Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IndemnificationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to indemnification issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IndemnificationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IndemnificationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmendmentToLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment to the University of Bristol License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmendmentToLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment To License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmendmentToLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment to license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of contingent consideration [note 4 and note 5]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of contingent consideration [note 5 and note 6]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PikeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pike [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PikeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pike [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PikeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pike.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants [note 10[g]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In June Two Thousand Twenty Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in June two thousand twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in June 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liablilty Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt compound interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible debt, stated rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Indebtedness [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeiture rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Agency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_KristenSlaouiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Kristen Slaoui [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_KristenSlaouiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Kristen Slaoui.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCostsForContractsOrProgramsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Costs for Contracts or Programs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCostsForContractsOrProgramsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office Space Leased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AreaOfOfficeSpaceLeased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space leased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period of securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Period Of Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity period of securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyConsultingFeeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Consulting Fee Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyConsultingFeeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party consulting fee incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyConsultingFeeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting fees incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in allowance considered deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax expense (benefit) excluding adjustment for reversal of deferred tax liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense/(recovery), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments and Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax rate assumed for both State and Foreign deferred tax calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax recovery at U.S. federal statutory income tax rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense/(recovery), Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense/(recovery), Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccretionOfDiscountOnModificationDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of discount on modification of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccretionOfDiscountOnModificationDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion of Discount On Modification Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccretionOfDiscountOnModificationDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of discount on modification debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Examination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Examination [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax basis in excess of book value of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adare Pharma Solutions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Related Parties [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant awarded.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Non Employee Director Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Non Employee Director Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Non Employee Director Equity Incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentWithdrawalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Drawn amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentWithdrawalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Withdrawal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentWithdrawalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument withdrawal amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Optioned Common Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Attributable to Common Shareholders Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net loss per common share [note 10 [i]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockSharesAvailableForFutureGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for sale under offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockSharesAvailableForFutureGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Available For Future Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockSharesAvailableForFutureGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, shares available for future grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Outstanding Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares reserved for options currently outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Optioned Common Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Optioned Common Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ReimbursementsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Equity Securities, FV-NI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash proceeds from the sale and issuance of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, Federal, after Refund Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Paid, Federal, after Refund Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum beneficial ownership percentage of outstanding common stock for warrant holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Beneficial Ownership Percentage Of Outstanding Common Stock For Warrant Holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum beneficial ownership percentage of outstanding common stock for warrant holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Examination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of cross-border laws, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable [note 4]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Optioned Common Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Optioned Common Shares, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock and warrant, public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction in R&amp;D expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses Increase Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses increase (decrease).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RegistrationRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registration Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RegistrationRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Registration rights agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RegistrationRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registration Rights Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Weighted Average Remaining Contractual Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, repayment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax recovery at U.S. federal statutory income tax rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per Common Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board Of Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BoardOfDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Board of directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range ten [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Ten [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range ten.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grant [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grant [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Option Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares authorized to purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Maximum Number Of Shares Authorized To Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation, maximum number of shares authorized to purchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grant [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grant [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2010 Performance Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands And Ten Performance Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information pertaining to 2010 performance incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_November2022PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2022 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_November2022PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November2022 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_November2022PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">November2022 Private Placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reporting Currency and Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets [note 12]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Current Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Return Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of unrecognized tax benefits, excluding amounts pertaining to examined tax return roll forward.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits of Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deffered tax liabilities, right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deffered Tax Liabilities, Right of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Twenty Twenty Five Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June twenty twenty five public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2025 Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Decrease Resulting From Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases decrease resulting from current period tax positions,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions (reductions) from tax positions taken in the current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price exceeds in measurement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Exercise Price Exceeds In Measurement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of exercise price exceeds in measurement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from earning per share computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants Issued in August 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In August Two Thousand Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in August two thousand twenty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sopharma</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sopharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option exercises, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositAnnualPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, security deposit, annual payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositAnnualPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Security Deposit Annual Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositAnnualPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease security deposit annual payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unclaimed tax deductions related to scientific research and experimental development expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unclaimed tax deductions related to scientific research and experimental development expenditures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold consecutive trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Lender</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic state &amp; local income tax, net of federal income tax effect, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, security deposit payment remaining amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Security Deposit Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease security deposit thereafter.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Tax Effects of Temporary Differences and Carryforwards Rise to Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share holding percentage of shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Holding Percentage Of Shares Issued And Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share holding percentage of shares issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Optioned Common Shares, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, Foreign, after Refund Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Paid, Foreign, after Refund Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">More than 5 years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SeattleOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle Lease Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SeattleOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Seattle Office Operating Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SeattleOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Seattle office operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Number of Vested Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TaxCreditCarryForwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carry forward expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Corporate Bonds and Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Convertible Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Convertible Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Convertible Term Loan Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent fees and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Fees And Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent fees and offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extension term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, amortized cost and estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Prepayment Fee Percentage On Or After First Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt prepayment fee percentage on or after first anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage on or after first anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DiscountOnModificationOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Discount on modification of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DiscountOnModificationOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discount On Modification of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DiscountOnModificationOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discount on modification of debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Instrument Convertible Beneficial Ownership Percentage for Exercise Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity instrument convertible beneficial ownership percentage for exercise option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity instrument, convertible beneficial ownership percentage for exercise by holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial paper cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper (cash equivalents) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Paper (Cash Equivalents) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average daily trading volume for measurement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average Daily Trading Volume For Measurement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Average daily trading volume for measurement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_StockUnitsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Units Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_StockUnitsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Units Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_StockUnitsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of stock units issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases decrease resulting from prior period tax positions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions (reductions) from tax positions taken in prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax penalties or accrued interest recorded</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment under capital lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Held under Capital Leases [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies Open Market Sale Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Open Market Sale Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies open market sale agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NIDA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institute On Drug Abuse [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National Institute on Drug Abuse.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computation of basic net loss per common share [note 10 [i]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ORCAV1ClinicalStudyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORCA-V1 Clinical Study Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ORCAV1ClinicalStudyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">O R C A V1 Clinical Study Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ORCAV1ClinicalStudyCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ORCA-V1 Clinical study costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of the exercisable outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of securities called by warrants or rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares to be issued accompanying warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Attributable to Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued paid-in-kind interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Prepayment Fee Percentage On Original Aggregate Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Prepayment Fee Percentage On Original Aggregate Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage on original aggregate principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Outstanding Shares Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfOutstandingSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements and equipment under capital lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands And Seventeen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information pertaining to 2017 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average days to maturity of Company's portfolio of cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Average Period To Maturity For Portfolio Of Cash And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Average period to maturity for portfolio of cash and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfUnitsIssuedInFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of units issued in financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfUnitsIssuedInFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Units Issued In Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfUnitsIssuedInFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of units issued in financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Owned and Sold, Not yet Purchased Fair Value, Security Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for lease obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank And S V B Innovation Credit Fund V I I I L P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ProceedsFromFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax assets liabilities, valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities valuation allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, security deposit payment first anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Security Deposit Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease security deposit year one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WarrantsIssuedInMayTwoThousandNinteenMember.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in May 2019 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In May Two Thousand Ninteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_VancouverOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vancouver Lease Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_VancouverOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vancouver Office Operating Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_VancouverOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vancouver Office Operating Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_VancouverOfficeOperatingLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vancouver office operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business, Basis of Presentation and Going Concern Uncertainty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Outstanding and Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MeasurementInputProbabilityOfSuccessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input, probability of success.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MeasurementInputProbabilityOfSuccessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Probability of Success [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Impact Of Tax Attribute Expirations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation impact of tax attribute expirations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of tax attribute expirations, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contigent consideration [note 6 and note 7]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Agency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, All Other Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Percentage Of Average Closing Sale Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price percentage of Average closing sale price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price percentage of average closing sale price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other foreign jurisdictions, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Convertible Debt Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Convertible Debt Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContingentConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent convertible debt agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range nine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per share of warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in November 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In November Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Issued In November Two Thousand Twenty Two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionAmountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionAmountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction amounts payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionAmountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfVotingPower_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Voting Power</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfVotingPower_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of voting power.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PercentageOfVotingPower_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of voting power</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NIDA/NIH</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institute On Drug Abuse And National Institutes Of Health [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National institute on drug abuse and national institutes of health.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum maturity period of cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Maturity Period Of Cash And Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum maturity period of cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Unit Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleDebtAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Debt Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enactment of new tax laws, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AtMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AtMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AtMarketSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-Market Sales Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other foreign jurisdictions, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Gross Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrantPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computation of Diluted net loss per common share [note 10 [i]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount of term loan advances extended percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extended Percentage Of Aggregate Principal Amount Of Term Loan Advances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extended percentage of aggregate principal amount of term loan advances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonConvertibleTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Convertible Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonConvertibleTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Convertible Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonConvertibleTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-convertible term loans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation Fiscal Year Maturity Schedule [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Fiscal Year Maturity Schedule [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation fiscal year maturity schedule.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of transaction cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AmortizationOfTransactionCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License agreement [note 4 and note 5]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in December 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In December Two Thousand Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued In December two thousand twenty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enactment of new tax laws, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated rent and facilities expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Standards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Annual Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DrSlaouiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Slaoui.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DrSlaouiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dr. Slaoui [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period of liquid investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity period of highly liquid investments to be considered as cash equivalent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Securities Exercised Accompanying Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities exercised accompanying warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities exercised accompanying warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of principal amount to be repaid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation Fiscal Year Maturity Schedule [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Fiscal Year Maturity Schedule [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual obligation fiscal year maturity schedule table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense related to the Company's restricted stock unit awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Stock Price Trigger</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock trigger price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SharePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contractual Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Silicon Valley Bank Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four silicon valley bank convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 SVB Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock and Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Or Right Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants or right expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent, maximum annual increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Base Rental Payments Maximum Annual Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly base rental payments maximum annual increase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Additional Number of Shares to be Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, additional number of shares to be issued in transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of shares to be issued as option in part</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation, Pecent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Award Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of the outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Term Loan Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinitely.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Covenant compliance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Covenant Compliance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, to be Paid, Year Two and Three, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1-3 years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Two and Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_OtherAddressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Address [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_OtherAddressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Address</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related party transaction expenses expected to incur</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction expenses expected to incur.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses expected to incur</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount payable under license agreement, tied to milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Required Payment Under License Agreement Upon Completion Of Various Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum required payment under license agreement upon completion of various milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Upper Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reductions due to lapses of statute of limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of U.S. and Foreign Components of Income (Loss) before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt, Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of tax attribute expirations, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Impact Of Tax Attribute Expirations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation impact of tax attribute expirations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Percentage Of Closing Trading Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion Price Percentage Of Closing Trading Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price percentage of closing trading share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 SVB Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Silicon Valley Bank Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three silicon valley bank convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan amount drawn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In February Two Thousand And Twenty Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Issued In February Two Thousand And Twenty Four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in February 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Depreciation on Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property plant and equipment estimated useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage after second anniversary before maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Prepayment Fee Percentage After Second Anniversary And Before Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt prepayment fee percentage after second anniversary before maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2022 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly base rental payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MonthlyBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Base Rental Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money market securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market securities (cash equivalents) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days Option Granted To Purchase Additional Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days option granted to purchase additional shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days option granted to purchase additional shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Gross unrecognized tax benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Gross unrecognized tax benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range one [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation shares authorized under stock option plans by exercise price range one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock aggregate maximum offering amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Aggregate Maximum Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock aggregate maximum offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Years open to examination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RegulatoryAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_RegulatoryAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Vested Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Vested Under Stock Option Plans By Exercise Price Range Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based compensation shares vested under stock option plans by exercise price range.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, to be Paid, Year Four and Five, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">3-5 years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year Four and Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable Subject to Certain Ownership Limitations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercisable Subject to Certain Ownership Limitations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercisable subject to certain ownership limitations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock unit settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock unit settlements, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SweepAccountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sweep Account [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SweepAccountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sweep account.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right New Exercise Price Of Warrants Or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right new exercise price of warrants or rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in April two thousand twenty 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in April 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In April Two Thousand Twenty1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, liquidity ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value of total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value of total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WorkingCapitalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WorkingCapitalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WorkingCapitalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares agreed to issue and sell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Potential Number of Shares to be Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, potential number of shares to be issued in transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UniversityOfBristolMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Bristol [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UniversityOfBristolMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Bristol [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UniversityOfBristolMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Bristol.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic state &amp; local income tax, net of federal income tax effect, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Future Amortization Expense Related to Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future enacted income tax rate assumed for both Federal and state deferred tax calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Income Tax Rate Assumed For Deferred Tax Calculations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future income tax rate assumed for deferred tax calculations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in April 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In April Two Thousand Twenty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in April two thousand twenty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-capital loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Capital Gain Loss Carryforwards Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non capital gain loss carryforwards amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flows Information Related To Leases Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flows information related to leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, security deposit payment two anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Security Deposit Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_LeaseSecurityDepositYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease security deposit year two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash, Cash Equivalents and Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of cross-border laws, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage occurs after first anniversary but on or prior to the second anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Prepayment Fee Percentage Occurs After First Anniversary But On Or Prior To The Second Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt prepayment fee percentage occurs after first anniversary but on or prior to the second anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Lower Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties related to income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AfterEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 18-Month Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AfterEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">After Eighteen Month Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AfterEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">After eighteen month anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of required consecutive days weighted average trading price for cancelation or recall of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Required Consecutive Days Weighted Average Trading Price for Cancelation or Recall of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of required consecutive days weighted average trading price for cancelation or recall of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Weighted Average Vested Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from offering, net of issuance costs [note 11[b]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PaymentsUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments under license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PaymentsUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PaymentsUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, State and Local, after Refund Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Paid, State and Local, after Refund Received, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_UnderwritingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreements Executed In November Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Agreements Executed In November Two Thousand Twenty Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription Agreements Executed In November Two Thousand Twenty Two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net loss per common share [note 10 [i]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Changes in Fair Value of Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of changes in fair value of liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Fair Value of Level 3 Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BeforeEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Before 18-Month Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BeforeEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Before Eighteen Month Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_BeforeEighteenMonthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Before eighteen month anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Equity Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible debt principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt, Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial paper marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommercialPaperMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper (marketable securities) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Prior Notice to Increase or Decrease Ownership Limitation on Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days prior notice to increase or decrease ownership limitation on warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of days prior notice to increase or decrease ownership limitation on warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Lease Term Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndLenderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank And Lender [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndLenderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank And Lender [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_SiliconValleyBankAndLenderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB and Lender [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in April two thousand twenty 2.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in April 2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In April Two Thousand Twenty2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockPricePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, price per unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockPricePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Price Per Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_CommonStockPricePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock price per unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Book Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Years Open to Examination Under Different Jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Examinations [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation [note 10[c], note 10[d], note 10[e]] and note 10[f]]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financing costs relating to purchase agreement with Lincoln Park Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent fees and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_GovernmentGrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MinimumMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum market capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MinimumMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Market Capitalization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_MinimumMarketCapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market capitalization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Discount Rate Operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_ConvertibleTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA-BC_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vancouver, British Columbia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA-BC_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BRITISH COLUMBIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents, amortized cost and estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrepaidExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrepaidExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrepaidExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment of expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NonRule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonRule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDevelopmentAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of development agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NumberOfDevelopmentAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of development agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range, Number of Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Threshold Percentage Of Conversion Amount Of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument convertible threshold percentage of conversion amount of debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold percentage of conversion amount of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrimeRateMinusOnePercentageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate Minus 1.0% [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrimeRateMinusOnePercentageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate Minus One Percentage [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_PrimeRateMinusOnePercentageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prime rate minus one percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense related to stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewEmployeeInducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Employee Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewEmployeeInducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Employee Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_NewEmployeeInducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New employee inducement grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number of Securities Underwriters Exercised by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Number of Securities Underwriters Exercised by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number of securities underwriters exercised by warrants or rights in part</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt conversion description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper (short term investments) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares reserved for issuance under incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period, restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued in December 2019 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In December Two Thousand Nineteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued in december two thousand nineteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 1 year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock" xlink:to="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IndemnificationExpense" xlink:to="achv_IndemnificationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AmendmentToLicenseAgreementMember" xlink:to="achv_AmendmentToLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PikeMember" xlink:to="achv_PikeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:to="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RestrictedCashMember" xlink:to="achv_RestrictedCashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="us-gaap_RegulatoryAgencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_KristenSlaouiMember" xlink:to="achv_KristenSlaouiMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:to="us-gaap_InventoryCostsForContractsOrProgramsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AreaOfOfficeSpaceLeased" xlink:to="achv_AreaOfOfficeSpaceLeased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MaturityPeriodOfSecurities" xlink:to="achv_MaturityPeriodOfSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RelatedPartyConsultingFeeIncurred" xlink:to="achv_RelatedPartyConsultingFeeIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_EmployeesAndConsultantsMember" xlink:to="achv_EmployeesAndConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AccretionOfDiscountOnModificationDebt" xlink:to="achv_AccretionOfDiscountOnModificationDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConvertibleDebtTable" xlink:to="achv_ConvertibleDebtTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AccountingPoliciesTable" xlink:to="achv_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxExaminationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PreFundedWarrantsMember" xlink:to="achv_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GrantAwarded" xlink:to="achv_GrantAwarded_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" xlink:to="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtInstrumentWithdrawalAmount" xlink:to="achv_DebtInstrumentWithdrawalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommonStockSharesAvailableForFutureGrant" xlink:to="achv_CommonStockSharesAvailableForFutureGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PercentageOfOutstandingSharesOfCommonStock" xlink:to="achv_PercentageOfOutstandingSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ReimbursementsReceived" xlink:to="achv_ReimbursementsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" xlink:to="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ResearchAndDevelopmentExpensesIncreaseDecrease" xlink:to="achv_ResearchAndDevelopmentExpensesIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RegistrationRightsAgreementMember" xlink:to="achv_RegistrationRightsAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_BoardOfDirectorsMember" xlink:to="achv_BoardOfDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DirectOfferingMember" xlink:to="achv_DirectOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_GovernmentGrantLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" xlink:to="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GovernmentGrantTable" xlink:to="achv_GovernmentGrantTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandsAndTenPerformanceIncentivePlanMember" xlink:to="achv_TwoThousandsAndTenPerformanceIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_November2022PrivatePlacementMember" xlink:to="achv_November2022PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" xlink:to="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DefferedTaxLiabilitiesRightOfUseAssets" xlink:to="achv_DefferedTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PublicOfferingMember" xlink:to="achv_PublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_JuneTwentyTwentyFivePublicOfferingMember" xlink:to="achv_JuneTwentyTwentyFivePublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UnderwritingDiscounts" xlink:to="achv_UnderwritingDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" xlink:to="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" xlink:to="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInAugustTwoThousandTwentyMember" xlink:to="achv_WarrantsIssuedInAugustTwoThousandTwentyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SopharmaMember" xlink:to="achv_SopharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AmortizationOfTransactionCosts" xlink:to="achv_AmortizationOfTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_LeaseSecurityDepositAnnualPayment" xlink:to="achv_LeaseSecurityDepositAnnualPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" xlink:to="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_LeaseSecurityDepositThereafter" xlink:to="achv_LeaseSecurityDepositThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="achv_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" xlink:to="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsPolicyTextBlock" xlink:to="achv_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SeattleOfficeOperatingLeaseMember" xlink:to="achv_SeattleOfficeOperatingLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_LeaseAgreementCommencementDate" xlink:to="achv_LeaseAgreementCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TaxCreditCarryForwardExpirationYear" xlink:to="achv_TaxCreditCarryForwardExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NewConvertibleTermLoanMember" xlink:to="achv_NewConvertibleTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PlacementAgentFeesAndOfferingExpenses" xlink:to="achv_PlacementAgentFeesAndOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" xlink:to="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DiscountOnModificationOfDebt" xlink:to="achv_DiscountOnModificationOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConvertibleDebtLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ComputerSoftwareMember" xlink:to="achv_ComputerSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" xlink:to="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommercialPaperCashEquivalentsMember" xlink:to="achv_CommercialPaperCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ProceedsFromIssuanceOfCommonStockGross" xlink:to="achv_ProceedsFromIssuanceOfCommonStockGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AverageDailyTradingVolumeForMeasurementPeriod" xlink:to="achv_AverageDailyTradingVolumeForMeasurementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_StockUnitsDescription" xlink:to="achv_StockUnitsDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_JefferiesOpenMarketSaleAgreementMember" xlink:to="achv_JefferiesOpenMarketSaleAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NationalInstituteOnDrugAbuseMember" xlink:to="achv_NationalInstituteOnDrugAbuseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ORCAV1ClinicalStudyCostsMember" xlink:to="achv_ORCAV1ClinicalStudyCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" xlink:to="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PercentageOfOutstandingSharesAcquired" xlink:to="achv_PercentageOfOutstandingSharesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" xlink:to="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" xlink:to="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfUnitsIssuedInFinancing" xlink:to="achv_NumberOfUnitsIssuedInFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:to="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ProceedsFromFinancing" xlink:to="achv_ProceedsFromFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DeferredTaxAssetsLiabilitiesValuationAllowance" xlink:to="achv_DeferredTaxAssetsLiabilitiesValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_LeaseSecurityDepositYearOne" xlink:to="achv_LeaseSecurityDepositYearOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ContingentConsiderationMember" xlink:to="achv_ContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="achv_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInMayTwoThousandNinteenMember" xlink:to="achv_WarrantsIssuedInMayTwoThousandNinteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_VancouverOfficeOperatingLeaseMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MeasurementInputProbabilityOfSuccessMember" xlink:to="achv_MeasurementInputProbabilityOfSuccessMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" xlink:to="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" xlink:to="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConversionPricePercentageOfAverageClosingSalePrice" xlink:to="achv_ConversionPricePercentageOfAverageClosingSalePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ContingentConvertibleDebtAgreementMember" xlink:to="achv_ContingentConvertibleDebtAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" xlink:to="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RelatedPartyTransactionAmountsPayable" xlink:to="achv_RelatedPartyTransactionAmountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PercentageOfVotingPower" xlink:to="achv_PercentageOfVotingPower_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" xlink:to="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MaximumMaturityPeriodOfCashAndCashEquivalents" xlink:to="achv_MaximumMaturityPeriodOfCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConvertibleDebtAgreementMember" xlink:to="achv_ConvertibleDebtAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AtMarketSalesAgreementMember" xlink:to="achv_AtMarketSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GrantPolicyTextBlock" xlink:to="achv_GrantPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" xlink:to="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NonConvertibleTermLoansMember" xlink:to="achv_NonConvertibleTermLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="achv_ContractualObligationFiscalYearMaturityScheduleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AmortizationOfTransactionCost" xlink:to="achv_AmortizationOfTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DrSlaouiMember" xlink:to="achv_DrSlaouiMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" xlink:to="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfSecuritiesExercisedAccompanyingWarrants" xlink:to="achv_NumberOfSecuritiesExercisedAccompanyingWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:to="achv_ContractualObligationFiscalYearMaturityScheduleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SharePurchaseAgreementMember" xlink:to="achv_SharePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" xlink:to="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommonStockAndWarrantsMember" xlink:to="achv_CommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ClassOfWarrantsOrRightExpirationDate" xlink:to="achv_ClassOfWarrantsOrRightExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" xlink:to="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" xlink:to="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_OperatingLossCarryforwardsIndefinitely" xlink:to="achv_OperatingLossCarryforwardsIndefinitely_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherAddressMember" xlink:to="dei_OtherAddressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RelatedPartyTransactionExpensesExpectedToIncur" xlink:to="achv_RelatedPartyTransactionExpensesExpectedToIncur_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" xlink:to="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GrossProceedsFromIssuanceOfCommonStock" xlink:to="achv_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" xlink:to="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConversionPricePercentageOfClosingTradingSharePrice" xlink:to="achv_ConversionPricePercentageOfClosingTradingSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" xlink:to="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" xlink:to="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" xlink:to="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MonthlyBaseRentalPayments" xlink:to="achv_MonthlyBaseRentalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" xlink:to="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommonStockAggregateMaximumOfferingAmount" xlink:to="achv_CommonStockAggregateMaximumOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_RegulatoryAssetsAbstract" xlink:to="achv_RegulatoryAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="achv_NatureOfBusinessAndBasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ExercisableSubjectToCertainOwnershipLimitationsMember" xlink:to="achv_ExercisableSubjectToCertainOwnershipLimitationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SweepAccountMember" xlink:to="achv_SweepAccountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" xlink:to="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WorkingCapitalBalance" xlink:to="achv_WorkingCapitalBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" xlink:to="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UniversityOfBristolMember" xlink:to="achv_UniversityOfBristolMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" xlink:to="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInAprilTwoThousandTwentyMember" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwentyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NonCapitalGainLossCarryforwardsAmount" xlink:to="achv_NonCapitalGainLossCarryforwardsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" xlink:to="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_LeaseSecurityDepositYearTwo" xlink:to="achv_LeaseSecurityDepositYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" xlink:to="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AfterEighteenMonthAnniversaryMember" xlink:to="achv_AfterEighteenMonthAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" xlink:to="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PaymentsUnderLicenseAgreement" xlink:to="achv_PaymentsUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_UnderwritingMember" xlink:to="achv_UnderwritingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" xlink:to="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" xlink:to="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_BeforeEighteenMonthAnniversaryMember" xlink:to="achv_BeforeEighteenMonthAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:to="achv_TwoThousandTwentyFourEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="achv_NatureOfBusinessAndBasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommercialPaperMarketableSecuritiesMember" xlink:to="achv_CommercialPaperMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" xlink:to="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_SiliconValleyBankAndLenderMember" xlink:to="achv_SiliconValleyBankAndLenderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_CommonStockPricePerUnit" xlink:to="achv_CommonStockPricePerUnit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_OperatingLossCarryforwardsExpirationYear" xlink:to="achv_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_GovernmentGrantsTextBlock" xlink:to="achv_GovernmentGrantsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_MinimumMarketCapitalization" xlink:to="achv_MinimumMarketCapitalization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_Rule10B51ArrModifiedFlag" xlink:to="achv_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_ConvertibleTermLoanMember" xlink:to="achv_ConvertibleTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA-BC" xlink:to="stpr_CA-BC_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PrepaidExpensesRelatedParty" xlink:to="achv_PrepaidExpensesRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NonRule10B51ArrModifiedFlag" xlink:to="achv_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NumberOfDevelopmentAgreements" xlink:to="achv_NumberOfDevelopmentAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_IncomeTaxesTable" xlink:to="achv_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" xlink:to="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_PrimeRateMinusOnePercentageMember" xlink:to="achv_PrimeRateMinusOnePercentageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_NewEmployeeInducementGrantsMember" xlink:to="achv_NewEmployeeInducementGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" xlink:to="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionDescription" xlink:to="us-gaap_DebtConversionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherAddressMember" xlink:label="dei_OtherAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="dei_OtherAddressMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonRule10B51ArrModifiedFlag" xlink:label="achv_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_Rule10B51ArrModifiedFlag" xlink:label="achv_Rule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="achv_NonRule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="achv_Rule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRisk" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrant" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantsTextBlock" xlink:label="achv_GovernmentGrantsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="achv_GovernmentGrantsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangibles" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTax" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock" xlink:label="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:label="us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrantPolicyTextBlock" xlink:label="achv_GrantPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsPolicyTextBlock" xlink:label="achv_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryCostsForContractsOrProgramsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_GrantPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_WarrantsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" xlink:label="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" xlink:label="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxExaminationsTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConvertibleDebtAgreementMember" xlink:label="achv_ContingentConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WorkingCapitalBalance" xlink:label="achv_WorkingCapitalBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ContingentConvertibleDebtAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_NatureOfBusinessAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="achv_NatureOfBusinessAndBasisOfPresentationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="achv_WorkingCapitalBalance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesTable" xlink:label="achv_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesLineItems" xlink:label="achv_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="achv_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesTable" xlink:to="achv_AccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RegulatoryAssetsAbstract" xlink:label="achv_RegulatoryAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_RegulatoryAssetsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SweepAccountMember" xlink:label="achv_SweepAccountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfSecurities" xlink:label="achv_MaturityPeriodOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="achv_SweepAccountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="achv_MaturityPeriodOfSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseMember" xlink:label="achv_NationalInstituteOnDrugAbuseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantLineItems" xlink:label="achv_GovernmentGrantLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrantAwarded" xlink:label="achv_GrantAwarded"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantTable" xlink:label="achv_GovernmentGrantTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ORCAV1ClinicalStudyCostsMember" xlink:label="achv_ORCAV1ClinicalStudyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ResearchAndDevelopmentExpensesIncreaseDecrease" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ReimbursementsReceived" xlink:label="achv_ReimbursementsReceived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_NationalInstituteOnDrugAbuseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_GrantAwarded" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="achv_GovernmentGrantTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_ORCAV1ClinicalStudyCostsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_ResearchAndDevelopmentExpensesIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantTable" xlink:to="achv_GovernmentGrantLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_ReimbursementsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmendmentToLicenseAgreementMember" xlink:label="achv_AmendmentToLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UniversityOfBristolMember" xlink:label="achv_UniversityOfBristolMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementMember" xlink:label="achv_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PaymentsUnderLicenseAgreement" xlink:label="achv_PaymentsUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SopharmaMember" xlink:label="achv_SopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesAcquired" xlink:label="achv_PercentageOfOutstandingSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_AmendmentToLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_UniversityOfBristolMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SharePurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_PaymentsUnderLicenseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_SopharmaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_PercentageOfOutstandingSharesAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementMember" xlink:label="achv_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfSecurities" xlink:label="achv_MaturityPeriodOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumMaturityPeriodOfCashAndCashEquivalents" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MeasurementInputProbabilityOfSuccessMember" xlink:label="achv_MeasurementInputProbabilityOfSuccessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SharePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="achv_MaturityPeriodOfSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="achv_MaximumMaturityPeriodOfCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="achv_MeasurementInputProbabilityOfSuccessMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConsiderationMember" xlink:label="achv_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperCashEquivalentsMember" xlink:label="achv_CommercialPaperCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RestrictedCashMember" xlink:label="achv_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperMarketableSecuritiesMember" xlink:label="achv_CommercialPaperMarketableSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="achv_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperCashEquivalentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_RestrictedCashMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperMarketableSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperCashEquivalentsMember" xlink:label="achv_CommercialPaperCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConsiderationMember" xlink:label="achv_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="achv_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ComputerSoftwareMember" xlink:label="achv_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="achv_ComputerSoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtTable" xlink:label="achv_ConvertibleDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtLineItems" xlink:label="achv_ConvertibleDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrimeRateMinusOnePercentageMember" xlink:label="achv_PrimeRateMinusOnePercentageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConvertibleDebtAgreementMember" xlink:label="achv_ContingentConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BeforeEighteenMonthAnniversaryMember" xlink:label="achv_BeforeEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndLenderMember" xlink:label="achv_SiliconValleyBankAndLenderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonConvertibleTermLoansMember" xlink:label="achv_NonConvertibleTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtAgreementMember" xlink:label="achv_ConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AfterEighteenMonthAnniversaryMember" xlink:label="achv_AfterEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleTermLoanMember" xlink:label="achv_ConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RegistrationRightsAgreementMember" xlink:label="achv_RegistrationRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfAverageClosingSalePrice" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfClosingTradingSharePrice" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MinimumMarketCapitalization" xlink:label="achv_MinimumMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentWithdrawalAmount" xlink:label="achv_DebtInstrumentWithdrawalAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="achv_ConvertibleDebtTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="achv_PrimeRateMinusOnePercentageMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ContingentConvertibleDebtAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="achv_BeforeEighteenMonthAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndLenderMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_NonConvertibleTermLoansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ConvertibleDebtAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="achv_AfterEighteenMonthAnniversaryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_LineOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_ConvertibleTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_RegistrationRightsAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_VariableRateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtTable" xlink:to="achv_ConvertibleDebtLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtConversionDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConversionPricePercentageOfAverageClosingSalePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConversionPricePercentageOfClosingTradingSharePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_MinimumMarketCapitalization" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtInstrumentWithdrawalAmount" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewConvertibleTermLoanMember" xlink:label="achv_NewConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCost" xlink:label="achv_AmortizationOfTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DiscountOnModificationOfDebt" xlink:label="achv_DiscountOnModificationOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccretionOfDiscountOnModificationDebt" xlink:label="achv_AccretionOfDiscountOnModificationDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCosts" xlink:label="achv_AmortizationOfTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_NewConvertibleTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AmortizationOfTransactionCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_DiscountOnModificationOfDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AccretionOfDiscountOnModificationDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AmortizationOfTransactionCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesLineItems" xlink:label="achv_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesTable" xlink:label="achv_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsLiabilitiesValuationAllowance" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsExpirationYear" xlink:label="achv_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsIndefinitely" xlink:label="achv_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TaxCreditCarryForwardExpirationYear" xlink:label="achv_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonCapitalGainLossCarryforwardsAmount" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="achv_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_DeferredTaxAssetsLiabilitiesValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesTable" xlink:to="achv_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_OperatingLossCarryforwardsIndefinitely" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_TaxCreditCarryForwardExpirationYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_NonCapitalGainLossCarryforwardsAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_CA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DefferedTaxLiabilitiesRightOfUseAssets" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="achv_DefferedTaxLiabilitiesRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxPaidForeignAfterRefundReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" xlink:label="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OpenTaxYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxExaminationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DirectOfferingMember" xlink:label="achv_DirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AtMarketSalesAgreementMember" xlink:label="achv_AtMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_November2022PrivatePlacementMember" xlink:label="achv_November2022PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromIssuanceOfCommonStockGross" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AverageDailyTradingVolumeForMeasurementPeriod" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PlacementAgentFeesAndOfferingExpenses" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfUnitsIssuedInFinancing" xlink:label="achv_NumberOfUnitsIssuedInFinancing"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockPricePerUnit" xlink:label="achv_CommonStockPricePerUnit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_StockUnitsDescription" xlink:label="achv_StockUnitsDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromFinancing" xlink:label="achv_ProceedsFromFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_DirectOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_AtMarketSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_November2022PrivatePlacementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ProceedsFromIssuanceOfCommonStockGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_GrossProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AverageDailyTradingVolumeForMeasurementPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_PlacementAgentFeesAndOfferingExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfUnitsIssuedInFinancing" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockPricePerUnit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_StockUnitsDescription" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ProceedsFromFinancing" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JefferiesOpenMarketSaleAgreementMember" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAggregateMaximumOfferingAmount" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockSharesAvailableForFutureGrant" xlink:label="achv_CommonStockSharesAvailableForFutureGrant"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_JefferiesOpenMarketSaleAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockAggregateMaximumOfferingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockSharesAvailableForFutureGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExercisableSubjectToCertainOwnershipLimitationsMember" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PublicOfferingMember" xlink:label="achv_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingMember" xlink:label="achv_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JuneTwentyTwentyFivePublicOfferingMember" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAndWarrantsMember" xlink:label="achv_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfSecuritiesExercisedAccompanyingWarrants" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingDiscounts" xlink:label="achv_UnderwritingDiscounts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="achv_ExercisableSubjectToCertainOwnershipLimitationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_UnderwritingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_JuneTwentyTwentyFivePublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="achv_CommonStockAndWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_OwnershipAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfSecuritiesExercisedAccompanyingWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_GrossProceedsFromIssuanceOfCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_UnderwritingDiscounts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EmployeesAndConsultantsMember" xlink:label="achv_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewEmployeeInducementGrantsMember" xlink:label="achv_NewEmployeeInducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BoardOfDirectorsMember" xlink:label="achv_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndTenPerformanceIncentivePlanMember" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandAndEighteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="achv_EmployeesAndConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_NewEmployeeInducementGrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="achv_BoardOfDirectorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandsAndTenPerformanceIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandTwentyFourEquityIncentivePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:label="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInMayTwoThousandNinteenMember" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantsOrRightExpirationDate" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAugustTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInMayTwoThousandNinteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwentyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_ClassOfWarrantsOrRightExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAugustTwoThousandTwentyMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfVotingPower" xlink:label="achv_PercentageOfVotingPower"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesOfCommonStock" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_PercentageOfVotingPower" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_PercentageOfOutstandingSharesOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDevelopmentAgreements" xlink:label="achv_NumberOfDevelopmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_KristenSlaouiMember" xlink:label="achv_KristenSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionExpensesExpectedToIncur" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DrSlaouiMember" xlink:label="achv_DrSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrepaidExpensesRelatedParty" xlink:label="achv_PrepaidExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyConsultingFeeIncurred" xlink:label="achv_RelatedPartyConsultingFeeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionAmountsPayable" xlink:label="achv_RelatedPartyTransactionAmountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_NumberOfDevelopmentAgreements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="achv_KristenSlaouiMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyTransactionExpensesExpectedToIncur" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="achv_DrSlaouiMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_PrepaidExpensesRelatedParty" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyConsultingFeeIncurred" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyTransactionAmountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="achv_ContractualObligationFiscalYearMaturityScheduleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:to="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA-BC" xlink:label="stpr_CA-BC"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseAgreementCommencementDate" xlink:label="achv_LeaseAgreementCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PikeMember" xlink:label="achv_PikeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SeattleOfficeOperatingLeaseMember" xlink:label="achv_SeattleOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AreaOfOfficeSpaceLeased" xlink:label="achv_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPayments" xlink:label="achv_MonthlyBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositAnnualPayment" xlink:label="achv_LeaseSecurityDepositAnnualPayment"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearOne" xlink:label="achv_LeaseSecurityDepositYearOne"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearTwo" xlink:label="achv_LeaseSecurityDepositYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositThereafter" xlink:label="achv_LeaseSecurityDepositThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IndemnificationExpense" xlink:label="achv_IndemnificationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA-BC" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseAgreementCommencementDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_PikeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SeattleOfficeOperatingLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_AreaOfOfficeSpaceLeased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_MonthlyBaseRentalPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositAnnualPayment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositYearOne" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositYearTwo" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositThereafter" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_IndemnificationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended"/>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherAddressMember" xlink:label="dei_OtherAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_OtherAddressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" xlink:label="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="achv_NatureOfBusinessAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConvertibleDebtAgreementMember" xlink:label="achv_ContingentConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WorkingCapitalBalance" xlink:label="achv_WorkingCapitalBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="achv_NatureOfBusinessAndBasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ContingentConvertibleDebtAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="achv_WorkingCapitalBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesLineItems" xlink:label="achv_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccountingPoliciesTable" xlink:label="achv_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" xlink:label="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="achv_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_AccountingPoliciesTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SweepAccountMember" xlink:label="achv_SweepAccountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfSecurities" xlink:label="achv_MaturityPeriodOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" xlink:label="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="achv_SweepAccountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="achv_MaturityPeriodOfSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantLineItems" xlink:label="achv_GovernmentGrantLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GovernmentGrantTable" xlink:label="achv_GovernmentGrantTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseMember" xlink:label="achv_NationalInstituteOnDrugAbuseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrantAwarded" xlink:label="achv_GrantAwarded"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyAxis" xlink:label="us-gaap_RegulatoryAgencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAgencyDomain" xlink:label="us-gaap_RegulatoryAgencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ORCAV1ClinicalStudyCostsMember" xlink:label="achv_ORCAV1ClinicalStudyCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ResearchAndDevelopmentExpensesIncreaseDecrease" xlink:label="achv_ResearchAndDevelopmentExpensesIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" xlink:label="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ReimbursementsReceived" xlink:label="achv_ReimbursementsReceived"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_GovernmentGrantTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_NationalInstituteOnDrugAbuseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_GrantAwarded" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_GovernmentGrantTable" xlink:to="us-gaap_RegulatoryAgencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_ORCAV1ClinicalStudyCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_ResearchAndDevelopmentExpensesIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_GovernmentGrantLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_GovernmentGrantLineItems" xlink:to="achv_ReimbursementsReceived" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmendmentToLicenseAgreementMember" xlink:label="achv_AmendmentToLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" xlink:label="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UniversityOfBristolMember" xlink:label="achv_UniversityOfBristolMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementMember" xlink:label="achv_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PaymentsUnderLicenseAgreement" xlink:label="achv_PaymentsUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SopharmaMember" xlink:label="achv_SopharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesAcquired" xlink:label="achv_PercentageOfOutstandingSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_AmendmentToLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_UniversityOfBristolMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_PaymentsUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_SopharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="achv_PercentageOfOutstandingSharesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SharePurchaseAgreementMember" xlink:label="achv_SharePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaturityPeriodOfSecurities" xlink:label="achv_MaturityPeriodOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumMaturityPeriodOfCashAndCashEquivalents" xlink:label="achv_MaximumMaturityPeriodOfCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MeasurementInputProbabilityOfSuccessMember" xlink:label="achv_MeasurementInputProbabilityOfSuccessMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SharePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="achv_MaturityPeriodOfSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="achv_MaximumMaturityPeriodOfCashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="achv_MeasurementInputProbabilityOfSuccessMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConsiderationMember" xlink:label="achv_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperCashEquivalentsMember" xlink:label="achv_CommercialPaperCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RestrictedCashMember" xlink:label="achv_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperMarketableSecuritiesMember" xlink:label="achv_CommercialPaperMarketableSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="achv_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_RestrictedCashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommercialPaperCashEquivalentsMember" xlink:label="achv_CommercialPaperCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:label="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="achv_CommercialPaperCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" xlink:label="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConsiderationMember" xlink:label="achv_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="achv_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ComputerSoftwareMember" xlink:label="achv_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="achv_ComputerSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtLineItems" xlink:label="achv_ConvertibleDebtLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtTable" xlink:label="achv_ConvertibleDebtTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" xlink:label="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrimeRateMinusOnePercentageMember" xlink:label="achv_PrimeRateMinusOnePercentageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContingentConvertibleDebtAgreementMember" xlink:label="achv_ContingentConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BeforeEighteenMonthAnniversaryMember" xlink:label="achv_BeforeEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SiliconValleyBankAndLenderMember" xlink:label="achv_SiliconValleyBankAndLenderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonConvertibleTermLoansMember" xlink:label="achv_NonConvertibleTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleDebtAgreementMember" xlink:label="achv_ConvertibleDebtAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AfterEighteenMonthAnniversaryMember" xlink:label="achv_AfterEighteenMonthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConvertibleTermLoanMember" xlink:label="achv_ConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RegistrationRightsAgreementMember" xlink:label="achv_RegistrationRightsAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionDescription" xlink:label="us-gaap_DebtConversionDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfAverageClosingSalePrice" xlink:label="achv_ConversionPricePercentageOfAverageClosingSalePrice"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ConversionPricePercentageOfClosingTradingSharePrice" xlink:label="achv_ConversionPricePercentageOfClosingTradingSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" xlink:label="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" xlink:label="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" xlink:label="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" xlink:label="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" xlink:label="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" xlink:label="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:label="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MinimumMarketCapitalization" xlink:label="achv_MinimumMarketCapitalization"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DebtInstrumentWithdrawalAmount" xlink:label="achv_DebtInstrumentWithdrawalAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConvertibleDebtTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="achv_PrimeRateMinusOnePercentageMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ContingentConvertibleDebtAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="achv_BeforeEighteenMonthAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="achv_SiliconValleyBankAndLenderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_NonConvertibleTermLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_ConvertibleDebtAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="achv_AfterEighteenMonthAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_ConvertibleTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="achv_RegistrationRightsAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ConvertibleDebtTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtConversionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConversionPricePercentageOfAverageClosingSalePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ConversionPricePercentageOfClosingTradingSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_MinimumMarketCapitalization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ConvertibleDebtLineItems" xlink:to="achv_DebtInstrumentWithdrawalAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewConvertibleTermLoanMember" xlink:label="achv_NewConvertibleTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCost" xlink:label="achv_AmortizationOfTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DiscountOnModificationOfDebt" xlink:label="achv_DiscountOnModificationOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AccretionOfDiscountOnModificationDebt" xlink:label="achv_AccretionOfDiscountOnModificationDebt"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCosts" xlink:label="achv_AmortizationOfTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="achv_NewConvertibleTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AmortizationOfTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_DiscountOnModificationOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AccretionOfDiscountOnModificationDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="achv_AmortizationOfTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesLineItems" xlink:label="achv_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxesTable" xlink:label="achv_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" xlink:label="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsLiabilitiesValuationAllowance" xlink:label="achv_DeferredTaxAssetsLiabilitiesValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsExpirationYear" xlink:label="achv_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_OperatingLossCarryforwardsIndefinitely" xlink:label="achv_OperatingLossCarryforwardsIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TaxCreditCarryForwardExpirationYear" xlink:label="achv_TaxCreditCarryForwardExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NonCapitalGainLossCarryforwardsAmount" xlink:label="achv_NonCapitalGainLossCarryforwardsAmount"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_DeferredTaxAssetsLiabilitiesValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_OperatingLossCarryforwardsIndefinitely" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_TaxCreditCarryForwardExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_NonCapitalGainLossCarryforwardsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DirectOfferingMember" xlink:label="achv_DirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AtMarketSalesAgreementMember" xlink:label="achv_AtMarketSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_November2022PrivatePlacementMember" xlink:label="achv_November2022PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromIssuanceOfCommonStockGross" xlink:label="achv_ProceedsFromIssuanceOfCommonStockGross"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" xlink:label="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AverageDailyTradingVolumeForMeasurementPeriod" xlink:label="achv_AverageDailyTradingVolumeForMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" xlink:label="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PlacementAgentFeesAndOfferingExpenses" xlink:label="achv_PlacementAgentFeesAndOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfUnitsIssuedInFinancing" xlink:label="achv_NumberOfUnitsIssuedInFinancing"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockPricePerUnit" xlink:label="achv_CommonStockPricePerUnit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_StockUnitsDescription" xlink:label="achv_StockUnitsDescription"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" xlink:label="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ProceedsFromFinancing" xlink:label="achv_ProceedsFromFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_DirectOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_AtMarketSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_November2022PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ProceedsFromIssuanceOfCommonStockGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AverageDailyTradingVolumeForMeasurementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_PlacementAgentFeesAndOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfUnitsIssuedInFinancing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockPricePerUnit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_StockUnitsDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ProceedsFromFinancing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JefferiesOpenMarketSaleAgreementMember" xlink:label="achv_JefferiesOpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAggregateMaximumOfferingAmount" xlink:label="achv_CommonStockAggregateMaximumOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockSharesAvailableForFutureGrant" xlink:label="achv_CommonStockSharesAvailableForFutureGrant"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_JefferiesOpenMarketSaleAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockAggregateMaximumOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_CommonStockSharesAvailableForFutureGrant" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ExercisableSubjectToCertainOwnershipLimitationsMember" xlink:label="achv_ExercisableSubjectToCertainOwnershipLimitationsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PublicOfferingMember" xlink:label="achv_PublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingMember" xlink:label="achv_UnderwritingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_JuneTwentyTwentyFivePublicOfferingMember" xlink:label="achv_JuneTwentyTwentyFivePublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_CommonStockAndWarrantsMember" xlink:label="achv_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" xlink:label="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" xlink:label="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" xlink:label="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfSecuritiesExercisedAccompanyingWarrants" xlink:label="achv_NumberOfSecuritiesExercisedAccompanyingWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" xlink:label="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" xlink:label="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_GrossProceedsFromIssuanceOfCommonStock" xlink:label="achv_GrossProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_UnderwritingDiscounts" xlink:label="achv_UnderwritingDiscounts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="achv_ExercisableSubjectToCertainOwnershipLimitationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_PublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_UnderwritingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="achv_JuneTwentyTwentyFivePublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="achv_CommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfSecuritiesExercisedAccompanyingWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_UnderwritingDiscounts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="achv_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EmployeesAndConsultantsMember" xlink:label="achv_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NewEmployeeInducementGrantsMember" xlink:label="achv_NewEmployeeInducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_BoardOfDirectorsMember" xlink:label="achv_BoardOfDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" xlink:label="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandsAndTenPerformanceIncentivePlanMember" xlink:label="achv_TwoThousandsAndTenPerformanceIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:label="achv_TwoThousandTwentyFourEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="achv_EmployeesAndConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_NewEmployeeInducementGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="achv_BoardOfDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandsAndTenPerformanceIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="achv_TwoThousandTwentyFourEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" xlink:label="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" xlink:label="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInMayTwoThousandNinteenMember" xlink:label="achv_WarrantsIssuedInMayTwoThousandNinteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" xlink:label="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ClassOfWarrantsOrRightExpirationDate" xlink:label="achv_ClassOfWarrantsOrRightExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" xlink:label="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInAugustTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInAugustTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" xlink:label="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" xlink:label="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInMayTwoThousandNinteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwentyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_ClassOfWarrantsOrRightExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInAugustTwoThousandTwentyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" xlink:label="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" xlink:label="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PreFundedWarrantsMember" xlink:label="achv_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfVotingPower" xlink:label="achv_PercentageOfVotingPower"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PercentageOfOutstandingSharesOfCommonStock" xlink:label="achv_PercentageOfOutstandingSharesOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="achv_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_PercentageOfVotingPower" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="achv_PercentageOfOutstandingSharesOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_NumberOfDevelopmentAgreements" xlink:label="achv_NumberOfDevelopmentAgreements"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_KristenSlaouiMember" xlink:label="achv_KristenSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionExpensesExpectedToIncur" xlink:label="achv_RelatedPartyTransactionExpensesExpectedToIncur"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DrSlaouiMember" xlink:label="achv_DrSlaouiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PrepaidExpensesRelatedParty" xlink:label="achv_PrepaidExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyConsultingFeeIncurred" xlink:label="achv_RelatedPartyConsultingFeeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_RelatedPartyTransactionAmountsPayable" xlink:label="achv_RelatedPartyTransactionAmountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_NumberOfDevelopmentAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="achv_KristenSlaouiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyTransactionExpensesExpectedToIncur" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="achv_DrSlaouiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_PrepaidExpensesRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyConsultingFeeIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="achv_RelatedPartyTransactionAmountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="achv_ContractualObligationFiscalYearMaturityScheduleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="achv_ContractualObligationFiscalYearMaturityScheduleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA-BC" xlink:label="stpr_CA-BC"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseAgreementCommencementDate" xlink:label="achv_LeaseAgreementCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_PikeMember" xlink:label="achv_PikeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_SeattleOfficeOperatingLeaseMember" xlink:label="achv_SeattleOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AreaOfOfficeSpaceLeased" xlink:label="achv_AreaOfOfficeSpaceLeased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPayments" xlink:label="achv_MonthlyBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" xlink:label="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositAnnualPayment" xlink:label="achv_LeaseSecurityDepositAnnualPayment"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearOne" xlink:label="achv_LeaseSecurityDepositYearOne"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositYearTwo" xlink:label="achv_LeaseSecurityDepositYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_LeaseSecurityDepositThereafter" xlink:label="achv_LeaseSecurityDepositThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:label="us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IndemnificationExpense" xlink:label="achv_IndemnificationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA-BC" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseAgreementCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="achv_PikeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_SeattleOfficeOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_AreaOfOfficeSpaceLeased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_MonthlyBaseRentalPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositAnnualPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositYearOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_LeaseSecurityDepositThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GuaranteeObligationsCurrentCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="achv_IndemnificationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_VancouverOfficeOperatingLeaseMember" xlink:label="achv_VancouverOfficeOperatingLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="achv_VancouverOfficeOperatingLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_DeferredFinanceCostsNet" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ConvertibleDebt" xlink:to="achv_AmortizationOfTransactionCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_AmortizationOfTransactionCost" xlink:label="achv_AmortizationOfTransactionCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingencies" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="14" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="17" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" xlink:label="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" xlink:label="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" xlink:label="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="achv_DefferedTaxLiabilitiesRightOfUseAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DefferedTaxLiabilitiesRightOfUseAssets" xlink:label="achv_DefferedTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="achv-20251231.xsd#achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxPaidForeignAfterRefundReceived" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="3" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" name="IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" name="SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" name="NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_IndemnificationExpense" name="IndemnificationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_OperatingLossCarryforwardsIndefinitely" name="OperatingLossCarryforwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_WarrantsIssuedInAprilTwoThousandTwenty2Member" name="WarrantsIssuedInAprilTwoThousandTwenty2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ConversionPricePercentageOfClosingTradingSharePrice" name="ConversionPricePercentageOfClosingTradingSharePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ProceedsFromFinancing" name="ProceedsFromFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_BoardOfDirectorsMember" name="BoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SiliconValleyBankAndLenderMember" name="SiliconValleyBankAndLenderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_MinimumMarketCapitalization" name="MinimumMarketCapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_MaximumMaturityPeriodOfCashAndCashEquivalents" name="MaximumMaturityPeriodOfCashAndCashEquivalents" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_LeaseSecurityDepositYearTwo" name="LeaseSecurityDepositYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_UnderwritingDiscounts" name="UnderwritingDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_WarrantsIssuedInAprilTwoThousandTwentyMember" name="WarrantsIssuedInAprilTwoThousandTwentyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" name="SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TwoThousandTwentyFourEquityIncentivePlanMember" name="TwoThousandTwentyFourEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AreaOfOfficeSpaceLeased" name="AreaOfOfficeSpaceLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_RegistrationRightsAgreementMember" name="RegistrationRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ClassOfWarrantsOrRightExpirationDate" name="ClassOfWarrantsOrRightExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_WarrantsIssuedInMayTwoThousandNinteenMember" name="WarrantsIssuedInMayTwoThousandNinteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TaxCreditCarryForwardExpirationYear" name="TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_CommonStockPricePerUnit" name="CommonStockPricePerUnit" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ConvertibleTermLoanMember" name="ConvertibleTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PikeMember" name="PikeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations" name="FutureIncomeTaxRateAssumedForDeferredTaxCalculations" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_JefferiesOpenMarketSaleAgreementMember" name="JefferiesOpenMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_GovernmentGrantTable" name="GovernmentGrantTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" name="EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_RelatedPartyTransactionAmountsPayable" name="RelatedPartyTransactionAmountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_NewConvertibleTermLoanMember" name="NewConvertibleTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" name="DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" name="ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ORCAV1ClinicalStudyCostsMember" name="ORCAV1ClinicalStudyCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" name="ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares" name="NumberOfDaysOptionGrantedToPurchaseAdditionalShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" name="EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_MeasurementInputProbabilityOfSuccessMember" name="MeasurementInputProbabilityOfSuccessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_UnderwritingMember" name="UnderwritingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DirectOfferingMember" name="DirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NumberOfSecuritiesExercisedAccompanyingWarrants" name="NumberOfSecuritiesExercisedAccompanyingWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_SweepAccountMember" name="SweepAccountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" name="WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" name="MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_RelatedPartyConsultingFeeIncurred" name="RelatedPartyConsultingFeeIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_SeattleOfficeOperatingLeaseMember" name="SeattleOfficeOperatingLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" name="ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_RegulatoryAssetsAbstract" name="RegulatoryAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AmortizationOfTransactionCosts" name="AmortizationOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_LeaseSecurityDepositAnnualPayment" name="LeaseSecurityDepositAnnualPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ContingentConvertibleDebtAgreementMember" name="ContingentConvertibleDebtAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AmortizationOfTransactionCost" name="AmortizationOfTransactionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" name="TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" name="ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" name="AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_GovernmentGrantsTextBlock" name="GovernmentGrantsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" name="IncomeTaxReconciliationTaxCreditsResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding" name="ShareHoldingPercentageOfSharesIssuedAndOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" name="NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations" name="IncomeTaxReconciliationImpactOfTaxAttributeExpirations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_AfterEighteenMonthAnniversaryMember" name="AfterEighteenMonthAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" name="DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_PlacementAgentFeesAndOfferingExpenses" name="PlacementAgentFeesAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_ExercisableSubjectToCertainOwnershipLimitationsMember" name="ExercisableSubjectToCertainOwnershipLimitationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" name="UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" name="MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_WorkingCapitalBalance" name="WorkingCapitalBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_NationalInstituteOnDrugAbuseMember" name="NationalInstituteOnDrugAbuseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AccretionOfDiscountOnModificationDebt" name="AccretionOfDiscountOnModificationDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ContractualObligationFiscalYearMaturityScheduleLineItems" name="ContractualObligationFiscalYearMaturityScheduleLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NonCapitalGainLossCarryforwardsAmount" name="NonCapitalGainLossCarryforwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_GrantAwarded" name="GrantAwarded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" name="MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ConvertibleDebtLineItems" name="ConvertibleDebtLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AtMarketSalesAgreementMember" name="AtMarketSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TwoThousandsAndSeventeenEquityIncentivePlanMember" name="TwoThousandsAndSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_November2022PrivatePlacementMember" name="November2022PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_CommercialPaperCashEquivalentsMember" name="CommercialPaperCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NewEmployeeInducementGrantsMember" name="NewEmployeeInducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PercentageOfOutstandingSharesOfCommonStock" name="PercentageOfOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_UniversityOfBristolMember" name="UniversityOfBristolMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PrepaidExpensesRelatedParty" name="PrepaidExpensesRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_CommonStockAggregateMaximumOfferingAmount" name="CommonStockAggregateMaximumOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_WarrantsIssuedInDecemberTwoThousandTwentyMember" name="WarrantsIssuedInDecemberTwoThousandTwentyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NumberOfDevelopmentAgreements" name="NumberOfDevelopmentAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ContractualObligationFiscalYearMaturityScheduleTable" name="ContractualObligationFiscalYearMaturityScheduleTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_JuneTwentyTwentyFivePublicOfferingMember" name="JuneTwentyTwentyFivePublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_StockUnitsDescription" name="StockUnitsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" name="WarrantsIssuedInNovemberTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_BeforeEighteenMonthAnniversaryMember" name="BeforeEighteenMonthAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" name="TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_AverageDailyTradingVolumeForMeasurementPeriod" name="AverageDailyTradingVolumeForMeasurementPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_CommercialPaperMarketableSecuritiesMember" name="CommercialPaperMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_RelatedPartyTransactionExpensesExpectedToIncur" name="RelatedPartyTransactionExpensesExpectedToIncur" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_GrantPolicyTextBlock" name="GrantPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_NumberOfUnitsIssuedInFinancing" name="NumberOfUnitsIssuedInFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember" name="WarrantsIssuedInJuneTwoThousandTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ConversionPricePercentageOfAverageClosingSalePrice" name="ConversionPricePercentageOfAverageClosingSalePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_DefferedTaxLiabilitiesRightOfUseAssets" name="DefferedTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease" name="MonthlyBaseRentalPaymentsMaximumAnnualIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_WarrantsIssuedInAugustTwoThousandTwentyMember" name="WarrantsIssuedInAugustTwoThousandTwentyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" name="TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" name="SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_TwoThousandsAndTenPerformanceIncentivePlanMember" name="TwoThousandsAndTenPerformanceIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_CommonStockSharesAvailableForFutureGrant" name="CommonStockSharesAvailableForFutureGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PaymentsUnderLicenseAgreement" name="PaymentsUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" name="AdditionalNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ConvertibleDebtTable" name="ConvertibleDebtTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SopharmaMember" name="SopharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_AmendmentToLicenseAgreementMember" name="AmendmentToLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" name="DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" name="SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PercentageOfVotingPower" name="PercentageOfVotingPower" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_LeaseSecurityDepositYearOne" name="LeaseSecurityDepositYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_PercentageOfOutstandingSharesAcquired" name="PercentageOfOutstandingSharesAcquired" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PercentageOfExercisePriceExceedsInMeasurementPeriod" name="PercentageOfExercisePriceExceedsInMeasurementPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_WarrantsIssuedInAprilTwoThousandTwenty1Member" name="WarrantsIssuedInAprilTwoThousandTwenty1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_KristenSlaouiMember" name="KristenSlaouiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock" name="SharePurchaseAgreementContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_MaturityPeriodOfSecurities" name="MaturityPeriodOfSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_ComputerSoftwareMember" name="ComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DiscountOnModificationOfDebt" name="DiscountOnModificationOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_DeferredTaxAssetsLiabilitiesValuationAllowance" name="DeferredTaxAssetsLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_LeaseSecurityDepositThereafter" name="LeaseSecurityDepositThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" name="DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DebtInstrumentWithdrawalAmount" name="DebtInstrumentWithdrawalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_LeaseAgreementCommencementDate" name="LeaseAgreementCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" name="AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="achv_DrSlaouiMember" name="DrSlaouiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ReimbursementsReceived" name="ReimbursementsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ResearchAndDevelopmentExpensesIncreaseDecrease" name="ResearchAndDevelopmentExpensesIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="achv_WarrantsIssuedInDecemberTwoThousandNineteenMember" name="WarrantsIssuedInDecemberTwoThousandNineteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_VancouverOfficeOperatingLeaseMember" name="VancouverOfficeOperatingLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" name="NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_PrimeRateMinusOnePercentageMember" name="PrimeRateMinusOnePercentageMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ConvertibleDebtAgreementMember" name="ConvertibleDebtAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_NonConvertibleTermLoansMember" name="NonConvertibleTermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" name="DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="achv_GovernmentGrantLineItems" name="GovernmentGrantLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_MonthlyBaseRentalPayments" name="MonthlyBaseRentalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" name="ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Apr. 20, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACHV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Achieve Life Sciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000949858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">033-80623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4343413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1040 West Georgia Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V6E 4H1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">210-2217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,659,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,958,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vancouver, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 1 on Form 10-K/A (&#8220;Amendment No. 1&#8221;) is being filed to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#8220;Original Filing&#8221;), filed with the U.S. Securities and Exchange Commission (the "SEC") on March 24, 2026 (the &#8220;Original Filing Date&#8221;). We are amending and refiling Part III to include information required by Items 10, 11, 12, 13 and 14 because our definitive proxy statement will not be filed within 120 days after December 31, 2025, the end of the fiscal year covered by our Annual Report on Form 10-K. &#160;Pursuant to the rules of the SEC, we have also included as exhibits currently dated certifications required under Section 302 of The Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, certifications pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 are not being furnished herewith.  We are amending and refiling Part IV to reflect the inclusion of those certifications, along with any changes to Part IV that occurred after the date of the Original Filing. &#160;In addition, we made certain revisions to the cover page, including the deletion of the reference to our proxy statement and the amendment to our Annual Report on Form 10-K and inclusion of updated outstanding share information. Except as described above, no other changes have been made to the Original Filing. &#160;Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. The filing of this Amendment is not a representation that any statements contained in items of our annual report on Form 10-K other than Part III, Items 10 through 14, Part IV and the aforementioned portions of the cover page are true or complete as of any date subsequent to the Original Filing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember', window );">Other Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">22722 29th Drive SE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_OtherAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do not time</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equity grants to take advantage of a depressed stock price or an anticipated increase in stock price and generally grant awards in January and ensure that awards cannot be timed to take advantage of material non-public information.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New hire stock awards to employees, including executive officers, are generally granted at the next Board of Directors&#8217; meeting following their start date, and initial awards to non-employee directors are granted on the date of the non-employee director&#8217;s initial appointment or election to our Board of Directors.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New hire stock awards to employees, including executive officers, are generally granted at the next Board of Directors&#8217; meeting following their start date, and initial awards to non-employee directors are granted on the date of the non-employee director&#8217;s initial appointment or election to our Board of Directors.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">do not time</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equity grants to take advantage of a depressed stock price or an anticipated increase in stock price and generally grant awards in January and ensure that awards cannot be timed to take advantage of material non-public information.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>44</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="achv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="achv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="achv-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" isDefinitelyFs="true" isUsgaap="true" original="achv-20251231.htm">achv-20251231.htm</File>
    <File>achv-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "achv-20251231.htm": {
   "nsprefix": "achv",
   "nsuri": "http://ir.achievelifesciences.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "achv-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "achv-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 44,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 782,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 44,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f776d48-5b0a-46cc-a2be-c94c6ea73471",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "achv-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Line Items]",
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "achv_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-02 [Member]",
        "label": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2020-06 [Member]",
        "label": "Accounting Standards Update 2020-06 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-07 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AccretionOfDiscountOnModificationDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AccretionOfDiscountOnModificationDebt",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of discount on modification of debt",
        "label": "Accretion of Discount On Modification Debt",
        "documentation": "Accretion of discount on modification debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "terseLabel": "Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "achv_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AdditionalNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Number of Securities Called by Warrants or Rights",
        "documentation": "Additional number of securities called by warrants or rights.",
        "terseLabel": "Additional number of shares to be issued accompanying warrants"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AdditionalNumberOfSecuritiesUnderwritersExercisedByWarrantsOrRights",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Number of Securities Underwriters Exercised by Warrants or Rights",
        "documentation": "Additional Number of Securities Underwriters Exercised by Warrants or Rights",
        "terseLabel": "Additional number of securities underwriters exercised by warrants or rights in part"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AfterEighteenMonthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AfterEighteenMonthAnniversaryMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 18-Month Anniversary [Member]",
        "label": "After Eighteen Month Anniversary [Member]",
        "documentation": "After eighteen month anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r32",
      "r42",
      "r75"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r45",
      "r78"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r70",
      "r79",
      "r83",
      "r91"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "achv_AmendmentToLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AmendmentToLicenseAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment to the University of Bristol License Agreement [Member]",
        "label": "Amendment To License Agreement [Member]",
        "documentation": "Amendment to license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement amortization expense",
        "label": "Amortization of Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AmortizationOfTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AmortizationOfTransactionCost",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails": {
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of transaction costs",
        "label": "Amortization of Transaction Cost",
        "documentation": "Amortization of transaction cost.",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AmortizationOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AmortizationOfTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Transaction Costs",
        "documentation": "Amortization of transaction costs.",
        "terseLabel": "Amortization of transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from earning per share computation",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AreaOfOfficeSpaceLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AreaOfOfficeSpaceLeased",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space leased",
        "label": "Area Of Office Space Leased",
        "documentation": "Area of office space leased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "terseLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldUnderCapitalLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsHeldUnderCapitalLeasesMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment under capital lease [Member]",
        "label": "Assets Held under Capital Leases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AtMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AtMarketSalesAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Sales Agreement [Member]",
        "label": "At Market Sales Agreement [Member]",
        "documentation": "At-the-Market Sales Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "achv_AverageDailyTradingVolumeForMeasurementPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AverageDailyTradingVolumeForMeasurementPeriod",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average daily trading volume for measurement period",
        "label": "Average Daily Trading Volume For Measurement Period",
        "documentation": "Average daily trading volume for measurement period."
       }
      }
     },
     "auth_ref": []
    },
    "achv_AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average days to maturity of Company's portfolio of cash equivalents and marketable securities",
        "label": "Average Period To Maturity For Portfolio Of Cash And Marketable Securities",
        "documentation": "Average period to maturity for portfolio of cash and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "achv_BeforeEighteenMonthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "BeforeEighteenMonthAnniversaryMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Before 18-Month Anniversary [Member]",
        "label": "Before Eighteen Month Anniversary [Member]",
        "documentation": "Before eighteen month anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "achv_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board Of Directors [Member]",
        "documentation": "Board of directors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "terseLabel": "Loss on contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration [note 4 and note 5]",
        "negatedLabel": "Change in fair value of contingent consideration [note 5 and note 6]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of the contingent consideration",
        "verboseLabel": "Contigent consideration [note 6 and note 7]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input [Extensible Enumeration]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business, Basis of Presentation and Going Concern Uncertainty"
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CA",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada [Member]",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA-BC": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA-BC",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vancouver, British Columbia [Member]",
        "label": "BRITISH COLUMBIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash equivalents, amortized cost and estimated fair value",
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price per Share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per share of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ClassOfWarrantOrRightNewExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New exercise price per share",
        "label": "Class Of Warrant Or Right New Exercise Price Of Warrants Or Rights",
        "documentation": "Class of warrant or right new exercise price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock",
        "terseLabel": "Warrants to purchase common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Outstanding and Exercisable",
        "label": "Class of Warrant or Right, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ClassOfWarrantsOrRightExpirationDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ClassOfWarrantsOrRightExpirationDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Class Of Warrants Or Right Expiration Date",
        "documentation": "Class of warrants or right expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommercialPaperCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommercialPaperCashEquivalentsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper Cash Equivalents [Member]",
        "documentation": "Commercial paper cash equivalents.",
        "terseLabel": "Commercial paper (cash equivalents) [Member]",
        "verboseLabel": "Commercial Paper (Cash Equivalents) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommercialPaperMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommercialPaperMarketableSecuritiesMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper Marketable Securities [Member]",
        "documentation": "Commercial paper marketable securities.",
        "terseLabel": "Commercial paper (marketable securities) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper (short term investments) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommonStockAggregateMaximumOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommonStockAggregateMaximumOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate maximum offering amount",
        "label": "Common Stock Aggregate Maximum Offering Amount",
        "documentation": "Common stock aggregate maximum offering amount."
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommonStockAndWarrantsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Warrants Member",
        "documentation": "Common stock and warrants.",
        "terseLabel": "Common Stock and Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommonStockPricePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommonStockPricePerUnit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, price per unit",
        "label": "Common Stock Price Per Unit",
        "documentation": "Common stock price per unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "achv_CommonStockSharesAvailableForFutureGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "CommonStockSharesAvailableForFutureGrant",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for sale under offering",
        "label": "Common Stock Shares Available For Future Grant",
        "documentation": "Common stock, shares available for future grant."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Unit Awards",
        "label": "Compensation Related Costs, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment [Member]",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer software.",
        "terseLabel": "Computer software [Member]",
        "label": "Computer Software [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ContingentConvertibleDebtAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ContingentConvertibleDebtAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Convertible Debt Agreement [Member]",
        "label": "Contingent Convertible Debt Agreement [Member]",
        "documentation": "Contingent convertible debt agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Contractual Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueAfterFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 5 years",
        "label": "Contractual Obligation, to be Paid, after Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFourthAndFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueInFourthAndFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contractual Obligation, to be Paid, Year Four and Five, Total",
        "terseLabel": "3-5 years",
        "label": "Contractual Obligation, to be Paid, Year Four and Five"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 1 year",
        "label": "Contractual Obligation, to be Paid, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondAndThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueInSecondAndThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contractual Obligation, to be Paid, Year Two and Three, Total",
        "terseLabel": "1-3 years",
        "label": "Contractual Obligation, to be Paid, Year Two and Three"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ContractualObligationFiscalYearMaturityScheduleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ContractualObligationFiscalYearMaturityScheduleLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Obligation Fiscal Year Maturity Schedule [Line Items]",
        "label": "Contractual Obligation Fiscal Year Maturity Schedule [Line Items]",
        "documentation": "Contractual obligation fiscal year maturity schedule."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ContractualObligationFiscalYearMaturityScheduleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Obligation Fiscal Year Maturity Schedule [Table]",
        "label": "Contractual Obligation Fiscal Year Maturity Schedule [Table]",
        "documentation": "Contractual obligation fiscal year maturity schedule table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contractual Obligations",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConversionPricePercentageOfAverageClosingSalePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConversionPricePercentageOfAverageClosingSalePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Price Percentage Of Average Closing Sale Price",
        "documentation": "Conversion price percentage of Average closing sale price.",
        "terseLabel": "Conversion price percentage of average closing sale price"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConversionPricePercentageOfClosingTradingSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConversionPricePercentageOfClosingTradingSharePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Price Percentage Of Closing Trading Share Price",
        "documentation": "Conversion Price Percentage Of Closing Trading Share Price",
        "terseLabel": "Conversion price percentage of closing trading share price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Convertible debt",
        "terseLabel": "Convertible Debt, Carrying Value",
        "label": "Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConvertibleDebtAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConvertibleDebtAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt Agreement [Member]",
        "label": "Convertible Debt Agreement [Member]",
        "documentation": "Convertible Debt Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt, Fair Value",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConvertibleDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConvertibleDebtLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt [Line Items]",
        "label": "Convertible Debt [Line Items]",
        "documentation": "Convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Indebtedness [Member]",
        "label": "Convertible Debt [Member]",
        "verboseLabel": "Convertible Debt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConvertibleDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConvertibleDebtTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt [Table]",
        "label": "Convertible Debt [Table]",
        "documentation": "Convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtTables",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt",
        "label": "Convertible Debt [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ConvertibleTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ConvertibleTermLoanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Term Loan [Member]",
        "label": "Convertible Term Loan [Member]",
        "documentation": "Convertible term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r106"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r104"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r97"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r99"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r101"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r101"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r105"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r103"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r100"
     ]
    },
    "us-gaap_DebtConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionDescription",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Description",
        "terseLabel": "Debt conversion description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt, interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, liquidity ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "terseLabel": "Stock trigger price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfConversionAmountOfDebt",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Convertible Threshold Percentage Of Conversion Amount Of Debt",
        "documentation": "Debt instrument convertible threshold percentage of conversion amount of debt.",
        "terseLabel": "Threshold percentage of conversion amount of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCovenantCompliance",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant compliance",
        "label": "Debt Instrument, Covenant Compliance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails": {
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible debt principal amount",
        "terseLabel": "Convertible Debt, Principal Amount",
        "label": "Debt Instrument, Face Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt compound interest",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Convertible debt, stated rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, repayment terms",
        "label": "Debt Instrument, Payment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Redemption, Period",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount to be repaid",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtInstrumentWithdrawalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtInstrumentWithdrawalAmount",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drawn amount",
        "label": "Debt Instrument Withdrawal Amount",
        "documentation": "Debt instrument withdrawal amount."
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtPrepaymentFeePercentageAfterSecondAnniversaryAndBeforeMaturity",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee percentage after second anniversary before maturity",
        "label": "Debt Prepayment Fee Percentage After Second Anniversary And Before Maturity",
        "documentation": "Debt prepayment fee percentage after second anniversary before maturity."
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtPrepaymentFeePercentageOccursAfterFirstAnniversaryButOnOrPriorToTheSecondAnniversary",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee percentage occurs after first anniversary but on or prior to the second anniversary",
        "label": "Debt Prepayment Fee Percentage Occurs After First Anniversary But On Or Prior To The Second Anniversary",
        "documentation": "Debt prepayment fee percentage occurs after first anniversary but on or prior to the second anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtPrepaymentFeePercentageOnOrAfterFirstAnniversary",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Prepayment Fee Percentage On Or After First Anniversary",
        "documentation": "Debt prepayment fee percentage on or after first anniversary.",
        "terseLabel": "Prepayment fee percentage on or after first anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DebtPrepaymentFeePercentageOnOriginalAggregatePrincipal",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Prepayment Fee Percentage On Original Aggregate Principal",
        "documentation": "Debt Prepayment Fee Percentage On Original Aggregate Principal",
        "terseLabel": "Prepayment fee percentage on original aggregate principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Costs, Noncurrent, Total",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails": {
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Capitalized Research And Development Expenses",
        "documentation": "Deferred tax assets capitalized research and development expenses.",
        "terseLabel": "Capitalized R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DeferredTaxAssetsLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DeferredTaxAssetsLiabilitiesValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets liabilities, valuation allowance",
        "label": "Deferred Tax Assets Liabilities Valuation Allowance",
        "documentation": "Deferred tax assets liabilities valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax basis in excess of book value of assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred Tax Liabilities, Net",
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DefferedTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DefferedTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfTaxEffectsOfTemporaryDifferencesAndCarryforwardsRiseToDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Deffered tax liabilities, right of use assets",
        "label": "Deffered Tax Liabilities, Right of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DirectOfferingMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct Offering [Member]",
        "label": "Direct Offering [Member]",
        "documentation": "Direct offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DiscountOnModificationOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DiscountOnModificationOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discount on modification of debt",
        "label": "Discount On Modification of Debt",
        "documentation": "Discount on modification of debt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28",
      "r71"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US [Member]",
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_DrSlaouiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "DrSlaouiMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Slaoui.",
        "label": "Dr. Slaoui [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year [Member]",
        "label": "Earliest Tax Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per common share, basic",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net loss per common share [note 10 [i]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net loss per common share, diluted",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted net loss per common share [note 10 [i]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Income tax expense/(recovery), Percent",
        "totalLabel": "Income tax expense/(recovery), Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax rate assumed for both State and Foreign deferred tax calculations",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Income tax recovery at U.S. federal statutory income tax rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enactment of new tax laws, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total",
        "terseLabel": "Effect of cross-border laws, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total",
        "terseLabel": "Effect of cross-border laws, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Other foreign jurisdictions, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "achv_EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationImpactOfTaxAttributeExpirations",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of tax attribute expirations, Percent",
        "label": "Effective Income Tax Rate Reconciliation Impact Of Tax Attribute Expirations",
        "documentation": "Effective income tax rate reconciliation impact of tax attribute expirations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Based Compensation, Pecent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic state &amp; local income tax, net of federal income tax effect, Percent",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total",
        "terseLabel": "Changes in unrecognized tax benefits, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "negatedLabel": "Other, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development tax credits, Percent",
        "negatedLabel": "Research and development tax credits, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period, restricted stock awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation expense related to the Company's restricted stock unit awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to stock options granted",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "achv_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Consultants [Member]",
        "label": "Employees And Consultants [Member]",
        "documentation": "Employees and consultants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "EquityInstrumentConvertibleBeneficialOwnershipPercentageForExerciseOption",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Instrument Convertible Beneficial Ownership Percentage for Exercise Option",
        "documentation": "Equity instrument convertible beneficial ownership percentage for exercise option.",
        "terseLabel": "Equity instrument, convertible beneficial ownership percentage for exercise by holder"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r32",
      "r42",
      "r75"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r29",
      "r39",
      "r72"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "achv_ExercisableSubjectToCertainOwnershipLimitationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ExercisableSubjectToCertainOwnershipLimitationsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable Subject to Certain Ownership Limitations [Member]",
        "label": "Exercisable Subject to Certain Ownership Limitations [Member]",
        "documentation": "Exercisable subject to certain ownership limitations."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ExtendedPercentageOfAggregatePrincipalAmountOfTermLoanAdvances",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount of term loan advances extended percentage",
        "label": "Extended Percentage Of Aggregate Principal Amount Of Term Loan Advances",
        "documentation": "Extended percentage of aggregate principal amount of term loan advances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Corporate Bonds and Commercial Paper"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Liablilty Class"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring [Member]",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments and Risk",
        "label": "Financial Instruments Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets, Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, Fair Value",
        "label": "Finite-Lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "terseLabel": "Intangible assets, Gross Carrying Value",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesEstimatedFutureAmortizationExpenseRelatedToIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Intangible assets, Net Carrying Value",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "License agreement [note 4 and note 5]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada [Member]",
        "label": "Foreign Tax Jurisdiction [Member]",
        "verboseLabel": "Foreign Tax Jurisdiction [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Currency and Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r79"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r79"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r79"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r79"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r79"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_FutureIncomeTaxRateAssumedForDeferredTaxCalculations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "FutureIncomeTaxRateAssumedForDeferredTaxCalculations",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future enacted income tax rate assumed for both Federal and state deferred tax calculations",
        "label": "Future Income Tax Rate Assumed For Deferred Tax Calculations",
        "documentation": "Future income tax rate assumed for deferred tax calculations."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UK [Member]",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative [Member]",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_GovernmentGrantLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GovernmentGrantLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grant [Line Items]",
        "label": "Government Grant [Line Items]",
        "documentation": "Government grant."
       }
      }
     },
     "auth_ref": []
    },
    "achv_GovernmentGrantTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GovernmentGrantTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grant [Table]",
        "label": "Government Grant [Table]",
        "documentation": "Government grant."
       }
      }
     },
     "auth_ref": []
    },
    "achv_GovernmentGrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GovernmentGrantsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrant"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grant",
        "label": "Government Grants [Text Block]",
        "documentation": "Government grants."
       }
      }
     },
     "auth_ref": []
    },
    "achv_GrantAwarded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GrantAwarded",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant awarded",
        "label": "Grant Awarded",
        "documentation": "Grant awarded."
       }
      }
     },
     "auth_ref": []
    },
    "achv_GrantPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GrantPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant.",
        "terseLabel": "Government Grants",
        "label": "Grant Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant receivable [note 4]",
        "verboseLabel": "Grant receivable",
        "label": "Grants Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "achv_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from issuance of common stock",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification obligations",
        "label": "Guarantor Obligations, Current Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r28"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property",
        "label": "In Process Research and Development, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfUSAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "terseLabel": "Tax penalties or accrued interest recorded",
        "label": "Income Tax Examination, Penalties and Interest Accrued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Table]",
        "label": "Income Tax, Examination [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability",
        "documentation": "Income tax expense (benefit) excluding adjustment for reversal of deferred tax liability.",
        "totalLabel": "Income tax expense/(recovery), Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Income Tax Paid, Federal, after Refund Received",
        "totalLabel": "Income Tax Paid, Federal, after Refund Received, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidForeignAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, Foreign, after Refund Received",
        "totalLabel": "Income Tax Paid, Foreign, after Refund Received, Total",
        "terseLabel": "Foreign"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "totalLabel": "Income Tax Paid, State and Local, after Refund Received, Total",
        "terseLabel": "State and local"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Enactment of new tax laws, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Other foreign jurisdictions, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IncomeTaxReconciliationImpactOfTaxAttributeExpirations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IncomeTaxReconciliationImpactOfTaxAttributeExpirations",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Impact Of Tax Attribute Expirations",
        "documentation": "Income tax reconciliation impact of tax attribute expirations.",
        "terseLabel": "Impact of tax attribute expirations, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax recovery at U.S. federal statutory income tax rate, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock Based Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "Domestic state &amp; local income tax, net of federal income tax effect, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total",
        "terseLabel": "Changes in unrecognized tax benefits, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "terseLabel": "Other, Amount",
        "negatedLabel": "Other, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research and development tax credits, Amount",
        "negatedLabel": "Research and development tax credits, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IncomeTaxReconciliationTaxCreditsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IncomeTaxReconciliationTaxCreditsResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail": {
       "parentTag": "achv_IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfIncomeTaxAttributableToOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credits.",
        "label": "Income Tax Reconciliation Tax Credits Research And Development",
        "negatedLabel": "Research and development tax credits, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureIncomeTaxSummaryOfComponentsOfCashIncomeTaxesPaidNetOfRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_IndemnificationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "IndemnificationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses related to indemnification issues",
        "label": "Indemnification Expense",
        "documentation": "Indemnification expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r70",
      "r79",
      "r83",
      "r91"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r95"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r95"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r95"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangibles"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Intangible Assets Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued paid-in-kind interest",
        "label": "Interest Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCostsForContractsOrProgramsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCostsForContractsOrProgramsPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Costs for Contracts or Programs, Policy [Policy Text Block]",
        "terseLabel": "Inventory Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_JefferiesOpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "JefferiesOpenMarketSaleAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies Open Market Sale Agreement [Member]",
        "label": "Jefferies Open Market Sale Agreement [Member]",
        "documentation": "Jefferies open market sale agreement."
       }
      }
     },
     "auth_ref": []
    },
    "achv_JuneTwentyTwentyFivePublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "JuneTwentyTwentyFivePublicOfferingMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Twenty Twenty Five Public Offering [Member]",
        "documentation": "June twenty twenty five public offering.",
        "terseLabel": "June 2025 Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_KristenSlaouiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "KristenSlaouiMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kristen Slaoui [Member]",
        "documentation": "Kristen Slaoui."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Latest Tax Year [Member]",
        "label": "Latest Tax Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_LeaseAgreementCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "LeaseAgreementCommencementDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement commencement date",
        "label": "Lease Agreement Commencement Date",
        "documentation": "Lease agreement commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial term of lease expiration date",
        "label": "Lease Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "achv_LeaseSecurityDepositAnnualPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "LeaseSecurityDepositAnnualPayment",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, security deposit, annual payment",
        "label": "Lease Security Deposit Annual Payment",
        "documentation": "Lease security deposit annual payment."
       }
      }
     },
     "auth_ref": []
    },
    "achv_LeaseSecurityDepositThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "LeaseSecurityDepositThereafter",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, security deposit payment remaining amount",
        "label": "Lease Security Deposit Thereafter",
        "documentation": "Lease security deposit thereafter."
       }
      }
     },
     "auth_ref": []
    },
    "achv_LeaseSecurityDepositYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "LeaseSecurityDepositYearOne",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, security deposit payment first anniversary",
        "label": "Lease Security Deposit Year One",
        "documentation": "Lease security deposit year one."
       }
      }
     },
     "auth_ref": []
    },
    "achv_LeaseSecurityDepositYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "LeaseSecurityDepositYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, security deposit payment two anniversary",
        "label": "Lease Security Deposit Year Two",
        "documentation": "Lease security deposit year two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements and equipment under capital lease [Member]",
        "label": "Leaseholds and Leasehold Improvements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement",
        "label": "Lessee, Operating Lease, Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Future Minimum Annual Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, extension term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialLiabilitiesDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities",
        "periodStartLabel": "Fair value of total financial liabilities",
        "periodEndLabel": "Fair value of total financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "License Agreements [Member]",
        "label": "Licensing Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balance",
        "totalLabel": "Long-Term Line of Credit, Total",
        "verboseLabel": "Loan amount drawn",
        "label": "Long-Term Line of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement expiration date",
        "label": "Line of Credit Facility, Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Abstract]",
        "terseLabel": "Convertible Term Loan Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment [Member]",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity period of liquid investments",
        "label": "Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent",
        "documentation": "Maturity period of highly liquid investments to be considered as cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "achv_MaturityPeriodOfSecurities": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MaturityPeriodOfSecurities",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity period of securities",
        "label": "Maturity Period Of Securities",
        "documentation": "Maturity period of securities."
       }
      }
     },
     "auth_ref": []
    },
    "achv_MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MaximumBeneficialOwnershipPercentageOfOutstandingCommonStockForWarrantHolders",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum beneficial ownership percentage of outstanding common stock for warrant holders",
        "label": "Maximum Beneficial Ownership Percentage Of Outstanding Common Stock For Warrant Holders",
        "documentation": "Maximum beneficial ownership percentage of outstanding common stock for warrant holders."
       }
      }
     },
     "auth_ref": []
    },
    "achv_MaximumMaturityPeriodOfCashAndCashEquivalents": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MaximumMaturityPeriodOfCashAndCashEquivalents",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum maturity period of cash and cash equivalents",
        "label": "Maximum Maturity Period Of Cash And Cash Equivalents",
        "documentation": "Maximum maturity period of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MaximumRequiredPaymentUnderLicenseAgreementUponCompletionOfVariousMilestones",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount payable under license agreement, tied to milestones",
        "label": "Maximum Required Payment Under License Agreement Upon Completion Of Various Milestones",
        "documentation": "Maximum required payment under license agreement upon completion of various milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MeasurementInputProbabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, probability of success.",
        "label": "Measurement Input, Probability of Success [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MinimumMarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MinimumMarketCapitalization",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum market capitalization",
        "label": "Minimum Market Capitalization",
        "documentation": "Minimum market capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market securities [Member]",
        "terseLabel": "Money market securities (cash equivalents) [Member]",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MonthlyBaseRentalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MonthlyBaseRentalPayments",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly base rental payments.",
        "terseLabel": "Monthly base rent",
        "label": "Monthly Base Rental Payments"
       }
      }
     },
     "auth_ref": []
    },
    "achv_MonthlyBaseRentalPaymentsMaximumAnnualIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "MonthlyBaseRentalPaymentsMaximumAnnualIncrease",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly base rent, maximum annual increase",
        "label": "Monthly Base Rental Payments Maximum Annual Increase",
        "documentation": "Monthly base rental payments maximum annual increase."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "achv_NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NationalInstituteOnDrugAbuseAndNationalInstitutesOfHealthMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIDA/NIH",
        "label": "National Institute On Drug Abuse And National Institutes Of Health [Member]",
        "documentation": "National institute on drug abuse and national institutes of health."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NationalInstituteOnDrugAbuseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NationalInstituteOnDrugAbuseMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIDA",
        "label": "National Institute On Drug Abuse [Member]",
        "documentation": "National Institute on Drug Abuse."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NatureOfBusinessAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NatureOfBusinessAndBasisOfPresentationLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature Of Business And Basis Of Presentation [Line Items]",
        "label": "Nature Of Business And Basis Of Presentation [Line Items]",
        "documentation": "Nature of business and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NatureOfBusinessAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NatureOfBusinessAndBasisOfPresentationTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature Of Business And Basis Of Presentation [Table]",
        "label": "Nature Of Business And Basis Of Presentation [Table]",
        "documentation": "Nature of business and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "negatedLabel": "Net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NewConvertibleTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NewConvertibleTermLoanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureConvertibleDebtScheduleOfConvertibleTermLoanBalanceIncludingConvertibleDebtBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Convertible Term Loan [Member]",
        "label": "New Convertible Term Loan [Member]",
        "documentation": "New Convertible Term Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NewEmployeeInducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NewEmployeeInducementGrantsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Employee Inducement Grants [Member]",
        "label": "New Employee Inducement Grants [Member]",
        "documentation": "New employee inducement grants."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NonCapitalGainLossCarryforwardsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NonCapitalGainLossCarryforwardsAmount",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital loss carryforwards",
        "label": "Non Capital Gain Loss Carryforwards Amount",
        "documentation": "Non capital gain loss carryforwards amount."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NonConvertibleTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NonConvertibleTermLoansMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Convertible Term Loans [Member]",
        "label": "Non Convertible Term Loans [Member]",
        "documentation": "Non-convertible term loans."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r46",
      "r70",
      "r79"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "achv_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRule10b51ArrModifiedFlag",
        "documentation": "NonRule10b51ArrModifiedFlag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "achv_November2022PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "November2022PrivatePlacementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2022 Private Placement [Member]",
        "label": "November2022 Private Placement [Member]",
        "documentation": "November2022 Private Placement."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfDaysOptionGrantedToPurchaseAdditionalShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfDaysOptionGrantedToPurchaseAdditionalShares",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Days Option Granted To Purchase Additional Shares",
        "documentation": "Number of days option granted to purchase additional shares.",
        "terseLabel": "Number of days option granted to purchase additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfDaysPriorNoticeToIncreaseOrDecreaseOwnershipLimitationOnWarrants",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Days Prior Notice to Increase or Decrease Ownership Limitation on Warrants",
        "documentation": "Number of days prior notice to increase or decrease ownership limitation on warrants.",
        "terseLabel": "Number of days prior notice to increase or decrease ownership limitation on warrants"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfDevelopmentAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfDevelopmentAgreements",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of development agreements",
        "documentation": "Number of development agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of required consecutive days weighted average trading price for cancelation or recall of warrants",
        "label": "Number of Required Consecutive Days Weighted Average Trading Price for Cancelation or Recall of Warrants",
        "documentation": "Number of required consecutive days weighted average trading price for cancelation or recall of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfSecuritiesExercisedAccompanyingWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfSecuritiesExercisedAccompanyingWarrants",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Securities Exercised Accompanying Warrants",
        "documentation": "Number of securities exercised accompanying warrants.",
        "terseLabel": "Number of securities exercised accompanying warrants"
       }
      }
     },
     "auth_ref": []
    },
    "achv_NumberOfUnitsIssuedInFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "NumberOfUnitsIssuedInFinancing",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of units issued in financing",
        "label": "Number Of Units Issued In Financing",
        "documentation": "Number of units issued in financing."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ORCAV1ClinicalStudyCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ORCAV1ClinicalStudyCostsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORCA-V1 Clinical Study Costs",
        "label": "O R C A V1 Clinical Study Costs [Member]",
        "documentation": "ORCA-V1 Clinical study costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Years open to examination",
        "label": "Open Tax Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "terseLabel": "Expenses incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated rent and facilities expense",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "terseLabel": "Right-of-use assets [note 12]",
        "label": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Discount Rate Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Lease Term Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "achv_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "achv_OperatingLossCarryforwardsIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "OperatingLossCarryforwardsIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards indefinitely",
        "label": "Operating Loss Carryforwards Indefinitely",
        "documentation": "Operating loss carryforwards indefinitely."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "terseLabel": "Other Address",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r44",
      "r77"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r37",
      "r47",
      "r80"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r37",
      "r47",
      "r80"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rent expense",
        "label": "Payments for Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing costs relating to purchase agreement with Lincoln Park Capital",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Placement agent fees and offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PaymentsUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PaymentsUnderLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments under license agreement",
        "label": "Payments Under License Agreement",
        "documentation": "Payments under license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "achv_PercentageOfExercisePriceExceedsInMeasurementPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PercentageOfExercisePriceExceedsInMeasurementPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price exceeds in measurement period",
        "label": "Percentage Of Exercise Price Exceeds In Measurement Period",
        "documentation": "Percentage of exercise price exceeds in measurement period."
       }
      }
     },
     "auth_ref": []
    },
    "achv_PercentageOfOutstandingSharesAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PercentageOfOutstandingSharesAcquired",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares acquired.",
        "label": "Percentage of Outstanding Shares Acquired",
        "terseLabel": "Percentage of outstanding shares acquired"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PercentageOfOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PercentageOfOutstandingSharesOfCommonStock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Outstanding Shares of Common Stock",
        "documentation": "Percentage of outstanding shares of common stock.",
        "terseLabel": "Percentage of outstanding shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PercentageOfVotingPower": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PercentageOfVotingPower",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Voting Power",
        "documentation": "Percentage of voting power.",
        "terseLabel": "Percentage of voting power"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PikeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PikeMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pike [Member]",
        "label": "Pike [Member]",
        "documentation": "Pike."
       }
      }
     },
     "auth_ref": []
    },
    "achv_PlacementAgentFeesAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PlacementAgentFeesAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent fees and offering expenses",
        "label": "Placement Agent Fees And Offering Expenses",
        "documentation": "Placement agent fees and offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "achv_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre-funded warrants.",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockAuthorizedAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PrepaidExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PrepaidExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses Related Party",
        "documentation": "Prepaid expenses related party.",
        "terseLabel": "Prepayment of expenses"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PrimeRateMinusOnePercentageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PrimeRateMinusOnePercentageMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate Minus 1.0% [Member]",
        "label": "Prime Rate Minus One Percentage [Member]",
        "documentation": "Prime rate minus one percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2022 Private Placement [Member]",
        "label": "Private Placement [Member]",
        "verboseLabel": "Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ProceedsFromFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ProceedsFromFinancing",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from financing",
        "label": "Proceeds From Financing",
        "documentation": "Proceeds from financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offering, net of issuance costs [note 11[b]]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "documentation": "Proceeds from issuance of common stock gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "terseLabel": "Net cash proceeds from the sale and issuance of equity securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants",
        "terseLabel": "Proceeds from exercise of warrants [note 10[g]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Book Value",
        "label": "Property, Plant and Equipment, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Member]",
        "documentation": "Public Offering.",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r29",
      "r39",
      "r72"
     ]
    },
    "achv_RegistrationRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RegistrationRightsAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Rights Agreement [Member]",
        "documentation": "Registration rights agreement.",
        "terseLabel": "Registration Rights Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAgencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegulatoryAgencyAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Agency",
        "label": "Regulatory Agency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAgencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegulatoryAgencyDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Agency",
        "label": "Regulatory Agency [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_RegulatoryAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RegulatoryAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Assets [Abstract]",
        "documentation": "Regulatory assets."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ReimbursementsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ReimbursementsReceived",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursements received",
        "label": "Reimbursements Received",
        "documentation": "Reimbursements received."
       }
      }
     },
     "auth_ref": []
    },
    "achv_RelatedPartyConsultingFeeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RelatedPartyConsultingFeeIncurred",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Consulting Fee Incurred",
        "documentation": "Related party consulting fee incurred.",
        "terseLabel": "Consulting fees incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Adare Pharma Solutions [Member]",
        "verboseLabel": "Related Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_RelatedPartyTransactionAmountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RelatedPartyTransactionAmountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Amounts Payable",
        "documentation": "Related party transaction amounts payable.",
        "terseLabel": "Amounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "achv_RelatedPartyTransactionExpensesExpectedToIncur": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RelatedPartyTransactionExpensesExpectedToIncur",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction expenses expected to incur",
        "documentation": "Related party transaction expenses expected to incur.",
        "terseLabel": "Expenses expected to incur"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development [Member]",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ResearchAndDevelopmentExpensesIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureGovernmentGrantAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction in R&amp;D expense",
        "label": "Research And Development Expenses Increase Decrease",
        "documentation": "Research and development expenses increase (decrease)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Credits [Member]",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r30",
      "r40",
      "r73"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r31",
      "r41",
      "r74"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r38",
      "r48",
      "r81"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash and Cash Equivalents, Total",
        "verboseLabel": "Restricted cash, amortized cost and estimated fair value",
        "label": "Restricted Cash and Cash Equivalent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash [Member]",
        "label": "Restricted Cash [Member]",
        "documentation": "Restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Unit Awards [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "achv_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfOtherInformationRelatedToLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "documentation": "Right-of-use assets obtained in exchange for lease obligations."
       }
      }
     },
     "auth_ref": []
    },
    "achv_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule10b51ArrModifiedFlag",
        "documentation": "Rule10b51ArrModifiedFlag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "achv_SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SaleOfStockAdditionalNumberOfSharesToBeIssuedInTransaction",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Additional Number of Shares to be Issued in Transaction",
        "documentation": "Sale of stock, additional number of shares to be issued in transaction.",
        "terseLabel": "Additional number of shares to be issued as option in part"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SaleOfStockPotentialNumberOfSharesToBeIssuedInTransaction",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares agreed to issue and sell",
        "label": "Sale of Stock, Potential Number of Shares to be Issued in Transaction",
        "documentation": "Sale of stock, potential number of shares to be issued in transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of common stock and warrant, public offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of Components of Cash Income Taxes Paid Net of Refunds"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ScheduleOfChangesInFairValueOfLiabilitiesTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Fair Value of Liabilities [Table Text Block]",
        "documentation": "Schedule of changes in fair value of liabilities.",
        "terseLabel": "Schedule of Changes in Fair Value of Level 3 Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Tax Effects of Temporary Differences and Carryforwards Rise to Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Basic and Diluted Net Loss Attributable to Common Shareholders Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Income Tax Attributable to Operations",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesComponentsOfIntangibleAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of U.S. and Foreign Components of Income (Loss) before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Depreciation on Property and Equipment",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life Table [Text Block]",
        "documentation": "Schedule of property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesSummaryOfDepreciationOnPropertyAndEquipmentDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Unit Award Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Outstanding Options",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Vested Options",
        "label": "Schedule Of Share Based Compensation Shares Vested Under Stock Option Plans By Exercise Price Range Table [Text Block]",
        "documentation": "Schedule of share based compensation shares vested under stock option plans by exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Option Awards",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Activity",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ScheduleOfSupplementalCashFlowsInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Information Related to Leases",
        "label": "Schedule Of Supplemental Cash Flows Information Related To Leases Table [Text Block]",
        "documentation": "Schedule of supplemental cash flows information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnRollForwardTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Return Roll Forward [Table Text Block]",
        "documentation": "Schedule of unrecognized tax benefits, excluding amounts pertaining to examined tax return roll forward.",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits of Uncertain Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIntangiblesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Future Amortization Expense Related to Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SeattleOfficeOperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SeattleOfficeOperatingLeaseMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seattle Lease Arrangement [Member]",
        "label": "Seattle Office Operating Lease [Member]",
        "documentation": "Seattle office operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Owned and Sold, Not yet Purchased Fair Value, Security Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation [note 10[c], note 10[d], note 10[e]] and note 10[f]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Cancelled/Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Beginning Balance",
        "periodEndLabel": "Number of Shares, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value, Released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeiture rate",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rates",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance",
        "terseLabel": "Restricted shares reserved for issuance under incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance under incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Optioned Common Shares, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Optioned Common Shares, Forfeited",
        "verboseLabel": "Number of Shares, Cancelled/Forfeited",
        "negatedLabel": "Number of Optioned Common Shares, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares granted",
        "terseLabel": "Number of Optioned Common Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of the outstanding options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for options currently outstanding",
        "periodStartLabel": "Number of Optioned Common Shares, Beginning Balance",
        "periodEndLabel": "Number of Optioned Common Shares, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockRestrictedStockUnitAwardsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfRestrictedStockUnitAwardActivityDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled/Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationMaximumNumberOfSharesAuthorizedToPurchased",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares authorized to purchased",
        "label": "Share Based Compensation Maximum Number Of Shares Authorized To Purchased",
        "documentation": "Share based compensation, maximum number of shares authorized to purchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeEightMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range eight [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Eight [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range eight."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFiveMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range five [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Five [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range five."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeFourMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range four [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Four [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range four."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeNineMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range nine [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Nine [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range nine."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeOneMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range one [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range One [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range one."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSevenMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range seven [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Seven [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range seven."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeSixMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range six [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Six [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range six."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTenMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range ten [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Ten [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range ten."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeThreeMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range three [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Three [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range three."
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTwoMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range two [Member]",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Two [Member]",
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range, Lower Range Limit",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance",
        "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance",
        "terseLabel": "Exercise Price Range, Number of Vested Options",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance",
        "terseLabel": "Exercise Price Range, Number of Outstanding Options",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range, Upper Range Limit",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit"
       }
      }
     },
     "auth_ref": []
    },
    "achv_ShareHoldingPercentageOfSharesIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "ShareHoldingPercentageOfSharesIssuedAndOutstanding",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share holding percentage of shares issued and outstanding",
        "label": "Share Holding Percentage Of Shares Issued And Outstanding",
        "documentation": "Share holding percentage of shares issued and outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "achv_SharePurchaseAgreementContingentConsiderationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SharePurchaseAgreementContingentConsiderationPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement contingent consideration.",
        "label": "Share Purchase Agreement Contingent Consideration [Policy Text Block]",
        "terseLabel": "Share Purchase Agreement Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SharePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SharePurchaseAgreementMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfFairValueOfOptionAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of the exercisable outstanding options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range, Weighted Average Vested Price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfVestedOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Beginning Balance",
        "terseLabel": "Exercise Price Range, Weighted Average Exercise Price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionsOutstandingRegardingNumberOfCommonSharesIssuableUponExerciseOfOutstandingOptionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range, Weighted Average Remaining Contractual Life",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, price per share",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SiliconValleyBankAndLenderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SiliconValleyBankAndLenderMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Silicon Valley Bank And Lender [Member]",
        "documentation": "Silicon Valley Bank And Lender [Member]",
        "terseLabel": "SVB and Lender [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SiliconValleyBankAndSVBInnovationCreditFundVIIILPMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SVB [Member]",
        "label": "Silicon Valley Bank And S V B Innovation Credit Fund V I I I L P [Member]",
        "documentation": "Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P."
       }
      }
     },
     "auth_ref": []
    },
    "achv_SopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SopharmaMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sopharma",
        "label": "Sopharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r43",
      "r76"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Shares issued, Shares",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "terseLabel": "Restricted stock unit settlements",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock unit settlements, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option exercises, Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "auth_ref": []
    },
    "achv_StockUnitsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "StockUnitsDescription",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Units Description",
        "documentation": "Stock Units Description",
        "terseLabel": "Description of stock units issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SubscriptionAgreementsExecutedInNovemberTwoThousandTwentyTwoMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements Executed In November Two Thousand Twenty Two [Member]",
        "terseLabel": "Subscription Agreements Executed In November Two Thousand Twenty Two [Member]",
        "documentation": "Subscription Agreements Executed In November Two Thousand Twenty Two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Member]",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEmployeeStockPurchasePlanAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockOpenMarketSaleAgreementAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfIncomeTaxExaminationsTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Years Open to Examination Under Different Jurisdiction",
        "label": "Summary of Income Tax Examinations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_SweepAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "SweepAccountMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFinancialInstrumentsAndRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sweep Account [Member]",
        "documentation": "Sweep account."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "achv_TaxCreditCarryForwardExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TaxCreditCarryForwardExpirationYear",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards expiration year",
        "label": "Tax Credit Carry Forward Expiration Year",
        "documentation": "Tax credit carry forward expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxSummaryOfYearsOpenToExaminationUnderDifferentJurisdictionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "achv_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Equity Incentive Plan [Member]",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand and eighteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandTwentyFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandTwentyFourEquityIncentivePlanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Equity Inducement Plan [Member]",
        "label": "Two Thousand Twenty Four Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty four equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandTwentyFourSiliconValleyBankConvertibleDebtMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four Silicon Valley Bank Convertible Debt [Member]",
        "documentation": "Two thousand twenty four silicon valley bank convertible debt.",
        "terseLabel": "2024 SVB Convertible Debt"
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandTwentyThreeNonEmployeeDirectorEquityIncentivePlanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023 Non Employee Director Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Three Non Employee Director Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Three Non Employee Director Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandTwentyThreeSiliconValleyBankConvertibleDebtMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfPrincipalAmountOfConvertibleDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 SVB Convertible Debt",
        "label": "Two Thousand Twenty Three Silicon Valley Bank Convertible Debt [Member]",
        "documentation": "Two thousand twenty three silicon valley bank convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandsAndSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandsAndSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Equity Incentive Plan [Member]",
        "label": "Two Thousands And Seventeen Equity Incentive Plan [Member]",
        "documentation": "Information pertaining to 2017 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "achv_TwoThousandsAndTenPerformanceIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "TwoThousandsAndTenPerformanceIncentivePlanMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockEquityAwardsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Performance Incentive Plan [Member]",
        "label": "Two Thousands And Ten Performance Incentive Plan [Member]",
        "documentation": "Information pertaining to 2010 performance incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCorporateBondsAndCommercialPaperDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Securities [Member]",
        "label": "US Government Debt Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unclaimed tax deductions related to scientific research and experimental development expenditures",
        "label": "Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures",
        "documentation": "Unclaimed tax deductions related to scientific research and experimental development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "achv_UnderwritingDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UnderwritingDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts",
        "label": "Underwriting Discounts",
        "documentation": "Underwriting discounts."
       }
      }
     },
     "auth_ref": []
    },
    "achv_UnderwritingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UnderwritingMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Member",
        "documentation": "Underwriting.",
        "terseLabel": "Underwriting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "achv_UniversityOfBristolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UniversityOfBristolMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University of Bristol [Member]",
        "label": "University Of Bristol [Member]",
        "documentation": "University of Bristol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Gross unrecognized tax benefits, Beginning Balance",
        "periodEndLabel": "Gross unrecognized tax benefits, Ending Balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties related to income taxes",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued"
       }
      }
     },
     "auth_ref": []
    },
    "achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromCurrentPeriodTaxPositions",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Increases Decrease Resulting From Current Period Tax Positions",
        "documentation": "Unrecognized tax benefits increases decrease resulting from current period tax positions,",
        "negatedLabel": "Additions (reductions) from tax positions taken in the current year"
       }
      }
     },
     "auth_ref": []
    },
    "achv_UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreaseResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits Increases Decrease Resulting From Prior Period Tax Positions",
        "documentation": "Unrecognized tax benefits increases decrease resulting from prior period tax positions.",
        "negatedLabel": "Additions (reductions) from tax positions taken in prior years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxReconciliationOfUnrecognizedTaxBenefitsOfUncertainTaxPositionsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions due to lapses of statute of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in allowance considered deferred tax assets",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "auth_ref": []
    },
    "achv_VancouverOfficeOperatingLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "VancouverOfficeOperatingLeaseMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfContractualObligationsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumAnnualLeasePaymentsDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vancouver Lease Arrangement [Member]",
        "terseLabel": "Vancouver Office Operating Lease [Member]",
        "label": "Vancouver Office Operating Lease [Member]",
        "documentation": "Vancouver office operating lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureConvertibleDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockLossPerCommonShareAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockIssuedAndOutstandingSharesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration date",
        "label": "Warrants and Rights Outstanding, Maturity Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/DisclosureCommonStockPublicOfferingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInAprilTwoThousandTwenty1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInAprilTwoThousandTwenty1Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued in April two thousand twenty 1.",
        "terseLabel": "Warrants Issued in April 2020 [Member]",
        "label": "Warrants Issued In April Two Thousand Twenty1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInAprilTwoThousandTwenty2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInAprilTwoThousandTwenty2Member",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued in April two thousand twenty 2.",
        "terseLabel": "Warrants Issued in April 2020 [Member]",
        "label": "Warrants Issued In April Two Thousand Twenty2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInAprilTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInAprilTwoThousandTwentyMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in April 2020 [Member]",
        "label": "Warrants Issued In April Two Thousand Twenty [Member]",
        "documentation": "Warrants issued in April two thousand twenty."
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInAugustTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInAugustTwoThousandTwentyMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants Issued in August 2020 [Member]",
        "label": "Warrants Issued In August Two Thousand Twenty [Member]",
        "documentation": "Warrants issued in August two thousand twenty."
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInDecemberTwoThousandNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInDecemberTwoThousandNineteenMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in December 2019 [Member]",
        "label": "Warrants Issued In December Two Thousand Nineteen [Member]",
        "documentation": "Warrants issued in december two thousand nineteen."
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInDecemberTwoThousandTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInDecemberTwoThousandTwentyMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in December 2020 [Member]",
        "label": "Warrants Issued In December Two Thousand Twenty [Member]",
        "documentation": "Warrants issued In December two thousand twenty."
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInFebruaryTwoThousandAndTwentyFourMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued In February Two Thousand And Twenty Four [Member]",
        "documentation": "Warrants Issued In February Two Thousand And Twenty Four.",
        "terseLabel": "Warrants Issued in February 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInJuneTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInJuneTwoThousandTwentyFiveMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockStockWarrantsAdditionalInformationDetail",
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued In June Two Thousand Twenty Five [Member]",
        "documentation": "Warrants issued in June two thousand twenty five.",
        "terseLabel": "Warrants Issued in June 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInMayTwoThousandNinteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInMayTwoThousandNinteenMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WarrantsIssuedInMayTwoThousandNinteenMember.",
        "terseLabel": "Warrants Issued in May 2019 [Member]",
        "label": "Warrants Issued In May Two Thousand Ninteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsIssuedInNovemberTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsIssuedInNovemberTwoThousandTwentyTwoMember",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfOutstandingWarrantsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in November 2022 [Member]",
        "label": "Warrants Issued In November Two Thousand Twenty Two [Member]",
        "documentation": "Warrants Issued In November Two Thousand Twenty Two."
       }
      }
     },
     "auth_ref": []
    },
    "achv_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants Policy [Text Block]",
        "documentation": "Disclosure of accounting policy for warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "verboseLabel": "Shares used in computation of Diluted net loss per common share [note 10 [i]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureCommonStockComputationOfBasicAndDilutedNetLossAttributableToCommonShareholdersPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "verboseLabel": "Shares used in computation of basic net loss per common share [note 10 [i]]"
       }
      }
     },
     "auth_ref": []
    },
    "achv_WorkingCapitalBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ir.achievelifesciences.com/20251231",
     "localname": "WorkingCapitalBalance",
     "crdr": "debit",
     "presentation": [
      "http://ir.achievelifesciences.com/20251231/taxonomy/role/Role_DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityRiskAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital Balance",
        "documentation": "The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-197402-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-197402-xbrl.zip
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MJF92-9.Z/9,B/X4'&^,:LRQ@4AA3;!/91B>%7_JM!@O02W^(9L#=8)90B?)
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MSY2R2[E-%7'B0$LBD4P#^Z:B81H^&5%6C4KDQ 1/G,M;X.27+DP-TVH^;"1
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M8>X?N,5G8QYJ;5,XQK37^*!<QC&05A?CAC]2M*!:1D-.3XXY?!Q#@/,] S&
M.0T90?N[&T7HJZ&Q7YT=[+]Z@PO\RD)KJK4ZPLMTW<S8ZXFKZ;<0E[3%8_V3
M4^@7G0.N%/<><AE>>0(\6SL\/*00;A&!"?\*%Y"(\)+A8>.%=ACS603GU=!,
M. NSU<#&C#B:V8%#MQBF*. YJWX?%^@##:X6600F'(CG449#VN81C\C%R%+1
M^U CP6#UU(5?GS#)6<$4BAD3:[P>S[*#V:"GTJN" I<33FYQ2D(!ED2!Y=R!
M&Q.&EZ075+J+R19W?I*+:B2?8.)E#D(@/@WMDFM3!O>'>5&0149C5M#5U!UC
M_H$EFI5Y"[@V&(-@H:'*<87Y+=>\K9@OT38H8NZ\/%D"?FD91JNIO9>WV0_*
MH[>1GBBY,+W"<8%]-)975!9//C1Z-R^'9A,T@QA+ A".IC#O%"X]SMW4M UH
MW#><.!]-3F"-9#"Y")HM+KD!X _RF52"7T0X4#HFQM &%IV&+8D7]3S"X"-Y
MHDNLXOX>W8?2!6I:\_QHS:&OH2Z-"$UD9<9L@>=P=T5.(-U.28F(DVJHIS<D
MV5$AVC;W>)Q>%EX,=T*NN\SJ\0I2+%XJ*<H'KQ$#\9W"M4SF@KKE B(HM*,@
MI#11E./S6*,@813&QW@7Q["7!I*P@(*,U>4ENDK]F0D4<N/U':WOZ),=<(:^
MA*J7;L33Q"K!YER_L<1?4TV3[FXTY^P'#>#<Q'Y$HW(E8"!?59>,7@2QV@NB
M)(1Q,PX?BS7D.2CR0WZ1Y9&D/#!*QA$('SP3;Z[CA<3[)9]636VS/<('7""E
MGL**X"N9;XHSX@IR,DFV6EBH2ZH*#(@$APF"$Y80G$#F'P .*$VHD>HY\'T8
M)),IZ#>-E.&G9 W(#\T,Z\%L.4Q/E0T.BX24!),XQ/!CF9[- 1SBJ' +!)U5
MH*TC2&2S6](II!6OMJO7=O7:KEX1/EW;U;<(V9$U=8'9:%]<!S1%RT6Y$]2S
M0]^ZEZ#VX.N^K>0VW'; ;&4@<4[QI,#R]L57T;,ZMR>40EL/LNF=C@$V'ZOI
M[<!XI(EN[A9\77@Q8>LMXHLWBR?.YQL2%FZMB%AN_.(M*<UUU%O-5K__4W%Z
M^*[5?]!R $R;AN@X_"_ XOB[Z[KK;['C;$C+:!J;6T$H0C[)=HNB'J:(N?9M
M+,RCTW-49M(KS;8;![G%LRQ&##XU47V()A1/"-)*,*IG!M/=0=.*P30341\2
M4VGV!X5K^]9ELQ^> [<Z&W#@VT2O7W<7\K*@Y+05X,@/=MZ'YP=?-=-H5NLV
M/1&%>H("M<^)?Z9B(UJHOYO&=V&0#<+H>UHBZ;LHD/0=Y,!Y<'NQ<GM2Y(?#
MTX/]\^/3LX9V\.^#_3_.#[\=:,<?/Q[N'YR>::.C#]K^\>G)\>GH_$#[=/SM
MX/1H=+1_4,N<S_>JU"R\9N&[R\+-FH4_4[KTA"S<S#'N?''$IV3<&;?>/_YZ
M<G!T-CH_/#ZJ&?/SO0#/A3&;9LV97R!G;M6<^05;5!^:1;>^RS+GB^_!I0^J
M]=2=?P^<[S(,]OOX*7GU&;#JT\/SO[3C/X] K?Y\> (JM@8:]OGH\$A[?W!T
M /KVX>B+_)W4[J^CH]&G@Z\'1^?T\?3@"ZC@'[2S\^/]WS\??_EP< J/G)_#
MXS7/KRWK.\3]![O*_;=X'UZD -"N!8!: '@@ <!L/R5_5YR<F#1HX<CASPIL
M^_QT!!KZ/OW8H%^4X5T[//IP /K[AX/:KEZS\IUBY:V=5>1K5GX_5MZI67G-
MRA],E^]\GX>N;[ESYGV7_?J8'W]W.(] RP\O7.LIF?W)Z>'1_N$):.NC_?WC
M/X[.1Z"B?SPX$ S_[.#TV^'^0:V4UYQ\ESCY[9WEW6:_^Q"\_*;#FKFV[?%M
M4[3=]40!'N!/O[QJO:JA^FR@>CUA>4BZ\G" K?-7'ED)6,I?N:A@^LJW6DZJ
M=8D:IB\532L&TV<CSG<JR(!KP]PC&.:ZM6'N!1/^AS;,=;^KVI3?TYJ1W]/Z
M3-\C:_JT$;&?#]\?G@L[W,=#3%3!F)JS\]&YB*,YV_]\\.&/+[5QKN;F-3=_
MD=R\M;L6J1=$E5X6)!^.:4?P+8NQSN.3!K\>?CH:G?]Q6K/=YXS@SX;9#F_;
MTNV1E,675*2WWNON[U41!&J&(1P0V1*J!^>;RC)6%<Q50ZGG59_XQM*+-U^
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MXJG%0JX=9NMYS_P?9&:(M1-WSD/M-^8X(5N0=8+YM)FR?>36V3*,/BX1E]K
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MU&$%2HH%R(/6/L$%2%"I2V57B3!$H>=$>)@%EP3N"$UG$6(@]9R3KH!'$2$
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ME(2#+)MC!X47T &:L?]E%RAQW<^!C[*0R ^$L_L!*Y626IKKF/>'9A8#*TA
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M]UR;+I]5IU]C3%FI5%N:";.V9NZ'0OJU*"&PJGITL_X!/$I7Q$%HE!QWG4$
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M-)(A)&_^ZK*PHU#:XVS&0$+S82]CCH99U0,)+UA)#R24AEU'FV.KP%@^*OP
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M\.,P '1;1'BN-:[5N+9M7(,S$;@FA/YY&& 40(UI-:8]&%43F";24:,D)"M
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M$& *;K>X9'LJ[[W@XQ*GHBRD-H=#L]*@^R6HY0PD @>4H496 D;O%^Z2VF>
MPDGQ-D5$7(T$:Y3MII&N$9>5(9)$$)FRC[#-<%7@@&P:1QPRF[=Q_5ZS!U.V
MXF)SGUG>6D5%?D'8(ON6" HG6Y_ 8YX3&):W"#+&QR3$Q!TL&]:0?LD-RRR7
MG^5J@E!J(148B0@4"2-560UH$,$"[T($1)75C]Z\[$!JLRRSAJU>B12N KM3
M% )(@IB:B*+(\=J:T"0R%-6 4M,>8B0(2.6[7_91;UKF(;?5HN%PXUKYU[A"
MT\$%2B^;(%=\N.HN-H0#5UY)22U*Z=OF&TW+4Y0OE3PQLM#YIMYP;&PY"?"3
MU+@:Z2SEA8& PW!A[!>N^TA4V5 XEFU_F=RBD,Q$#S>LQ[Y$^"LE$]:2S0;U
M:4AQR1IO_ G:1.SQ,:@?0$1E+78X:"F2P!,SCO=AO)"5/62==AAHC!0!;D@B
M%?4H(56!8\F1P,O*OG@,_5>"BA$+\%1"=:BB^/#1=P56GH789QU(90Z1*&JH
M6+W$_W<;U]E'$82R/A7.OQ,6#O&=T&I3PJZ\1L@-1?2,N*A8F.M/4>1FXJ.7
MA\@LH)D+4 . "%<+QG@XG),:#C<V%LGDJ33"Y/"23W@+=?WSO#$M%1.OJ')4
MM=$1E>]Y^4FFDB6>(]Y\-YIE9\GDZ+18U6I!+0J[,0M_[O'7?VN?PB"9YYIV
MG?'P0@A2JN\O0!?P;4X%_K$#K\JE3X!\_I&&#A'0I7MLOUA^I8PQYPJK7$ZY
MZ$_@V]3)( H:VC2X1&^2M(!(^3<MH6:)PZ="3#96+IN($5*9W4E  %R1!7SJ
M&0CKU["9(=)R$J BX/ 4OR3./X?DD@'"6!:+2+94P,Q*F@(&\&QE,Q"7UM/Z
MVD.E2F<CMQEEBD[@%'GH21A,0C:KRV6G$%,=-Y:K8]Q.WA'EFS(BA#U&J!*5
MN$J:'1!IP\;9<8G2P.!" ZE#$^8/+JB:; ,"I 5+ZWMH+T3Y3%8-5 6B,J-;
M0-&"2%.R"!0FQ,LE%4AH-CPM3K;I%M<'_!5T0RI2@HVFB'*D;:.(^DL%R)82
M&9KPR.$,4$F*98O3196N94_688,?V8(V-0-"%=C4LA"^#/!P$6KJYPNB/*A1
M-PK%T)5.G%=]L8P:;"DK0B6+Q8E<-3B- $@C'J&N3 BY+30*3X,D$(E( FRE
M$U _QJ)-57%H:2+&2-H4&E2+C'F),F:'0H<7G1/SLO;[K(R<J\K+R6.FJL_2
MZGHGQ'YHS*V^/%P]&O@(O?E*]2YJ!NP%U@^!)(="WZ>*YH!!<WI\=X(?7C;?
M.PHVBXI?$Q.4=Q'ZJ0\H8PA( GGV!366R%C!L8]]7,7TIM&0C=JQIV"^.#]3
M12U)]$\+^),P6@S.S.M?F6MUK'2:G/]+J %9BRRD3FZ$.5%10GE[M#%!5K6/
MR,JDE8:\J$38Z;7,N)!UWDEM=_EEAR$:#[*%)P"<B'/5J( &0V8%BHBM:G#)
MWE_Z:N^OIJR^5>-Q>J5%OY-+A@D"4B_4J,.[_%O5T9!%RHH56]<:PPJQB4UM
MP]O2R!33W!*PTJL;Y0J2DJ 17/IBN*P3FVG\M#1SYF7\.R'AQ4>4%/KKHK3A
M72.]9XU<K6G9QH^435]TQ6.9QS/;&MUEV5V"L%+$+DMVG^J#95N);KF7:XV1
M:50FM;&!V2^9Z'=!'GUUKV&E0ADF<2<GU8UY?(F9/*_=-Z3';T#G5$L_J5UC
MF[RI2.=!JF)KHM*X^$@7VT8J(572R@HQ=8#?#@;X#>L OSK [R%Z0#P7GE].
MPH55^K6+-+^T$VR!&Z4$WW'#6<[$G9%_(/>2E2KJ+SY2#"%E"HAG\[;_/%-8
MPVE KOQ0+E,C=\]DZ9*\RDSF7F9J!87>RHLQ69M:XN<@0L@Y+LE9M?$L:V(A
M@O#:ZOQWWE#95-O=S)K3J10KKPT2$A*?N3U1'N,33WXXD1VI4>JK%:*T"F]$
M4KY"<V6D 2V2Y-83Z4ZB&ZDT<J":J1.[_*J^2;WEA3SQG#:U+E@JY&GK<!47
M0VY,2G+4$!:6!Q20[*5I'VO9"VX_BW-009UC\M_MD6C/_8E08# 6.M_V.A==
M,I=>547@J1,$,<U\GT!IE,R^:0@2CQI $@MS%]!JCT+#A Y$:>Q9JV_2]W($
M2EAIWPE^E%_H5&(OJ5D^C]U_! E:MX$UR_J'AP&<>H0*KN<Q&3\#L,'</"UB
M'A>:+XP8T2J6EA%-R=C!O,SLGI\FPX?\@ZI&^(2AHT^H@<&5M$DH_GOQ1DLB
MN<.YNJO%\2F&#)<=DU:*@-/$]5+>:])0"P^17T'S N;7WKZT+V;9W;Y_T]#G
M0@J5;Z^,I]]B0MB->X4S'24SH!Z6YMJ_O/KXO6590\<<#O0Q8VV],S0&.FN/
M37T\:,$WG7&OT^F\HDL(T#GESB^O]K\/G'Z_9W<&>G=L,+W3LRR=M<9  H<=
MJ\=9O]WIFZ\TG\U@A=RR]^0)GX?VB?32 -.S1B(8Y:/')J\T89/\Y95[!7JW
M>\5M/0X37I$3D&$S*4H6X/AKI60M[/I6>I^$_4M$X\C$;-E5MB'H+)"]MQE_
M<2.EGI405F1LN=HJA=C'O'U\+>,6T4AID(H*DKYTL8EK$*=<)&5&TC!_Z>=7
MD?@>VL\HH*T82?A'\ZR9?Q)#D<AUN^)#7+,^"@Q-O8+"32O\EC*W?65*5PX4
MRX%$]%/68CX7\93%[,E &RR.1TP*^]]2 ZA<D068$T-I1C#C?'&]/(3+=EQ/
M: H'5R2M:.:P:2H'\4@X54]EE(J/OH&99AKZ[[+#$1=ZG"@ \(%;0M=HF\JY
M(49/ VFP  2,\A43A+16I^[\5XS&<V>R5N(!V8JU3X#6\<U"_J-SMOMS$>Z8
MQMAP'+WG=#MZQ^PX^KAK#?2.8;$!8RW;;(WORT5&*!.>SR9?_;G[P8VL<QCJ
M/?IQ7VD\LM@<H;C*,^Z_MX'1Y2:W#=WDO9;>83;7A_U^2Q_"YYYACUF?6]O:
MV^?@$K>W[T<V?-YH@T\HECR,1,) &AG;P[X^,+M=O=,:M_6AT;/TMF$,.QVC
MW>[9?)NX)("] V*(#&+!',!=$$6$@TR;$-'+^K3;%_ 9TSO0$@:L%59!P514
MQP78JRL2I2A]4@9DD"L=8W<B+C)"LR<I)$FX!3TY%[G9;)(+?F/ [\*%S)C,
M\B+D$Q;S$:!C3C"UR]>81@"AR2"-$TY]Z,U=.(J'N:@#/FAW#-.&FSDT]<YX
M:.N#KN'H;:=E#%G/;#/F;.VB4F1<M2DBOC-%<Y! 4(EDF)*C9.*\1:(T !%>
M7L)F%.:$C<*'S9?8IE36IRI_DP4DPDLNNMO0CH8)7[*/')9TQH"V='GE-1/%
M8N029'-7JDHD;=NE;V6)7VH6T9M:A/%N4J?JIOM4Y6M6&[K+7%NGW$*M<U$;
M=E8,7]HHF211C&I3>WU[]S1IYSJP4NX*J6UPM4@Y7<BJ6\5Z?9E&ND[Y+ EI
M69DKRE5&%>D>ZYU1DOOB"D!G)XH3BO&$'5U6.526WWS 72,K:):+8,L,_EEI
M,YDLZ]ZXF)4.SD23\>4+KHM.UL7 [5R'2%FLY#K0--1#_$)F+C _G\N$V46R
M\98,TB::+?)L,T%CV;H@7+QE.=.YQIHB(=;A-EF:5\P?% A(H4TY\24+XZ.D
M&+PII:[%E6V*3**\P8'\",+F4&5S0UWQ?=>YBVJU:_9>LS?:^RR"[Y@B^#!T
M[C2](9GSK<IX<A-'VPJ>W(K)/@GJ/"RF2,&UT(-9$E!1@J-8MJA40)>U<= L
MCM$U:)%>B1;%-,")8HT4%94&CPB5..^BQ/(^6*6C0.24])PK0!"DN"VLR5EE
M@BRO.WLF2T&:!4IASK)=5Y;1U,ZR4""9!H86>@D=.Q\=E,A"%58P=X77%?.D
MB$>K5:V2;97=$P4>IP(44J'(!Z-CZ+KGBLF22$8Z1VDF+$76BW2=;%$J>178
MXP\?#\-AKI>(I%T"JZQO(1>&2Y+\&7.69=4K2H:BY#.$&8Z#_EX0#,8K:V8R
M(2EM"EU L'3_"> F-0H76U'F_LL091 ,NT>CAZJ*H:*XHWR.<+KI @RDUR$M
MJ J AUVN" +DB4;9QL-B,X 0L$)DN/<MB?IL6&<=4+R# <6F44<4UQ'%VRD9
MJIMFL],Q?THO,D'(-)JM&TP/@_N:'LAVBCW*OIOF]U3$^)[7.:LJ=Q^>'WS5
M '"[D1Q9R=4=_/M@_X_SPV\'VO[QUY.#H[/1^>'Q4:67_"*LFG=L:I)5Z\P;
M2^HH7@6?M2D"U*J)H<^M3,M"S8HRY>"I.8R 3D"O)!="R=7Q90!:6!1K4\
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M%/)6WKT]I=^A$X31K-M+<6]VV+JQO]#@#;V"YYV(X;(!>CYM<H9SEQYYAM=
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MA*DF[,K%A$T#+O.K?L+5$*::\&M_T.JR]]H<V.K)KIP4?L):PL&AU3^TAC4
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M#VPY7LS30YNR[=[2K427E1;JV J0N<RLC3(_=,8%^;MXIL38#K/.PUB^YO.
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M+*/-KWK6#K=,KPS3&L"4Z;5W9!Q90P;N<R3WX1_VR)-_^\O8O1*.9T?17U^
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M!HU2#U(>1ZI?]*.+"Y[@!UPA Q7"E"LY=1U/%B_%1X($T:X0[4=R;J.? M8
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M=.?A/;:,P0W=)1NL1+_>Y\%@8+2/MIG,VSMMMHUNO_CD,CJD/_]'B*)Z_O<
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M$ASZ)[5Q6LEPSH)$F<6KP+LB_7.D1%.7H5!](7XRK396+)-^E#F,#$8&XR/
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M?\_13: 2_"]5/LJDX"]1 C2):6DPF3^K?V!V.4Z5 R<HUP*B;!?12GE8FK\
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MJ;M?L[VGOF>AF>UIE&\H([=NF6T5(W?\O>2^VB/F^E!MY#AQ [6!XZ$[=OU
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ML:9S/5!#KZQ4>DU)!!@!(QD8-:P6"301CZ-XA-8@4*\#ZJ(-R+Y$!G '[C7
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M)'!)24-J*3>5+:I6SJUKM%NOR[J1R+(MT!(.JC47R4]I7G<M5P9OW84$E+6
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MU6JU.[=.'^O"=II4O#Y_R&^XCL6UXK_^I6M;G?VD-/W YH,@(C_$=][ 8#0
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M3])\(RC;4@:5#N"D"V?M9(1!!085Y$2)UG/U% [050(ZC)T!.V '[( =1>F
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M*$H'[( =L-,*NSIKA]5@JN.RZ2$ZB)4LE":^KFP)&%O]8;5W_6:[V>I8<TO
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M4/L(Q&9*P!6XTEWG!<R"69VLX^ 5O+YTKZ5BU9CU^'$H*USMM!6-[9566PK
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M]8:XX$L!CY1XA"\%4)*#4C:36^ 1/!+A$;X4^%)(ZPE?B@99/!JE1#VU W2
MKL[08<@,V $[8 ?L*$H'[( =L(,O13<15^E+(>%#6:!D;7PI- : GGH#NH?+
M1JNZEPFY4;-*</-W/_)^>L:T8O9:IM4Q[:;I=,UF;]?UAE<-V[0=2_QOVYZ5
M\Z$;<W::B2=P$_X*L\J!>&1^Q=GG8,#9N1?PL<>3'78R]@S:MA4$I)X!N9%A
MVL9OJ#3 *&5&3<=I=,VV[0!4@$H95#3! 2EY2']W1<.7V5W92"6R<E#E:=U&
MDFHA5>MD5UU^RXDK6&.T+99KG\D&=(!.)^T(08=1.V '[( =L*,H'; #=L"N
M'EF'*HF()5LJ9(VQ"9<Q^BA9@[FH:UZRI;-M^\OG0%3D"9?;!ZG56\2U+Z</
MO"]_C,7SQ8E<S44<^#$.DC0*'W7!W#7!_)J%4V;EDVW;=%PPB#WRL8?%6\!C
MS7C$XBV DAR4LL&,93+ (Q4>L7@+%F\AK2<EAPKEG)&>B4 :Q4L]M:MM]AG0
M 3J,N@$[8 ?L@!U1Z8 =L -VL+;H)B*L+16RMM"8%ZU]#J_ZF?K565NZ5L=J
MBE_YK6['ZK:5M67K"[L<C/C8ERNYL*_B[#1BCUA="I>*.\[<>,IL6PTL=!]8
M8)XRNLCCTB%?;).!Y04Q26GTS#(;_X#G!4"2 9+6@BY@$DRJAG3='5C]EMFU
M.7"D@*-TO-BYY:6[E)ZU[5[KD7E"J; 2BPR)7--J5QS6,Z&():/H:+DR>.LN
M)*"L!915'_T#EL 26 )+8$E/36 )+ FJ60\LGUP7=U52;GA9W$>U7)F.%8<1
M&V)5R!JET_KF^BA+88B'X-Y8SUBG6NUFJZ>VQ7+L;BO?$TOYIBXLL]<F89[B
MOG(VG?$D51ZIPV@TXK$7N.'M-EDL&K/S;#()E>7I5.V0Y?%,O4AV&D=^YJ7)
MG:6 \KT&K,ZK'59S&W#1\50AF+4/Y@UYKNI8]VQ 6@!;?4]6]?0%M95V;55/
M6@"[#E6_1%=\U.<QZQ%:SHA D[9FR45=-]TBE%U4B3+]<'PJO=C>R,3+#3AM
M]<S\TG!ZUU,[0 ?HZ@Q=U8>O@1VP W; #M@!.V!7&>QJN"JU/G+"WE1U>U.+
M1+&#]+&FXQTK,S79IMER6NW.O*G)[CC;]C1]YJFH[Z5-Z4\W#M2WE<:D<SY)
M\X&8W)UDFX^ZDW*+$_OC-_8Y& 5IZ9$*//%[\44IOW;C5!#D-/?S/V%50F"2
M'XB$00F8:H I;$E@51=6848"IAI@.K,@67;>\JTCL_JN' 4_$M:/>BJ#5<]1
M!DRG)ET_UE-(0%D+*'5K_P)+8$E02F )+ E*"2R!)4$I@:5&Z15-UY*"5ZA"
M7J&V1L60SFE>6M7C1KU"P<W?_<C[::%G2&)\ZQLR>RVU$E+3['8LJYO[AFSY
M<\=N;=LV="C^)0Z2:QV)?ZIWU \Y^\3[Z>TR2'=7.&JID93FSI-+&R5WUC8*
MPD!<DOWIAB&?LH_N^+OX@/G!59"(VY>FI>,@3M+&89"*%SE.U"'LK^YHLL^^
MQ5DB;VXD))K";H38)C_HV&W\AOH'C))FM-9>(Y"J$:EP&@%3#3#-V\:]O&U<
M1UZ1!H/+J)JY+XT3Q>2*FWIJ27@L2"\A 64MH-2M[0LL@25!*8$EL"0H); $
ME@2E!)8:I5?@,JIBID4OEY%."]IK7 S1JAT)+4AT:RRR':O;NUV0Z,+:MJWH
MG'M9'*2!$.,T$P_A)ORAG<A-E/.']^/,C<NMTY2Q*%^<R!U%X\NGW$7JJ'3(
MV:2X1IRP0!8WP2 0WQ^-U8>)4-M-LU@<YEZ*&Q*_BWD:E<"]4J.7:\ T,RNA
MB*!61,"K!$2!J(Y6)8!:0U U<RJ!T1HR>MO:UL^JI#&P2*7!J 2C$O+VU+4D
M/)RDEY" LA908HP36!(4$E@"2X)" DM@25!(8*DYELBNP*@$H]+C1J4NBB'B
M13KE48FW&Y6*G=.LGFEVND[WUJADMR[:;7/;9J6O@T'@<?:92Y?2O8W1S&ZS
MW6WWV$?CT&"?4S_W'"WT)+%OW!N.Q8U?2MM3OOJ1%XU&XD-Q"[<^)TL.O%@]
MN(,0E]1'"RT3]B P2IM1V(, JA:@ZK:),2"M(:2_NZ(EO\.LYKU&*G!%_DK[
M_%6]<U8:!P@*&Q):$A[#T4M(0%D+*#&P""P)"@DL@25!(8$EL"0H)+#4'$MD
M5^ .@COH\3$))'FI%^F4QR16Y@ZR'=-TNJ8YYPZR+PCLD);;@HYNQ(]JL[('
MRQA]XAX?]7G,K+::4FWOK-1$!)\0(I3ZJ"%\0F"4.J/P"0%4+4"5;7(;D )2
MRI JGU#9XD61BD16A1)9]4Y>:1P@*&Q(:$EX,$<O(0%E+:#$"".P)"@DL 26
M!(4$EL"2H)# 4G,LD5U97W9%_,/MAUQ\Y =7\C<?Q-_E]?^K\A,W>_;^(.0W
M#3^(N:?&[,4;R4;C?3]()J$[W9.?/I#6: D9Y:T5[J/\%__.DC083,N[5*<V
M^-C?GT1)H+X[YJ&;!E=\OQ_=2(WE8_:CV.>Q^.J;%R9H52KG;>5%<41.4_E3
M <FR"=S;>WWJWE[^ANWVG;=;OL+A+&%6W'8PE@:+1I*Z<;KG9FFT?_<#\0+R
M7\M]F/)<6L,="!7VW/#:G2;[[W;OLW$W N6KO:7EP5M?[<M]6]FEPWME"U^K
M5-\+W221[U6<61RO_A8_\_C=_<!M+5 ^3XQ^4&%_#Q.EB>*@>"?R6>7-"A7E
MX0T1[%%6')+?MV6*$O-]>;S0*W0G"=]+^,2-W93?U5>=]^Y!5K?O>M\OXR@;
M^XU"\('Z+Q?L.@>I'X7^_E60!/T@#-+I7GFI18G>_-8Z1J_5?3]/6BF80FWW
ML?.L)<YQ;,-RFLM<S%CF<AVCL]RC+76UGM'K;$K(KF%N[*59+:,IL^X;DM&R
M#<=Y_MF><O!V7V?@?=ALN[VU.+I>1:/JM8W5Q25\EX K=[Z<>7E)?70S%"52
M^J$?[_[M2R;-AB3Z!'1E?EG]QQY7\3EP'ZA92$)-44N<NE5T/_'$BX.);!V
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MFL]N[8BHHT@(HD[CJ(-IKI+Q1U=,F.:P\MK6,KETPP)E#($R!DH"2V"I@9+
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MM^RV99OMGKE;NH3L2JXI9'79'\:Y<6C,3#V6TS*?=?[TS';EG#^(:\)Q?=N
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MN&$X92[SHLE4?H,\LKQ64MPWB^(%=UW>]/G1(<LFXHHQ_T_&D]1XBS=CU6^
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MLA&>C<;[?I!,1.M^3W[ZL'1HB7) 7K\HY?)?_#M+TF P+6]%G=K@8]%<BI)
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M6,7Z7@VKVE%;\[K,T_L5+FR;D8).2(F/[P6-+,?5Y7)8AZ)A Q551D.\$5'
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M>23&P#0??Z[B\]#6O:NDYZPYM$5T15$KYC+O4-1@9!H/8-B:()L]),)7DNU
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MLWG>F(88*EF=P*FDH3G# L!>;A3]=\TV*&^K.PP^ALM^W6PT+6UG3N.N&!"
M5;P%_CG]1N4CZV,S.D*95"E[SAPKW&O/IE_^2JN+%>3;:=X?O%0\RVV35(EO
MNV=:]]4\9F;K?4&G(6\K4TR6OH;E#4TQM2*O.' 0UQZJ4[#6S,A\KFZ4VA>R
ME"F3[LRA]&>&<8G*"H&_$RRK\&M'78BH0UF^ [1B,*<GCU<A_5>,/M_/XF6N
M+218W7[$-"L9<RUPUIB<XMI3;%^EP2^]P9A[G>!BMC%E$-QWJ?LB%R6HS7:0
MO]O',M"@H':L\S/0 UOS(DN/3)X#^]I;Q-LXC K9T:I?BFX =,N?_AZF9F?5
MN!AE6\S!,>C."N!N9F7AF5#>$#W5IJ=IIMCVF<16R[*5-C6O#61)8='7HCR5
M37-[<W>5DFT+0^Q0CD[O%>%7@F;",&*E9:NNI:Y@QJJ70RM#F*O;S6;RTQG+
MSE_+2:_L/F_OS@?Z/*%_IXIM8G7*E0,W\"ZZ# *L_QF@%S*,M"(BJ$4G<]PF
MSC-_JR]BE.,XQ\771/66D--?&=#<'9!1U61:(:G!E%S1V-C@*^0<*=Z$&?GF
M@4:1R]4BF \6VJ,"7%0XJ+Z.].+07;= \9!<;A3E#GN*R^Z=AAXFO4T#."^*
M^KX^R4-U>W-^&2(]LBA!7N$D[#+D;/;ODXW%+PBV!%4/_5A8)JU;D61AJZQ6
MD6\QT6,F-L\57&Z6BQ77+CW[HACX6-MT)N:ENGQP92TU7TG,'4 &RE[0/6J1
M%IX76ZYP/BR[E9H[&4R:)?/(-"5A*&LY!X]"4=K[X8G2Z&/@QWNT\]9LDE9=
M3;AR,_&>599_=HK%Z1J;SS=@I2I:1";83VI9LD15CT^6)QC(6ZR-%$;4'B>5
M<6?\VC7E:]=R=HSQNJ!VS.U6HC;*H_^P=BBO8*HD"D'E0^#@:"TWGS3$YEF"
MRE7FXZ":R:.@%-'":@[AD^^R"IYPY:+.%?A = >YL YA/DAB.+S9*")RZILT
M (FY?2&CSU,P?P3&XXQN_ !5*OU40RUA&WS5:C+K<+_$RE>NN>>\?%)J349U
M/29EC9-\3&JAMA(_BOJVQF8>!8KEA@>+7EEK%O]U0U%]53O]C=UF%:.C*12[
M>]R.9L3FO9NR"6/8?H8+Y0:0NHHRN\GUJ264&>PA/5)[AYHOFO'-;<< XVES
M+@V>8/'X]$AS7PW&I#5T'] G&$F2IY6_JNVB#UIWGT#L?X2)I!96>6@K\RL]
M9G!H"^$!>+FD"L>.49C=H!G<?RZ0@&6E80,I,F*J]V_>@NTAS-N&=^7'P60F
M/ 79>.&1*+6R9!/4ZUL3L!6(N;B,U;I=E+<U-O1/5O [C? :2 7)6E&LIH/)
MVD[E>3H:E*?-_<:X*K# "[?/)GYX_/QRZRV,0\DD6GD'=(,RG]"XTNP^H13P
M*_5 W: <J[_BV:$<0%T9FA$Q'I_R.O%QV#L\+\S8>>#+,)F+6O1]^\5Q73C\
MN3K*8?[OVCN^.QSSHAJK\<:CH/M6B*ON/9*3;[UT5=O49&93F;LZ#6Z]B"F;
MMBMG$SVA>;J22V_56?>K2RWTD%EN-L#V9D/(:QCMQDXS$!9U*^MJ#+0C(YVY
M3 :WP'0R68IL#'U)4AH '=FI*%)7XG;2IH<Y3P/'<R)Z@Y=S_D7Z9/W3#YB%
MY=;:U8?N=(5BTG(6P?Z(8(=9(5K!\!^45IXM%TWDY=_6RJ&#0,ZFR%;=C57>
M=F8\;<]:$S*QF/@%*1,,:2<^5S_VF;@>?+(BKN*MKB-0TV%2&^PGN(1V\:[T
ML!9_G]GVU>'/4YN7EOV(BY(XB$WN;]1U?"8?15YF*26F+H-?16MSNI.,EWC^
M0:Y2?]1W,N\*R9+0ABPCXH^U#W)=#X,>%HFM*!E?Z\B-EIUU&QXRJD&11"A5
MTY1(IZV[S4#B2PO]E)CS1."VO?3N49&'44 L1+"CT5 '#I/YYOE%7<OYYUN9
MOR>$V%$UNTWY_[J"T9W&DKZHWIDTV-WX=::]VO:Z\R;(S)@+S!I^12GN:)DV
MI2+,N$-'@T(A\_6\LX(HF_"Q*6*@H9OY&' LL)(Q[%1)>-4=S+V8%$Y@3F%X
M3SWZPFO]53V5#;UFJWGHJ5TPO3YL@EOF5JWK\16*8TEXQ?PDL0Y#TYXF<A7=
M!73/1PM/@6)W]Y:!L%\$(0:0.9C,R0KRQK7^<,S9$^$&"BPT R[LG>.)&K//
MTFFQ5IQIUW<&;PV>ZZ1Z2.-#DVT]44#:(@:YQ,>-L;O.FS*+O\]$!<<8SH=]
M0"U@0W^U @<%!*RYV2[8IZ:[]F)W/%W=TOODVQAM)90).)[2,US77O/8%"89
MP=_4)62I;&O.5@R/_I7KOY14+.2/:@.KVKZ_]FE'EQD://B;"%ZF&MM?14O-
MX\F_C,I2\]P0J,=+HMC3-^7*#Z3V?EE6ZU S</VKL$/X&) -.Z"-=:M]/W,9
M&U@A@L117A0BSH8(R$I#!;^WM&:."^?"*@8DCX5%MTR.V3*I':)_&CHL(H[E
M1DFM5I9!OTM/W3E/.*-Y83GN0<29_NJ[<%S@$+3*NM@-@&YO")R7SQ[+(%-5
M]K2FX1Q2D=[!O 0C)B*M@F_>L8WGQN?U"*EGN<P[DSGFT0"$(9&3ILG!K244
M<\8?=O'\0EUN@SZW]DYDN5SHKL\\W=Q1=QYGEO@?Y@_8$H^[PV,P=N(E4Y/%
MN5U/W;I9MNK<SN=$P*PLO8L@WBY6<9W_6XM>YG0XOK>%?;M#-K<Q/V]%8W/U
MD61QWN22609)DNA0R0O=*?UT'[#&UB^GOLE6R5/"%E &7%<L:S<8FH_4\OY\
M\>O[<VB(0? /46P?6.QJ]7%JZ#%Q^D2>HEP43BT7*1N;FU5]KIKUBZM*E_W$
M:PF>O\"!8[%F2L,JQ<2("'6SJ;;M\&L[.0])1,>YY;K4/CM(CW*1=J(\85\?
M.#.PCK>1>CH:PWN G,%$]"\6/L0'O#W\&4Q15J=KR[BR-M37=)U?#&0C@]2F
MIT$QB LHL(5P?D4>1%YB9EV;K+--SQG5)TD9.!WLX# $\XD6O:5-,;RU7>82
M$=Z<1*6R_>S<2]KG9.@"P:B-HL;\8&Y@JLVK]OXN:6A>:Z5;GZT!L,&G68RN
M3[F1EIUGY>]T^<4)(\H4\UP$P@J?\$65EK(;C&E=.YRM V+08KL-Z!;+;(/X
MMG;VEMO#NZ,2E'GOTQ8.OI\]']ZHX)F+L?LXRI[$*CW"J*C,%0$(430,(V<'
M"UF9Q3_;:,1R8(J^2X1TK8&)#PIF@0X=#5XH</HQM2MS/)=_7._V 1:];XQK
M;-W=/('=:1J+C(XYL<4_> X_E*@-J]N:O^A2WK.]3WUIG_'29>'&9:5UAB3,
M:@G$G!>$%;CP D3 L&%H3>WV+V\[CH5?F(!]&0\*$O2='T0;WW7\Y48X,Y?E
MP*HQ^O>'J=L2*)2YS,(O"P2*.,#R5%,-/<S)UT+7@6Y)F.OJ 2['6S_Z.XWN
MXF#]A%JYY/C*MHWI  8"G8G?92.9E<TU[S9F%H"M$XJ@I.4J BRX@2Z_K)]X
M]L& /6UI+IBJX!4- ,VEV$O=>Q@S*_U'45ZOO?=:=-3M* 0L-G#:OZ*)YW!F
M>;_C*?CU[-KS_&<N;_.DV;%G_WI]?7US5Y,4I2>H$1W-:F^Z\H;:9<V<FD(1
MAAI5(7T@&+R@M[AO[^D>X[.Q3*>]NP8YX]FQ8\M]="(7LV9+7X5EP J]*(II
MO):8O,]4TY<>W%4\$+?R[AX+GW%E>%E9M?(V$Z171@9LZ57G"JIH;D[W!KQN
MXXN8:Z3?AQ]W)/>L#AU;;*PZ_^6Z#KKYWC5[4S"5*,:V.0U57^N:FY?N6@:L
M<R-@D-$YM=9?:<%ASOLL F$$WN3#@ODUP)"#>QB\[X'D<;AQ?J?N@0DJF5;W
M=,OBM[RHHT^:+F0CY5^4 LTGZZ"(SK<.$YK;EUBOZZYYY+_"J^['SRB2=4EF
MV*:;L=-[%H=P+D+5Y1P.#SLPR\U=0$-45C(+0(/"I@<@\UZ@K)Y7A#$TF_3+
MX5Z@[<'.JVY2=>KKUMW,IQZIR;J4;:/Y=L@+C"#3K$2HZG+S$*_1):3ZDNC0
M>W9."6<']9>:^>\ 8&Y&=!8-O[#_&8<\GV$W2WFA][S.?9WC74T'DVF0U6#;
M,EM!%34M>IKCI'D.['/D\8-#?;ZRLJ::+[2*O7R]V\.Q76Y0"1)%@;.*(ZHD
M8B^[W'I"FI\[9[N<):V[FPOX2@3)!WRX,6G/Y[UM18H6Y@;D@ KZVO:>9C\F
MN>.2"A390I4=-F0C*!/VWG-D 8)'_R6O0*EK:5R>./=W*Q'R6*%1:4K[T0?2
M1.LC]6S2\H'JJY+%*6UFD'O;8GU:/SA@1K5U/9]6TG36,?LMV;->H.;W#)7%
MY[?L-.]4_ZS,V&2Y_E5L!N4-S*K%=MK"==GF4[^J][]OV=ED $DF)7![]_4V
M/2?-%,Y8;1KL44+%B[RB4'-I,\/"+"9HY+6H\/F,X045.D@4O5EE<J5V+O!P
M@>4'-CRYP8'IRS%D!TO'^"X,;2LC>VH%X'$PCI+>*<0; J\$U3-3^ Z=PXY#
M+M=R^:U182_J"F4VSA"-T6DU'<SM:9 :G8"'4L&ML/=#RUUN,-$ JR4B*V5A
M"3:^>4I*9K63X\; 9$[D*ZTTUVB=;>PV:[90J$DR+2X<S ."SIB%. *MH,<T
M9*LZK!:I3UKWG3=W> ORX&3,H8)L!O'2FJJ[MPJPUHEK4A:-K5ME*1?UUWFI
MWS.;+_DQR>U0E1FC'RQS#Q#?,=0NWU B-6W5,]2N\\297/AVO_3LDDI'U>U&
M]J>XQ1@5V.2*5\3C"PP"W23:NU6T@#+IV69.A%AC1GH55LA?Y>W,.T<IG'1:
MC^47!P2$8/UTJ"^4UPF&;C_R<I/M8H=R;BC2.Y3ZB[?J.-&!O5YO I&G>1%%
M($MR%LZU\GX.#8U'C"+\U>=^?2_EY[.JZ83IZM"I+O\SO#^_4,N-GOKELFL#
M4K>;AO6%5703X4#\:DX"@>H++/0 ,(/:$6E>T?N'SRW+4I;U&3>[=CLQ9@SA
M16?B%,4MM<%I/-?8H(I0I*LI-WG6EBIOU]>\F]\#EC^@VP,,[R/P-0$&F-";
M"I_C8;#,I744#!R,B[/ZBE=>BX*<K;O/6M\C,Y)<>A;>8J+- "U/!4!S_&1U
MT>027Z8JAK(;$'-Y'A[X"6,5K^'"3_6/M:]88[=Y:[D> =ET:BX5FSG?790/
MX%GD<?.H=4*+T::D2&J(%HBP_*?ZFH,Z4>B. HK2=-1A"SZHMOW<'&=[JN#[
M0IM5*J;$,4GDX PO8HI!>8\O?@797:',(D%:C2=1H=D<7\XZ=YK&;IKO E9-
MK=X\6=UN;CG%+]!P*'2V87-P25<HNNO\L QGS(B1FO +^<*X FNYD653%_8S
M2@"EJH*!$"?U-KUR7#'CE6ZF2I/Y>2Y#RQ_?_5M]M8I6?2>:]7/D42O<NXJ_
MS\IEI.:^KVQN-F']* 4Q@1?94'@<X&$H+3UD8@2ZU<',YSI?*;HFC*V^PP@N
M$7@Z8LM-<\Y<@>!JN2Q5E5!;2,MVE<)G&"QC&UL^CPFS*+)P5!W-ZO;FSJ;%
MTMFCF(H>1? $IH:B^F11S1UURV@[3&WRW\+C04&'S@ZE0EIM!V-37IH]O^ID
MM.PT!\6[2$J%%V2SXEUM;/!A@@WRV+:04E7K.<I3M[3*.[BATTR2N"DO6,Z[
MMUWUW+K^(SM_7-!UN=M&>\^/)A!S4S!UTOEW@S&36[K>-:J\[?R"ECZ'=!.[
M-\ZF.MEZ<\_YW-8U0E!Y6W.,(GU1$D<%O@<?U]R+J(LW?&<P\U3%2DZ^526J
M/I!T9RT,'ES+CYWJ"SS70KN_3-;/Y1=G^X3YH^!PVDJLV:-_1F50+G*(63^8
M<C\:'8!G;8X&:=@&<7'-6 %Q,]>QJ,-@3NJ/F90DK_##S/Y^?-H?]I]?81/B
M9<=V:&V!0ETH1LHYG9K I078QKM\M[>\ V"7+&"I1J<CB)GP\/?4ICMN^LZ'
MY>44[]@2UJE*>S<8[#$%?X)0B?NQJNSK$(AF=7]ED2_]X9A[=-J$YMSZ[/6D
M_(*!!S2R7/5W5$#QS.IIX$X*B7?*:YJK'BQCXYG)-:.(^KQ$%-X*CX&SW=;H
MH5H#&,-126;3;^%G4MM^5MP]"EO+C3S+'9CY7$>#&<U<&*V/(WNF:B5743*S
MXF<UB5Z3$E<KBHE3+W2_HZLDN^'PQJL]P]5L5WX<%/+WYUS?6U6AZ0S.O*.V
M<">G(>9\V**CM5T2I-,3R,3!@>S@L(3W/"]^B8V_LNE\+"I*C$*U6K^IEW;>
M;[?S/?9<PMTE)8^ZN)&:]KK'E@G*#9.H7)G5L,0%OWT_W:H=N >?W .R6?<H
MQ;C2P5"$."T\+T;WUW6 3V6I#J<;!'->0U7.[0WYE9K[Z6;14L/VPK8='AJ7
MB.#, PX58M)6HSS.I0Q<?VA'IU<KESU*K/,C(C*GYL(EQAJ%\"9RKR$0J&C[
M;%OM^\_1WMS$^;;J:B[*!>M4"+$7-N$9]>C&B4(0=J._^3$K.PEG,MFM]?;-
MGL!FD.&D_%B51:1RY2F.OZT91S>6.;!G"HO5TNNET,.@M+O;QQ$-$@MOK=MN
M5>M9BBL]*T;40C)H.8Y2E6^E65AM<WR&'J%05.(*8 D"!^2Q->/Y=%M]&O&9
M4ZSYWA:.V2ZG'#B/ PRN$EHB\4<]V]P'DF9&.E7SP;8\!ZGJL/$#IDJ^!I9N
MPS@"-Q_7WJ7G;!30S]2S\-_='IC68N'"UMUF&;F.^MFJ:*&F;L=W%ZEESF)N
M9@Q1ZD#.Y +S&5&@M9KY&Q^OR8H?197M10RRVP,*;%@P^/')"6S4WU:R$1U
M3*0K%+G&6?;^4AZHHM%,'!.EMJ>59V+2^.LXE\B_7064RNS$4YW+4KS3)/T2
M"I#D:GCTK_$9+WM$.T(8)\?3/06)(4BFE.5$N''6.(+$FOEYC[H;> 0I#]3
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M\(/Y0ZC4$KD*Z+]BZJV[%\K.]S1\1:*')AO7#2+!1Z!:R5[7PQSC+#)EJZF
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MN%;GV\J&085*N[V8;XO-M^+E92GS3>5\;[+[>G3MZ /=[E1G%QX#H3,2@B.
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M3V.QUDY:8345$@-.HB4Q'-FJ9<-/32Y=A@M8]?(W*'H;*&ZAXOW]&T7"J+T
M$<C:TGN*E8^8UZC'WI/8<A]IL/LP2"]3XK!Q0B1F(E"3!#=1D$^2L_E(Y[B$
M&4N8K)0/DZS62:GC3"Y.O.6BX'#'-Q.KN3<%88AXD(DMEW3SA 1T+^8L0MC'
M0Y6K$'2M$"2WP..8Y*#&<P%H;$35IS9Y1NR2@ A"FNV0W2E'FUQ-(H\C>OG;
MP)P]^*Y]ZT=_I]$=]'K"0[^(KBPG8'+2 -]FB8A%0-B,,T-<)P2PD0.-2(+O
MA%A .Z#DLMG4GL]9TYOB-,Q81^$J G/"X^Y01HHC/SADS'=C^_7C!(FXOV0
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M TX0.H\9ER1>'BV)N;W:?C4G*#3*BJ+<64%T> PL+[1XM:3!54=Y61@&EZB
M)RQ"FOJ!^V&8B?<>Y'"1^GYCP9>,C'H\%+EY8A!B-DI_='4)!38EYZQ_3SWZ
M8KEX>?=VUD.H)_DP!$PYP$"SA^'(2*O8?IPNX.8PKRUPH-$$E#4Y;0V)?4QA
MDTI'K8D"'G63F=5)*H2N >Z)U/<S5^*09\W!=/<[=H=N4.YXGL)6HYMJM_6Z
M3G,@V3G4&?W) 1[1X'.7)(=I(FY\@H*RVFVZ16^QMM;RF;B '</TIDZ/;2=W
M#IZ,\YY9J5(U4239K!<"$^G0]^HNH"(+/HAT2D8P;QF(0.8@C!9P1F&4H17T
MS=W!W+Q27"C$9G*BP1P%A"$D#"-14![]'.0#\W$N]NE<@)2;28SF8=D^'MR]
M87-AI:C'C7Z:8C(RVIM^DS!Z0AN02 (+\]DL[)WC.2B68W8JH>48KC\5"!C#
M9V503.9B, J-;I&\+'2IJIJ,S*RH*0UCW3>M(HT5!.@$ZD0RF"Z:JH5GXDJ@
M1T)+46N36YJQZ+"I\X]%;#N1CQ?C[GI0JA\!"%_ ';F^F.V8W4F'6^YZSBQV
M#_"*6O;2^]4*'#0J8OFM0<7>54.)#?A.B./![\"RD6!R[WI])*I,F.IKSPVR
M' 4^N1()JV,V+J?AA"P?T=+[Y-O.QI$5ZG"(P_(G2LA(STZ!C0997-+YDY5;
M-$D/\,B?<O1<'!,])>FIZM9I7$Y7.>A(RXWCT>N([@890-3+@QVUWQ L87#'
M-1_KHL;]6@C)[;7\M3Y^NC,K?+IR_9>$(5E@J4CFD<55C'W-B)G]AJKBO>78
M+)4;KUR'@0X\E2]&/$1/E.RXMPL3LN!H9?D[&,^?CG8N7&4:$(%JVTIQH#(7
ML4SE!<S3)]/@P=]$+U:@)ZF*!$I" 77LVU$'#?D2FAD"IO&KT4.(FZ/A85(:
M\OI1Y3([ T$;WDW'<I<O('*'3\X^U=A<^8$,?.7ZQ[Z%;O.JS8P[43H$DHQ!
MU>SAU93$W_)Q?)VSE3NQE[+V3S)K:V765NFL^<FL[;.SEF1 XJF1QCWQQJ8M
M$_R>G[.3_I.V.K"B$R/[MZ7>G,R94VM*EIRC:$EJEHEN4.T4%A\W2>F>48JV
M?U8\2V 9_;'33F'NZ<N2]WV>OA^.=RFS_AN%/?M]?M..3ZID.Y/Z[&GI<RNB
MV?+GYT]HWKOV"M50T/;&[9<N,)9H/AVT Q@:%H/\+ $32T(^D<_E5SXCDIV0
MHR!*2G<<",F.Y(3PL>"LE97Q309$%I/-)'>$#?PUI7:(M5*P8!)B7FYXC0Z6
M!>5CX(>#% D, -D+/$=(C"O->QPX0>A$@L>,N+*BR?_/WM<V-ZX;Z?X5?+EW
MDRK/9F:RF]RM^TF6[3E./);++Y/*/95*T2(D,P.1"E_L47[]13< $B1!BA))
M$/*DMC;'8Y,-= ,$^O5IA'[$(4Z0RVKRLN)V!=P&BEMN<R\%MP+H<@U#C7NC
MR8R""R]@D+L,62#?(L;GRK6UKX4[X+B>+*6 A4Q=\&$DDHJAR"N.A>J8[GS8
MCEJL-3[CK,PS#D+D*$0, S6K1!MHY *U\7FN;/$CUGO<G8X?[U,8I,D%399Q
MT,?.%8<1$B,:-??G7P7@/54^])-%(X.= I&G#'D2[0)'9><IC+DNL@XA\YBK
M',("!E"<98R)H1=4_'!/DXR!OQ$NECN^W6/QF4'%:)0$?<#-]"F@VJ,F0?)9
M$#4-DL]#W+0X$U5LBG6G:C+O5FJ5;Z DO91+X%E)+\BEYROIQ;GT\.;>HO3$
MZ87O;M6DQCW+)A&?,80Z\WU!AOR&*]V9J$_ZK9!.22#\7]]I"!JZ$)J5OBNY
M]7+YP]L$(:[X'0T]AGT(L0<91NQGRV6<#=9T2AL,S PYG&I%)E($Y(BV>T^-
M)(=*K?TVYQF"38*FEAW!MV[L6^PT-@[3K,^ZCPY$A8;O+Y0)Q,VYMPU@J^+A
MT-]-572C%K#\2T%>!@QM>6V&YU&I[<)K )0E@Y)V7NMAPP7W)XJ%K#19\,])
M-#A_\%B!8M]_&?,1(!@:$C$&@4$TH/X3YI7]'&Q6])F"W0C8W0AV$V W!\<;
M5SNYQ9D(M,(@S5*Z""_B;#U[SH9(B+Z]OIB=V/3E1E2$24X9$K6 -D'BEO C
M!F>OBB)19S/2V1P]H^8F"M=0QPMI08_\A?X 0D#Q Z)A7&"F)U ]#2Y8,P.C
M8PLM=_[?Y[MGD"-VZM[=!\GWKU[HB3*IW )9R!8(*:7017[+?Q4,@'Y5&IK
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M,7%C]\J:2E"-P4M5;U6Y(@H;7(Y&8#CQX(FS7\>S4&(0NL6VU,E+B6$IQ9"
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M0.1 JA;A^O2YKN;P5E>:<[E5W#>L^>@1R<8VNT.@ L^L*&*#L\#TV3=T!K8
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M3I/B"[J-Z5)Z1C >*B:$(8A\-N].&FKE54;W8E5PCJ/CK5? S^83(&(&!*9
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M:2U1%L]"%LQ[LY<VU= 3N^^5T]((V^)=<KG9LFA'*1H@_5!Y)269HF4+-'$
M!DH;KLS%'1_Y!=PZD*PUJE\*T!&X/2@=?%>4RMWMK>EBN<SB9+;B\[P*X@3
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MDO2IL,0FY::\W[!#'GS#2FD;[./)*8^N#X["D;IO<RZ*A =%^(R<>PP]_+;
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M\TXP5('PV(/IU?2P$ZPT)7-UQ/8YX'4GV(600E/TS(D)ZC'BYEN@_I03DV\
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MEG:CS^"9!%'LNOKD9_!.0D\(Q3S[ [Z$8&5NV7-R/#KPO-Y_>T;P($D&>(<
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M%&>6/B<OT0YZA*^M#A"D$[G] +LDQG4_'\,W\MWM>[A]#9,(L8/M.VIR1O]
M79>J416O$W'_NP3SG(S\Z9O";6J,T)YWK\!-?$3[]'J791*Z.E_:9+?B"I>[
MY84$JQO?'$0.F3Z^OAZ=(_ICZ>1PF:) 1X-*G_>&!)0GW]D1\+E\A-'87&38
M8BDJD2?BAY[K.?!<HC?.3<=N;VX)N1<!OU$1GR]EWGC+X/8Q%_!<G0V7/]#;
MVF"KXW*#9CMSA--VI["NE(>6O H% ]LEO2/Y".Z\""!6O@/%CU'V:_1)1JYO
M'4OU$U\>!+MXC9,"D;K(%JZH[0PRM4+?O4GPA%*W?*KM/H)W\A.;NPEU5@ST
M*O[JP)\@QA=#5,C6;,"Y[8T!G],CTGA2@BS9&KXZ<4*\M.CR8$ OW%TQ^+G>
M@G[Y+"2=B?92KNV$.P#<"">*8S+$I7R)Q)1?"K0GT&1Z*IXO&;3UT[3Y"O:T
MB]$_)GC3D5B'].&T)L*UX_O O3K7^;0,RY<8536YH;L&6_L."/7*Q7/[0?;E
M/O@*'"RU'XNJ&U3:ZS",:N[Z!B#Z_HWC^6>D"6)^\CWTDR.X"Z'0&N0&4,V>
M,@K8 "2U0BP7!1$VN7AO:$+GZ#> =Q^XV1RSZ1&$T>RN\:GQTU)]< -VB'8N
M<@.5K>G[FEEA-4HO=3+5%M<JN[WJ(Y9?&*L#^L\= /CNR\4HWFNI8AT-VCCD
MF+YX/TUGZUN RPN1#;\/[KP ?1@!R3L?C!Z*YU?VR&:$B#],FQBKJ6K3,OX
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MWI@"09T2UY;!ZZ%8U\MIXSZ*$NSV^.J<M^_A]C5,(D0\CUX0 ]Y[S#+=[=H
MGBF0TV$QQMA@C*%N4)NAI:6378LIL6^9Y92[:>84*W3#^J7#OGU'M'$69Q7<
M_G9M1N6YB.+'*/LU8M68[3:6D6W[U'??/O7<.,;LJ1 ^@O<6%&GKZ#J4YOWX
M/TD &FC>>6] ?$?:AM"Z)U%!UR</ILY%='6T;P"CGQ'J_]R7^C_K0;KQ\>20
M1'$?GLL=0//L;\".?*?'_-N&T+R"Q_"-_GGT#^*+$!A%\SKNP M,D)98FL&J
MX!NEIVG;UR(XDAVFB59=LFQQX&IML["G">BMA8E22HV<+WI,\R*'-&>!EGIO
M#P__64 JIB.W0E911.<+G"#?XRO%LW  *&!\<_.9*#JJ[68*'6B^ ?@2C@#/
M7B?X4^T(3[N<NS@]]C/2Z !S8N38:AX:KHRZ;0B*$B3+0C5?Y'JQPL\URIOV
MF_"]\..;ZV;Q7'L?_%H-AK-(H.R#H(C!<A;YBWU %+66#I=%:&OL$?Y/CMYD
M\LZ6"*1A(Y H7/\127IR<4CM@]BU&6.+1IIDFA[24]^09O#D.SL2J<K-U&,T
M7N+#;(@/FT B[/1#W(K,!;!+D+3D@>C:\7W@7IU;PGE4C6J./)&P0YA&6@0!
MGZPP(">'0Z+</N92FZNSX?)^>EMS1'F17+F<OMENOB%A2WQE??.>(+A+L(*2
M?XF]2:RF!@6>< > &]TA73F;4PX?BPUQNZB&%HV+%<,#VL?O(7E2/7QG0,MH
MJG%&)<=XFGM'1*2<4[1-LJ6WQ5:3)6!J(%MG7>N=+X9+V)32H@(L/5<'9!:Z
M8Y=8,_5T.(92 ;Y%@"F*^)%1H>=!B"*:=:7 "EU_G3K]<=7V"MDUE>19$-(0
M,3LS#&KL41Y**5HVG<511W^.@^P8!Y=INYEOE"?[@/)O5AV(C?N0\HUK<PY]
M[9L,,,.(32JE\8VD"UA\L-KLM\.%MUH:SH59?))^;KV_<B)OMPK<&\]/\*LR
M('X(HV@5Q]![08W0@=Z&65\,YFOH(_0BA#?YZQCCOFX=&"#:*-;0$BK!;&[,
MNX/VZ#Y .P_(3O%G3V]K;.JUDO_5&H>E@]NR*NEAK%\P.88]5YN.80=9BI"C
MP>"&VIGFH4]O:QM!9>R[01-R),4<Q9J=RF8HN%=Y:SMDFK:+IRPQ,WC\+$QT
M72^),GZ2?'<6N'+E!B;QS<!F+G$NY6ES%L8Y%4>6<2DO^/5C>6S)8!;&4!V4
M60@APYEB+#4EX L"H5(R$$PF/6P5Q)Z+-]I[ Q<W_.W'SD_0M+#QMV)':7"O
M,WT 3B2XSB^:>V6'.J?F&^)"6)2ZF8OQ7YZKDWH6+7WU4?QQM$K[)>O*BJRK
M"3Z19OI^6!W#)& 1BIJQC4&S 8ABO1V6.O&)_A9X<;1Y_L;E ?P^YLQMJ0.*
M._5J&SO$W@&DE\HS+JVW_"PL+%I?*M*ZI;/8'E%9E/E07U66F05FRW-]IG=
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MOH0^96[5WP>]"N^#70@1%D0Z((4A2$(_/%^'+NVLB_0:= $;</"PTA'$N/H
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MJZ!CU9_M6S4C&$+'ZO]B[^H;418ZUO]7V]=?"=[0@<#?[$6@&1&B X"_VPM
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M'"[]M%^4-@/3(4]85$P5!*EY^=J,EYB%LH.L(8@6_9R.!#&>17-8R"9C =7
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M.FTVAZ\'YVC<:<79P*3465H?-385W<49MDA$!LM!.0A!#2$91>G,=-^W.8*
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M!B+FP#2$@=7ENUA[,MV%L=O HF>,J>M:,\"'(F*]A@N),N$(!E1L8!@*QF4
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MY,+VF,\N:"7#(A]'09O[FH@X;G)6Q;1>LL/!PZ?UCI:Z3 B8T2;FBM)](UO
ME93[MPP'R39@M?XF+JK%&=2JS;9.6*/3VL/T1;-$VU(5R9*/GQZ$I2B6+0 N
MT9-^+D6/;'2$)6I4$&\59%L?,V678_J "_K BD9<EB:[^CGQ-"D=.ST1**]_
M<]1TJ1X>#HGPEA9'K2SP)A[K%J:K%DX_=T4],VY+>^ (N2WY83(\/I"KKT>W
MHI&3;5O23DNX<?%89S.FM*3MK@+72T:4(QE1/U/_4NWLKTXMK=%4@Y<G(2/
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M1R,>Z^[6IR<D3M%3,JCV.%@"(GEZL1\DB#!2'U4_)L6OR2<3T;%S+<M/]TV
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MHN-D8L&%-^$LVRBCMZH[RY!P'Z4XB)+ 'Y-7:'W:6<1RFL1%L"G_GGO"7IU
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M/NTE.QP\?"H*$;;01?0*\D\T<0TUK<=C%;*/DW^M=\WG@156;%%+G^0%@Z\
MJ*YF!R2]2FLVOP4L_T &NWCP9)LGFF]\0%5SG(<"TXJJ8:H9T,!0%@-3SYD/
M*-,7HWM&"2)O^WX5;6_HXQ,?Z2Z+=Z*K*$KGS,G ^H(BHDR'9&^K[8$\R$E*
MS6GO2 <PO;G.YK*,]/J*$UNLOEB.!K5=$O&2]PXRYGKX&4>0@W@L*A]>R*C4
M2[[1D"LTL#&#R.XQ$.)(5'<WM]*2=1H1H]V2A*.!6[V1HBF'.&F >";_\ZN&
M%:)M\7I&;QX^Q\%49?]9-#MK!D X\[<CM5<4;5%VW.QB/9"%X(N _"S=D_,D
MSPVKU\]A@3HQDUI/(A:9UF7+&.EC $P: R"[.K5A&U)%?N!'@1DY>D.CL"^,
M\247T=8&I4=I\V%?6M#6YTN#[2V2PF26+\8Z$ELHQOW6/$CJ(?Y N'CG#H%9
MU65+GX1-7)N/^&+$=?[6/(CKV_%X:>)J?A(X<='(T<N1%_>U>1!8J1"UU9U+
MT)KBZ[#)CH:+7HSJN(\!JPK6\]C;Q]T(2:Q-N4)O0121L5=>2',2S.J(3;1%
MX.0;O%^.:7(?^TG(]QE1V9_\?!U'*?;\-/-"VL3X,PC*E>\.-M&^!#\N1K/G
M;P''"4VWO!Q6N*_!Q@LK#74QO/!?@XV7Q^""FC[W,=A8V5SP#FU4-\B-@(YQ
M/1$F!4N'FNU!NTRU?.LCVN*[XSP&&F$=P;[*D^\N^MV(&[!6$\".@\_2F<B/
M'O)9],[$L.*KJ5)WQW-]+,C7?99']9\X'K+CX!W@/#0+\J>X RTWSRQ+),&^
M [PC:4'_%+= Y8N:9<TAT!>"=W$MV#>Y#U!\4/.LD03[TG".M07[("^-PCDW
MRRI/H.\+Y].;9>$GV,CGG8>SK/@$&OTU'^4LBSZ!1C_O"IUEM2?0V-^8<IZ?
M.1?M.RMJMJ2A+6EH2QK:DH8&Z0([DX:VI+I )Z4ECVI)=5ERJ9:D%E?)JQ3G
MN;J?$V12";X.F^C<BNJ'E8C2/FR5@^@B>5.F6P).G,ZE5SA&H)-F2@W8'6RR
M7;)?ENR7)?MER7Y9LE_ IE_ QOZ2=@'G+&;J_QLWY-Q5Y'?'22UI%_.Y V.'
MG+N*_LO=@B7Q8O);,':<N:O8O]PE4%FNE\C_F87$NHK\[NLPF55]"?2?7>2R
MJ^@'=$N6/ M %V;T6/,ETT+7\; D6BRQYK9BS9]1DA(PTZ*%^#>RG[SU]6J[
M#7*X[J-=C \,@2 CQ_NTZ=4*I#%:&&Q$. =%(@-C2/"W_OJ3H2C? _F (D*[
M/@980)D.CL\ 1%O*R!Z]0Y_@ZH&?FK(K:).1)<\OW[KZ@2KFP*4!Y;G05!\B
M,^== Y416[8^,=V]SOLEDN,3@E-T+)-=>+W)DP&GU3'R,8[>66I7_FAOXM0+
M^=]IU\C'./T[2L_]),\KY9/6Z1[AS=Z+U,&FT^UG?D>0WYR[&!=_HN-D5_7"
MFYA95$T?X= D@L9 N@+MI=8*EA'*4=U.A:'2"VC$]=5W[8ATC6ZF*@D(,A:M
M10L9*SL\ AOD#1EA-LBN'S^T*IO.,F1A*(IUI=I9NKJ'(F]"J7F6OE:PYR$1
MH6=FGJU*@<CLM"L_#=X)O(ME=K',+I;9Q3*[6&9!LKG;?V:$2=]'!*J,'6!3
M?*B>P#R4SC8W-/[^#%'\A2R1)O=1+CE<',.-S\\0P7F1L<D0W/C\#!%,I-T=
M"J;$<7L',T1SQ0L;\6CL!M\0S?S."_!W+\RD@AF$K<WP8.HL%-[IF.YOAD=4
M9\+PCLAT?S,\HH*'9Q@U VX!G(_1YA9?Y>*K7'R5BZ]R\55"1IA[ODIS:\WB
MR+PH_INFG,45>E'T-PT]B^?SHN@7F(%FF0\']P1,+$2SS)6#>S3&-J)99M/!
M/1]C ]$L^QK!/1\SZY"3X3;"2)LJ4(G^QU.&_3U!'55DET3()=QF+N$V+]EK
M$FP##Y]>/ 8()795VQKI^.E .&^$FIC6NPW!>N+Y[%8J@VJZ)TZ?:$1WIPR,
M$8V\2''@K]Z/X) =RDI/;!"72K^)2Y[9=$K;6?-GRS%<_!BS]V/ ,"0KG@3(
MR-.1O+5?"F' .L^*06-"K\YUU\M?HPD-S(%&R:75,DOOYN)%$'FZK*9# 5-%
M-3(_N,:OOWB86;<FUCZO0R])UKMB-VO\3,T$79IEQZ3)Y#OAOE1JH&("+" 4
M>IU\/"P0E J=:H9EE:B\>+2Y,C5>?O5.FX]XLX^SA-S,1\(KD:H%BLET6 ?
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M_U/B F+8^.*X7QSW/[?C7O"HT<YJ9N[[[D66Z'B;0!$-\)U(\$^AYS,#NS)
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MQH;=<Y(69UUU-+ZFES#5LMDZ#OS05T/#? P90_8X9L?[XF@\E;D$*K740\:
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MRMV\7Q) 3)4R4'W8M7<,TKRJN=AC62!/G"WN+#+DC+/V2/QQG A.:^4Q18*
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M@ ,^DL$(8$RL#;JYT^-BK;CD\+8;<@G&PMJZA 7IPR-> ""0(D9C"*9@"8"
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M8^/(XHUJL,W0,IVQ,$\.?91WZC[:9CFMY:$@K;3OKH$@ 91(CSD?%5I]368
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MY0Q*$I<** 2Q@HXK>CO3Z$T$##<IHHAIA"7!%X]EEN,@^$5!]/+'])90WB1
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M,O5)]_,78L5_;N<FO'KSD6@WLVV#P5#1H5.M0\,Z5M5]D7DN)R8E#347S'P
M51CT' ]EH,=[XZ%"[4W3)$,M-"Y ]R*=&M1,U* BU%)!Q8J]OQT=#0<PWWWO
M(RI;^FFF =0T( ,T--8F@P!.L #^6JI"54\9:EMPWN(0#0EX,DUP(FD22%!S
M9<;SU-14YI(M9* FBER ;"]]Y!0([P!.)EA%R522'DL#HVH*X@GU1Y@V/$%J
M8N6%I#U6-+DYK.<T%;#;DS29EUHY_'> /LA43F2*3DCXHR&B--I@\8W9]A87
MN2);C/GV8!ESTLF83L:\?!DSWE[&C'U' 1TG<0$WO2)N)(F;=F["JS>E$OJ6
M:6^MN)$EJP?S::J0UP,'!%M?(OF"S.14(I\CJ<+,>P)_A/^LI$#7@)DK[5/I
MWZ*IES$2RY+?)B@>0'JY3!1_F:/O0!I/"'^M5XN[\'?*MS+UH437")P?,@'$
M$I\$)JYRD$<)S*B<Q#X8""HGW\&@*E_O68<<704Y[R>2>#3\^V:?S;J,8.D*
MS \7"]TS*(]@L'D2LN ;KZJ+HQT->DWT9,IYK$LQWE:FC[Q3\'94"$*O6"3L
M*A0<&B.)!K1KJ1MX<*!DEL.9T9XX\[A=UAIYL,BOUTC$E8=#-E'I7(8U1PH0
M]YM@'Q:J+1((H</CK!C2#8)XPKLGPT&Y(7,1UCUH$K08#Q/.4M9B\*.)F@ =
M,2@((:RMWAN0XT#P/,$_BPE_7^HG]5<D$*Y_A$,M47OADZVGN*[CY.*6E")]
M_CVXN\%,KP\N_T+/565$9A)/4:TKQG^@@PI==?@+*DIX$+U499^1 %B9B50Y
MIN#B(BV*=)&@@@,?&6WH:'A^96B]QJ!I#,]_@"V-"]R*$%09T%0$#(XN-'L3
MW<?+P*,^+XWG#4[G8,,-&CBWS;@>Z<()<SG2];\)5^6<BULU+^;ZHI%SKL:3
M1/ Y3I:1#*?6.:Q?A$L*BX2Z8"K_52C4V&(8<5H(5.ZD.:JN]O9@X__/#]_?
M)P5&G>K6J6[/H+H%VZANCU]6FF\H YV5<5' U%-\.3(A]864M0\2?T#^2"QF
MOTVZ6G/PSN@D-<I1,OR-K?D!LUNXLY$*2%:!S,) ' =?%D*%97A-L4946NPL
MOK2Y/D\*6(<Y'![[Y!CX\UJH1%65(8]EA,#("0[BA+'6O ?T%[3CU2V+ZFRS
M:A5J+P;(== J/*\+RG><N^/<FSEWN+W1'?@^JE3YRL>[FV$:#\;2:V9W:T-
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M>L BL)D;.=S@T;?7L#!]OAW.MBDF@TU#4TF"">6$"$,,#WFX&"R;]!5SCMP
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MPCK2%G" _Q7>/U"&?Z VSEKCT)[$5.:%:4.FN1P6Q,)@Z'7M:U7!=B8O=Y0
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MEAE+;=;%R()1I9 ['!X9@CZ*="QBF>W]>AO)E7<5$*D'P^$!Y9D))S)I><%
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M0;$0&K_LHYC(G,,S/TH1P6)<E4BY](@)T/QB'OE)C('H#U+C['AO$Y&&7L]
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M1SO?1SL?]-G/W*)UT935@ETI/9.03Z 7S-W:.=<XO-*.M90%8;!@C7*F 5P
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MO<3K49]]N&;<[Y_-#^+ABY%M(=G2(XI1ND *#28 Y()Q QYB"!F1(F=&*#!
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M=3O/61]N*/XFP9ON>\92& QO/802^)B,8/2_K+2H[85L+]14RRE0RE=\TOY
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M+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( )J"GEQ^L_4RO$0  +]1 @ 0
M          "  1C1 @!A8VAV+65X,3!?,3,N:'1M4$L! A0#%     @ FH*>
M7%$I(WR="   A3    \              ( ! A8# &%C:'8M97@S,5\Q+FAT
M;5!+ 0(4 Q0    ( )J"GEQ/E+XT+@D  '$]   /              "  <P>
G P!A8VAV+65X,S%?,BYH=&U02P4&      4 !0 V 0  )R@#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>achv-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="achv-20251231.xsd" xlink:type="simple"/>
    <context id="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3bd2bfc9-4d18-460c-ac43-0c2f6a4db5fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
        </entity>
        <period>
            <instant>2026-04-20</instant>
        </period>
    </context>
    <context id="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:OtherAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_778c1ce0-3ed5-4cde-9b17-19895c3b3431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_86f1564f-134f-47ea-88ea-abe5cce2350e">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_f61fbbb4-6fe8-4aa9-8736-74c3e6726099">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_709f50ba-ced4-4210-bde2-1a50a0292c13">0000949858</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_3a6952d4-a03d-4f6a-8453-592bf7d3cad2">BC</dei:EntityAddressStateOrProvince>
    <dei:DocumentType
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_a40fe607-1ec6-41dd-8a54-9dde2c87d9a3">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_60ab88cf-3e5d-4ffa-abe1-b6a5ef47bf64">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_5ee6480a-9b8b-4d07-96ca-226fd79a41b9">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_3a30c493-4d69-4ca9-a9ec-dc4392512b4a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_d866770b-09f8-41c1-9dd2-7f58afb64e23">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_57edad57-14d6-4ff0-ac56-c7e8370ce8f4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_af4f5873-f854-4930-9096-35a322c2265a">033-80623</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_fb3051d2-c7e9-4d48-91b0-5f26d182e01f">Achieve Life Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_0659e638-ffdc-40a4-9e39-44d06d02e200">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_69b3dee4-5531-452e-bcfe-3071d083b356">95-4343413</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"
      id="F_6c01361e-3720-49be-96b7-152d2595f15a">22722 29th Drive SE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"
      id="F_01e70611-9f94-4c60-b8f1-22201c3eb46e">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"
      id="F_47aa7fab-2044-47b6-92f7-0ad63c0f77a7">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"
      id="F_c2b724a8-f1f6-45cf-b0fc-bb1135fe4296">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_5283e90f-6bda-4a75-935b-04c28bd0b4fc"
      id="F_b0e4f7e3-83be-4abd-8dfd-5b4e13b4dceb">98021</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_7ff843e9-c51c-43c9-92a6-67ddbf9c362d">1040 West Georgia Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_6380820b-30ea-4d5d-9328-8e836273750d">Suite 1030</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_93e8f4af-f506-4975-b14b-5a146935b707">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_6b551ac6-979d-4463-b0db-3405ddb9cd5a">V6E 4H1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_bdf6d385-f6f6-4197-a1a3-fa074a36f854">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_69362f61-ff5c-44de-98cb-e1d7cae50679">210-2217</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_5fbd5cbc-b525-49df-875c-b29341131d78">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_307ee518-3d89-4f0f-b299-814831c8f3df">ACHV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_8fd8f9ec-08c0-4ac3-9f0d-10e87a9942fb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_b31fcd9d-97f8-4b5d-9c77-117c0aed7de3">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_08aefa21-9435-47ae-9e3d-1357b7c28610">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_50de6ee5-eb27-4e7d-84f4-9b985f839308">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_eb04f3cb-1dbb-4c16-8363-77941c3b8947">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_95d0ff99-7f1f-41ac-8f6a-388374f06462">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_9181d542-176c-41d3-8c68-023cde69b05c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_2a5b6166-6511-4152-942f-d61211085348">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_e41b9506-413e-41a9-9b0d-f7311e97b578">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_32d4fc83-5c89-438a-8e5c-90abd44e4fc6">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_3b837ef4-d3d9-47d3-b5ba-e54501764ef4">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_778c1ce0-3ed5-4cde-9b17-19895c3b3431"
      decimals="0"
      id="F_45385558-7e20-4339-8a96-0129768dc132"
      unitRef="U_USD">103958994</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_3bd2bfc9-4d18-460c-ac43-0c2f6a4db5fa"
      decimals="INF"
      id="F_e7fe364f-8638-4045-8a56-58d30543797d"
      unitRef="U_shares">102659057</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_d4b6313f-a132-44cb-8473-82f71578f243">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_283eff06-4ce9-40fc-b8db-6e302bb705ab">Vancouver, Canada</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_eca25279-3902-46a6-bec2-adf747926ae5">271</dei:AuditorFirmId>
    <dei:AmendmentDescription
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_292720f6-b21e-4828-976c-30080d870a68">This Amendment No. 1 on Form 10-K/A (&#x201c;Amendment No. 1&#x201d;) is being filed to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the &#x201c;Original Filing&#x201d;), filed with the U.S. Securities and Exchange Commission (the "SEC") on March 24, 2026 (the &#x201c;Original Filing Date&#x201d;). We are amending and refiling Part III to include information required by Items 10, 11, 12, 13 and 14 because our definitive proxy statement will not be filed within 120 days after December 31, 2025, the end of the fiscal year covered by our Annual Report on Form 10-K. &#160;Pursuant to the rules of the SEC, we have also included as exhibits currently dated certifications required under Section 302 of The Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, certifications pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 are not being furnished herewith.  We are amending and refiling Part IV to reflect the inclusion of those certifications, along with any changes to Part IV that occurred after the date of the Original Filing. &#160;In addition, we made certain revisions to the cover page, including the deletion of the reference to our proxy statement and the amendment to our Annual Report on Form 10-K and inclusion of updated outstanding share information. Except as described above, no other changes have been made to the Original Filing. &#160;Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. The filing of this Amendment is not a representation that any statements contained in items of our annual report on Form 10-K other than Part III, Items 10 through 14, Part IV and the aforementioned portions of the cover page are true or complete as of any date subsequent to the Original Filing.</dei:AmendmentDescription>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_2cc9f198-baa3-4908-a3b1-b82baa4b6444">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_ef10b0ff-6f54-414f-b5c8-40ca8aa2d12b">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;do not time&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equity grants to take advantage of a depressed stock price or an anticipated increase in stock price and generally grant awards in January and ensure that awards cannot be timed to take advantage of material non-public information.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New hire stock awards to employees, including executive officers, are generally granted at the next Board of Directors&#x2019; meeting following their start date, and initial awards to non-employee directors are granted on the date of the non-employee director&#x2019;s initial appointment or election to our Board of Directors.&lt;/span&gt;&lt;/span&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_805e1ed0-1e62-4ade-9772-91e660dba7ec">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;do not time&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equity grants to take advantage of a depressed stock price or an anticipated increase in stock price and generally grant awards in January and ensure that awards cannot be timed to take advantage of material non-public information.&lt;/span&gt;</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_a198bd97-8155-42b3-906c-3009440336de">true</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:AwardTmgMethodTextBlock
      contextRef="C_8f776d48-5b0a-46cc-a2be-c94c6ea73471"
      id="F_8e83401d-3091-4b9d-850f-3f209a613aaf">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New hire stock awards to employees, including executive officers, are generally granted at the next Board of Directors&#x2019; meeting following their start date, and initial awards to non-employee directors are granted on the date of the non-employee director&#x2019;s initial appointment or election to our Board of Directors.&lt;/span&gt;</ecd:AwardTmgMethodTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
